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2Abstract
The work presented in this thesis focusses on the sequence and structural analysis 
of antibodies and has fallen into three main areas.
First  I developed a method to assess how typical an antibody sequence is of the 
expressed human antibody repertoire.  My hypothesis was that the more  “human­
like”  an  antibody sequence  is  (in  other  words  how typical  it  is  of the expressed 
human  repertoire),  the  less  likely  it  is  to  elicit  an  immune  response  when  used 
in  vivo  in  humans.  In  practice,  I  found  that,  while  the  most  and  least-human 
sequences  generated  the  lowest  and  highest  anti-antibody reponses  in  the small 
available dataset, there was little correlation in between these extremes.
Second,  I  examined  the  distribution  of the  packing  angles  between  Vh  and  Vl 
domains of antibodies and whether residues in the interface influence the packing 
angle  angle.  This  is  an  important  factor  which  has  essentially  been  ignored  in 
modelling antibody structures since the packing angle can have a significant effect 
on  the  topography  of the  combining  site.  Finding  out  which  interface  residues 
have the greatest influence is also important in protocols for ‘humanizing’  mouse
3antibodies to make them more suitable for use in therapy in humans.
Third,  I  developed  a  method  to  apply  standard  Kabat  or  Chothia  numbering 
schemes to an antibody sequence automatically.  In brief, the method uses profiles 
to identify the ends of the framework regions and then fills in the numbers for each 
section.  Benchmarking the performance of this algorithm against annotations in 
the  Kabat  database  highlighted  several  errors  in the  manual  annotations  in the 
Kabat  database.  Based on structural  analysis of insertions  and  deletions  in the 
framework regions of antibodies, I have extended the Chothia numbering scheme 
to  identify  the  structurally  correct  positions  of  insertions  and  deletions  in  the 
framework regions.
4Abbr  e  viat ions
The following abbreviations have been used in this thesis:
Amino acids
One-letter
code
Three-letter 
code
Amino-acid
A Ala Alanine
C Cys Cysteine
D Asp Aspartic acid
E Glu Glutamic acid
F Phe Phenylalanine
G Gly Glycine
H His Histidine
I lie Isoleucine
K Lys Lysine
L Leu Leucine
M Met Methionine
N  ' Asn Asparagine
P Pro Proline
Q Gin Glutamine
R Arg Arginine
S Ser Serine
T Thr Threonine
V Val Valine
W Trp Tryptophan
Y Tyr Tyrosine
5Miscellaneous
ANN Artificial Neural Network
BLAST Basic Local Alignment and Search Tool
GA Genetic Algorithm
NH Number of hidden nodes in neural network
NN Neural Network
PDB Protein Data Bank
Rprop Resilience propogation
SNNS Stuggart Neural Network Simulator
SRS Sequence Retrieval Service
SSE Sum of Square Error
SSEARCH Sequence Search
SVM Support Vector Machine
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25Chapter  1
Introduction to immunology
The human body contains a number of microenvironments that provide an ideal 
niche for the growth and proliferation of several  pathogenic and non-pathogenic 
microorganisms.  In  order  to  prevent  the  entry  and  survival  of pathogens,  each 
of us is equipped with a complex immune system capable of efficiently combating 
invading microorganisms.  The human immune system can be broadly divided into 
two- the innate immune system and the acquired or adaptive immune system.  As 
the name suggests,  innate immunity is the inherent  immune system that the or­
ganism is born with.  The adaptive immune system, on the other hand, is acquired 
during the lifetime of the organism.  The innate adaptive system is well developed 
even in invertebrates,  like the nematode Caenorhabditis elegans while the adap­
tive immune system is a unique feature of higher vertebrates starting from jawed 
fishes.  Referred to as the immunological ‘Big Bang, the evolution of the adaptive 
immune system conferred many additional advantages to the organisms possessing
26them.
1.1  Innate immune system
The innate or the non-adaptive immune system offers the first line of defense and 
provides  a  quick  and  immediate  response  to  invading  pathogens.  This  branch 
of  immunity  comprises  of  several  players,  which  provide  a  physical  barrier  to 
pathogen entry,  physiological  barrier  to  their  survival,  and  their  elimination  by 
phagocytosis  or  extracellular  killing  of these  pathogens  to  eliminate  them  from 
circulation.
The skin is often the first barrier encountered by invading pathogens.  In addition 
to  being  impermeable,  the  lactic  acid  and  fatty  acids  in  sweat  and  sebaceous 
secretions from the skin are maintain a low pH,  which is inhibits the survival of 
most pathogens.  Mucous secreting cells and  cilia that propel mucous-entrapped 
pathogens out of the body guard the other openings of the body like the respiratory 
and urogenital tracts.  In addition,  many of the secretions of the body,  including 
the tears and saliva contain bactericidal factors like lysozyme, a hydrolytic enzyme 
that is capable of destroying the bacterial cell wall.
If  the  microorganism  manages  to  overcome  these  barriers  and  enter  a  tissue, 
it  encounters  resident  tissue  macrophages.  These  cells  are  derived  from  circu­
lating  monocytes  that  exit  from  circulation  and  settle  down  in  various  tissues. 
Macrophages are long-lived phagocytic cells that are usually the first cells of the
27innate immune system to recognize invading pathogens.  They do this using var­
ious  cell-surface  receptors  including  CD 14,  a  receptor  that  recognizes  bacterial 
lipopolysaccharide  (LPS).  Clustering  of  the  receptors  upon  ligand  binding  in­
duces phagocytosis of the pathogen into vesicles known as phagosomes inside the 
macrophage.  These  phagosomes then fuse with vesicles  called  lysosomes,  which 
are highly  acidic  compartments  harbouring enzymes  that  can  destroy the  inter­
nalized pathogen.  However,  the internalization of pathogens by macrophages re­
sults  not  only  in  their  destruction  by active  phagocytosis,  but  also  triggers  the 
macrophage to secrete various toxic chemicals  like hydrogen peroxide,  nitric ox­
ide and superoxide anion into the surrounding tissue.  In addition,  macrophages 
also secrete cytokines,  which are low molecular weight proteins that regulate the 
function of immune cells.  These cytokines attract another subset of phagocytes- 
the neutrophils.  These are short-lived polymorphonuclear neutrophilic leukocytes 
that  are found  in circulation.  Local  cytokine  release  induces  neutrophils to  mi­
grate to the site of injury  in large numbers.  Just  like  macrophages,  neutrophils 
are also phagocytic cells that actively engulf the pathogens and participate in the 
elimination of invading microorganisms.
Cytokines  also  trigger  a  local  inflammatory  response,  which  serves  to  not  only 
recruit more cells of the immune system, but also to restrict the area of infection. 
An inflammatory response is characterized by redness, pain, heat and swelling in 
the  area of infection.  The  inflammatory  mediators  induce  changes  in  the  local 
environment i.e.  they cause vasodilation of nearby blood vessels and increase the 
expression of adhesion molecules on the surface of endothelial cells.  These steps 
facilitate  the  recruitment  of  circulating  neutrophils  for  increased  phagocytosis, 
monocytes  that will mature  into more tissue  macrophages,  as well as  mast cells
28and eosinophils.
In addition to these  cell-mediated  innate  immune  responses,  tissue  damage  also 
activates  several  enzymatic  systems  in the  plasma.  One  of the  most  important 
of these  is  the complement  system.  Although it  was  first  discovered  as a factor 
that  augments  the  activity  of humoral  branch  of acquired  immunity,  hence  the 
name complement proteins,  it is now clear that it is first activated as part of the 
innate immunity.  The complement system comprises of a series of enzymatically 
catalyzed  reactions  whose  end  products  bring  about  various  effector  functions. 
These include the opsonization of antigen to facilitate recognition by macrophages 
thereby increasing their phagocytosis, promoting the inflammatory response, and 
the  formation  of a  membrane  attack  complex  that  lyses  pathogens  by  forming 
pores  on  their  surface.  The  complement  system  can  be  activated  on  microbial 
surfaces  and  also  by  antibodies,  hence  they  participate  in  both  the  innate  and 
adaptive immune system.
1.2  The Adaptive Immune system
The  most  important  cells  of the  adaptive  immune  system  are the  lymphocytes. 
These cells continuously circulate through the blood and the lymph, thus monitor­
ing the status of the body.  The two main types of lymphocytes that are involved 
in the adaptive  immune  system  are the B-lymphocytes  and  the  T-lymphocytes. 
These cell types differ not only in the surface receptors that they possess, but also 
their method of recognition of foreign antigen, and their effector mechanisms.  The
29key players of the adaptive immune system are:
•  B-Lymphocytes
•  T-Lymphocytes
•  MHC molecules
1.2.1  B-Lymphocytes
B-lymphocytes mature in the bone marrow in the adult mammals,  and are char­
acterized  by the presence of approximately  1.5A105  receptor  molecules  on  their 
cell surface that are actually membrane bound antibody molecules.  All such re­
ceptor molecules on a single B lymphocyte are specific for one particular antigen. 
The generation of the enormous diversity of these receptors is brought about by a 
process termed VDJ recombination-a process whereby the germline encoded gene 
segments for B lymphocyte receptors are recombined in different ways to give rise 
to unique combinations of final gene sequence coding for receptor proteins that are 
capable of recognizing two antigens differing only in one residue.  Upon recognition 
of an antigen  by the  receptor,  these  B-lymphocytes  eventually  differentiate  into 
effector  cells  called  plasma  cells,  which  secrete  soluble  antibody  molecules,  and 
memory B-cells.  B-lymphocytes constitute the humoral immune response branch 
of the  adaptive  immune  system,  as  they  can  directly  recognize  soluble  antigens 
in body fluids  (once known as humors).  Their only contribution to the adaptive 
immune system are the antibody molecules.
301.2.2  T-Lymphocytes
T-lymphocytes  mature in the  thymus  and  like  the B-cells,  also possess  cell  sur­
face receptors for antigen recognition.  However, unlike the B cell receptors which 
are  capable  of recognizing  soluble  antigens,  T  cell  receptors  can  only  recognize 
antigens displayed by special MHC molecules on the surface of antigen-presenting 
cells,  or  on  self-cells  infected  with  intracellular  pathogens  like  viruses.  Hence, 
T-cells constitute the cell-mediated immune response branch of the adaptive im­
mune system.  When  a T  cell  encounters  an  altered  self-cell,  it  is stimulated  to 
proliferate and differentiate into effector cells and memory T-cells.  There are two 
sub-populations of T-cells -  the T helper (Th ) cells and the T cytotoxic (T c) cells. 
They differ in the type of additional cell surface glycoprotein molecules  (CD4 or 
CD8)  they  possess.  Generally,  cells  possessing  CD4  function  as  TH  cells  while 
those possessing  CD8 function as  T c  cells.  Recognition of an MHC bound  anti­
genic  molecule by  TH  cells results  in their differentiation  into effector  cells that 
secrete various cytokines.  These cytokines serve as activating signals for B-cells, 
Tc  cells,  macrophages  and various other cells of the  immune  system.  Activated 
Tc cells display cytotoxic activity, and they destroy altered self-cells.
1.2.3  MHC  molecules
The  major  histocompatibility  complex  (MHC)  is  a  cluster  of genes  on chromo­
some  6  in  humans.  It  is  also known  as the  HLA  complex  in  humans.  The  loci 
constituting  the  MHC  complex  are  highly  polymorphic.  Several  alleles  exist  at
31each locus,  hence providing for a wide range of antigen-binding MHC molecules.
The MHC cluster can be subdivided into three regions encoding for three classes 
of MHC molecules.
1.  Class I MHC  genes encode glycoprotein molecules that are expressed on 
the surface of nearly all nucleated  cells.  They are important for displaying 
peptide antigens on the surface of infected or altered self-cells for recognition 
by T c cells.
2.  Class  II  MHC  genes encode glycoprotein molecules that  are mainly ex­
pressed on the surface of antigen- presenting cells i.e.  dendritic cells, macrophages 
and B-cells.  They are important for displaying peptide antigens for recogni­
tion by TH cells.
3.  Class III MHC genes encode a variety of secreted proteins involved in pro­
viding immunity,  including some complement  proteins,  soluble  serum  pro­
teins etc.
1.3  Activation of the adaptive immune system
The activation of the two branches of adaptive immune system occur in different 
manner.  B-cells can either be activated on their own by some non-protein antigens 
(e.g.  capsular polysaccharides  on the surface of certain bacteria),  or by interac­
tion  with  TH  cells  that  recognize  the  processed  antigen-MHC  Class  II  complex 
on the surface of B-cells.  Interactions between specific  co-stimulatory molecules
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Figure  1.1:  Activation of the adaptive immune system
on  the  TH  cells  and  B-cells,  and  directed  release  of cytokines  by  the  TH  cells 
stimulate  B  cell  proliferation  and  differentiation  into antibody  secreting  plasma 
cells and memory cells.  The activation of the adaptive immune system is shown 
in Figure 1.3.
The activation of T cell responses requires the interaction of naive T-cells by spe­
cialized cells called the  Antigen  Presenting  Cells  (APCs).  These cells internalize 
foreign  bodies  efficiently,  either  by  phagocytosis  or  endocytosis,  and  process  it 
intracellularly for display with class II  MHC complex on the cell surface.  Three 
types  of cells  function  as  professional  APCs,  namely  the  dendritic  cells,  B-cells 
and  macrophages.  Dendritic  cells  are  perhaps  the  most  important  professional 
APCs of the immune system.  They are phagocytic cells arising from bone marrow 
precursor cells, from where they migrate and settle down in various tissues.  After 
internalizing  a pathogen  in  the  infected  tissue,  dendritic  cells  are  stimulated  to
33migrate to  a peripheral lymph  node or  lymphoid  organ,  where  naive  T-cells  are 
constantly being circulated.  Here,  the dendritic  cells display the processed  anti­
genic fragments in a complex with MHC Class II molecules on their cell surface. 
T-lymphocytes possessing the antigen-specific receptor recognizing the displayed 
antigenic fragment become activated, and they proliferate and give rise to effector 
and memory cells.
The most important component of the B cell responses are the B-cell receptors and 
antibodies.  B-cell receptors are membrane-bound antibody molecules.  Antibodies 
belong to the immunoglobulin family of proteins,  as they possess a characteristic 
compact structure known as the immunoglobulin fold.
1.3.1  Structure of an antibody
The  basic structure  of an  antibody  is  shown  in  Figure  1.3.1.  Antibodies  are Y- 
shaped  immunoglobulin  molecules  comprised  of two  light  chains  and  two  heavy 
chains.  Each  chain  in  turn  is  composed  of a variable  region  at  the  N-terminus 
of the  protein  and  a constant  region  at  the  C-terminal  end  of the  protein.  The 
original four chain model was proposed by Porter  (1959).  The constant  regions 
of light chains have either of the two amino acid sequences named kappa («)  and 
lambda (A).  The constant regions of the heavy chains have one of five basic amino 
acid sequences i.e.  7 ,  a , /i,  S, or e.  These sequences determine the isotype of the 
antibody molecules,  and based on the isotype of the heavy chain constant region, 
immunoglobulins adopt one of 5 classes in humans - IgG,  IgA,  IgM,  IgD and IgE.
34The Y-shape of an antibody was first proposed by Valentine and Michael during 
their studies of an antibody-hapten complex through electron microscopy  (Valen­
tine and  Green,  1967).  The  variable region of an antibody  (Fv)  consists  of two 
identical light and heavy chain components on either arm of the molecule (marked 
Vl and Vl respectively in Figure 1.3.1).  The variable regions of an antibody con­
tain the interaction site of the antibody with the antigen.  The virtually infinite 
sequence diversity of the variable region allows an antibody to bind with a wide 
range of antigens.
Among the Immunoglobulin isotypes, IgG is the most abundant, making up about 
75% of all immunoglobulins found in the human serum  (Junqueira and Carneiro, 
2005).  Further,  IgGs  consist  of  four  subtypes:  IgG l,  IgG2,  IgGS,  and  IgG4 
(GREY and KUNKEL,  1964;  Gergely,  1967),  in  decreasing  order of occurrence. 
These subtypes differ mainly in their amino acid sequences as well as in the number 
of disulphide bonds between the heavy chains.
1.3.2  Generation of antibody diversity
The  ability  of the  B  cell  receptors  to  recognize  a  wide  range  of antigens  arises 
from the generation of a diverse  set  of B-cell receptors specific  for almost  every 
possible antigen that the organism might come across during it’s lifetime.  Instead 
of loading the genome with genes encoding for each specific  B  cell receptor,  the 
adaptive  immune  system  evolved  to  generate  diversity  from  a  handful  of gene 
segments by the simple process of recombination.
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Figure 1.2:  Structure of an Immunoglobulin  (IgGl) consisting of 12 domains
36The gene families encoding for B cell receptors are present on three chromosomes in 
humans.  The multigene families encoding for the k and Alight chains are present on 
chromosomes 2 and 22 respectively, while those encoding for the heavy chains are 
present  on chromosome  14.  The germline sequences  of these multigenic families 
consist  of a  number  of coding  sequences  called  gene  segments.  It  is  these  gene 
segments  that  are  rearranged  during  B  cell  maturation  to  give  rise  to  various 
combinations of sequences.  The «and Alight chain gene families consist of multiple 
V and J gene segments and a single C gene segment.  The heavy chain locus consists 
of multiple V, D and J gene segments,  as well as multiple C gene segments.  The 
rearranged V(D)J gene segments codes for the variable region of antibodies, while 
the C region codes for the constant region.
1.3.3  VDJ  Recombination
Recombination of the V, D and J gene segments is carried out with the help of lym­
phoidcell specific recombinase enzymes RAG-1 (Recombination Activating Genes) 
and RAG-2.  These enzymes recognize unique sequences  flanking the V,D and  J 
segments  called  the  Recombination  Signal Sequence  (RSS).  The  RSSs are made 
up of a conserved heptameric sequence (5’CACAGTG 3’) on one end, a conserved 
nonameric sequence (5’ACAAAAACC 3’) on the other end, and a spacer region in 
between containing  12 or 23 base pairs.  An RSS containing a  12 base spacer can 
only join to another gene segment possessing 23 base pair spacer, a rule known as 
the 12/23 rule.  EachV gene segment has an RSS on it’s 3 end, each J gene segment 
on it’s  5  end  and  each  D  gene  segment  has  an  RSS  on both sides.  The  nature 
of the spacer in the RSS of the V, D and J gene segments ensures that a V gene
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Figure 1.3:  VDJ recombination to produce light chains
segment joins only to a J and not to another V gene segment, and likewise, for the 
J gene segments.  The presence of different copies of each gene segment generates 
a combinatorial diversity that is a major contributing factor towards generating B 
cell receptor diversity.  Apart from this, several other mechanisms also add to the 
existing diversity.  In addition,  the diversity of antibodies is enhanced by combi­
natorial association between the light and heavy chain.  The VDJ recombination 
for light and heavy chains is shown in Figures 1.3 and 1.4 respectively.
Junctional flexibility
During  the  process  of VDJ  recombination,  the joining  of the  gene  segments  is 
often  imprecise,  leading  to  differences  in  the  final  coding  sequence  for  each  re­
combination event.  This junctional diversity has been shown to occur within the
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Figure 1.4:  VDJ recombination to produce heavy chains
third hypervariable region (CDR3) of the heavy and light chain.  Since CDR3 is a 
region important for antigen recognition, this process further increases the range 
of epitopes that can be recognized by antibodies.
P-Nucleotide and N-nucleotide addition
During the process of recombination, the 3-OH end of the strand cleaved by RAG 
enzymes forms a hairpin connecting it to the opposite DNA strand.  This hairpin 
is  cut,  sometimes  resulting  in  a short  single  stranded  region  referred  to  as  the 
P-nucleotides.  This  is because  addition of complementary  nucleotides  to fill  up 
the gap results in the generation of palindromic sequences.  N-nucleotide addition 
refers  to  the  addition  of  nucleotides  by  the  enzyme  terminal  deoxynucleotidyl
39transferase  (TdT).  Upto  20  nucleotides  can  be added.  N-nucleotides  are  found 
in V-D and D-J gene junctions of assembled heavy chains as the enzyme TdT is 
expressed exclusively at the time of heavy chain rearrangeent and not during light 
chain rearrangement.  These  nucleotides  are not encoded by the V,  D  or  J gene 
segments and thus lead to additional diversity of the antibody sequence.
Somatic hypermutation
There exists another mechanism that acts post gene rearrangements of the heavy 
and light chains to generate more antibody diversity.  Nucleotides in the V region 
of the  antibody  chain  are replaced  by  alternate  nucleotides  in  a  nearly  random 
manner.  These  mutations  occur  at  a  much  greater  frequency  as  compared  to 
normal mutations,  hence it  is called hypermutation.  It  aids in generating B  cell 
receptor sequences that may bind more strongly to antigens.  Such a B- cell is then 
selected for rapid proliferation in a process termed affinity maturation.
1.3.4  B-cell maturation,  activation and proliferation 
B-cell maturation
B-cells maturation begins in the embryo in the fetal liver, fetal bone marrow and 
the yolk sac, and continues during adulthood in the bone marrow.  The maturation 
process  involves  two  distinct  phases  -  antigen-independent  phase  and  antigen- 
dependent phase.
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Antigen-independent  phase ’This phase/occurs in the bone marrow in the ab­
sence of exposure to any antigen, and leads to the generation of naive B-cells 
that then enter into circulation.  Lymphoid stem cells give rise to the first B- 
Icell lineage cells-r the progenitor B-cells (pro-B cell).  In the niche provided by 
the bone marrow stromal cells, these pro-B-cells differentiate into precursor 
B-cells (pre-B-cells).  This occurs by the close association between pro-B-cells 
and stromal cells which is mediated by cel-cell adhesion molecules expressed 
on the pro-B celi and the corresponding receptor present on the bone marrow 
stromal cells.  Initial contact is mediated by moleeules like VLA-4 expressed 
on th*  pro-B-cells  that recognize  and  bind  to it ’s  ligand VCAM  -1  on the 
stromal cell.  This is followed by the activation of c-Kit receptors on the pro- 
B-cells by stromal cel surface molecules.  By virtue of it’s tyrosine kinase 
activity, c-Kit kick-starts a series of events that lead to the proliferation and 
differentiation of pro-B-cells into  pre-B-cells.  Cytokines  like  IL-T secreted 
by the stromal cells further contributes to the maturation process and also 
leads to the detachment of pre-B-cells from stromal cells.
The maturation of pro-B-cells involves Ig-Gene rearrangements.  These occur 
in a fixed order.  First the heavy chain gene rearrangement takes place.  The 
DH  -  J  H joint  is  formed,  followed  by  the  VH  -  DH  J  H  rearrangement 
to give rise to a productive gene arrangement.  At this stage,  the B-cell is 
:<   termed  pre-B  cell.  The subsequent  productive  rearrangement  of the  light 
chain gene gives rise to an immature B cell that expresses IgM on it’s cell 
surface.  The transition of immature B-cells to mature B-cells proceeds with 
the expression of IgD isotype of the B cell receptor in addition to the IgM 
isotype.
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Before mature B-cells enter into circulation,  they are tested for specificity 
to self-antigens.  Since the entry into circulhtion of B-cells reactive to self­
antigens can be-fatal, this process of negative election plays an important 
I role.  About 5x107 B-cells are produced per day by the bone marrow,  and 
only about 10% of these enter into circulation.  Recognition of a self-antigen 
by an immature B-cell leads to the crosslinking of membrane IgM molecules 
and subsequent death. However, in many cases, following self-antigen recog­
nition,  the immature B-cell quickly  edits it’s light  chain  in  an attempt to 
generate B-cell receptors that are no more specific towards the self-antigen. 
The antigen-independent phase of maturation is shown in Figure 1.3.4.
Ant  igen-depentdent phase  Mature B-cells that  enter circulation survive  only 
for a few weeks unless activated by an antigen against which their receptor 
displays specificity.  Antigens can trigger different routes of B cell activation 
depending on their nature.  Some antigens can directly activate B-cells by 
binding to the B cell receptor, while others stimulate B cell activation via a 
i   special class of T-cells called helper T-cells  (TH cells).  Therefore,  antigens 
stimulating B-cells can be classified as thymus-independent (TI) and thymus- 
dependent  (TD)  respectively.  The antigen-dependent  phase of maturation 
is shown in Figure 1.3.4.
Thymus-independent antigens can be of two types:
•  Type-I  TI  antigens  e.g.  gram-negative  bacterial  cell wall  component 
lipopolysaccharides,  which is capable to non-specifically activating B- 
cells  when  present  in  high  concentrations.  These  are  truly  thymus- 
independent  antigens  as  they  stimulate  B-cell  response  even  in  nude 
mice,  which  lack a thymus  and  hence  cannot produce  T-cells.  B-cell
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Figure 1.5:  Antigen-independent phase of B-cell maturation
response  to  these  antigens  is  not  accompanied  by  isotype  switching, 
affinity maturation or generation of memory cells.
•  Type-II TI antigens e.g.  bacterial cell wall polysaccharides.  These are 
usually highly repetitive molecules that lead to cross-linking of mlgM 
molecules on the B-cell surface and subsequent activation of the B-cell. 
The complete activation of B-cells by these type of antigens also require 
cytokines  secreted  by  TH  cells.  Affinity  maturation or  generation  of 
memory  cells  does  not  accompany  b-cell  response  to  these  antigens. 
However, there is some limited isotype switching involved.
Thymus-dependent antigens require the direct involvement of helper T cells 
for activation of the humoral response.  These are soluble protein antigens 
that  cannot  give  rise  to  effective  activation  of B  cells  on their  own.  The 
steps of activation by TD antigens are more complicated, but they result in 
isotype switching, affinity maturation and generation of memory cells.
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441.3.5  B-cell activation
When activated by an antigen,  naive B-cells are stimulated to exit  from the GO 
or resting phase of the cell cycle and begin replication and differentiation.  This 
activation involves two steps that require two types of signals:
•  Competence signals, which stimulate naive B-cells to exit from GO and enter 
the  G1  phase of the cell-cycle.  Two signals  (signal  1  and  2)  contribute to 
the competence signals.
•  Progression signals, which drive the cell from G1  to the S phase of the cell 
cycle, and ultimately to the replication and differentiation of B cells.
These two signals mediate their effects by activating signal transduction pathways 
downstream of the B-cell receptors.  The mlgM and mlgD have short cytoplasmic 
tails that are insufficient for efficient signal transduction.  To overcome this short­
coming,  mlgs associate with a disulfide-linked  heterodimer  Ig -a /lg -p to form the 
complete B-cell receptor  (BCR).  The cytoplasmic tails of lg-a/lg-/3 contain a se­
quence motif of 18 residues called the Immunoreceptor Tyrosine-based Activation 
Motif  (ITAM)  which  can  associate  with  several  downstream  intracellular  signal 
transducers like the Src and Syk tyrosine kinases when activated by crosslinking 
of mlgs.  This leads to the phosphorylation of tyrosine residues in the Ig-a/Ig~/3 
cytoplasmic tails and the activation of multiple downstream signaling pathways. 
The end result of these events is the transcriptional activation of several specific 
genes that are further needed for B-cell response to antigens.
454:
B-cell activation by thymus-dependent antigens
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TD-antigens are not  competent  enougli to induce  activation  of B-cells  on their 
own.  They are instead internalized  by B-cells that  recognize them and are dis­
played on the cell surface in conjugation with MHC-II molecules.  The antigenic 
peptide-MHC-II complex is recognized by TM«cell§ and this interaction leads to 
the formation of T-B conjugates.  This  conjugate formation  is  accompanied  by 
polarized intracellular rearrangement of the golgi and the microtubule-organizing 
center towards the site of T cell-B cell interaction.  This is believed to aid in the 
directed release of cytokines for B-cell activation.  MIgM cross-linking and interac­
tion of specific ligand-receptor molecules on the T cell and B-cell surface provides 
the competence signal needed to drive the B-cell from GO to Gl phase.  This signal 
enables B-cells to express cytokine receptors on their cell surface.  Cytokines (IL- 
2,  IL-4 and IL-5)  released from the TH-cells in a directed manner bind to these 
receptors and provide the progression signal, leading to the proliferation of these 
activated B-cells.  Subsequently, these B-cells undergo differentiation.
e   .   .
B-dell differentiation
B-cell  activation  and  differentiation  takes  place  in  peripheral  lymphoid  organs 
life  the  lymph  nodes.  These  are  specialized  organs  that  trap  antigens  circu­
lating through the lymphatic  system.  These  are  also organs  through which  T- 
lymphocytes and B-lymphoeytes constantly re-circulate.  Antigens that enter the 
body  are  processed  by  professional  antigen-presenting  cells  and  brought  to  the 
T-cell zone of local peripheral lymph nodes.  Circulating naive T-lymphocytes are
46exposed to the antigen and those displaying specific recognition for the antigen 
are trapped and activated to become TH  cells.  Circulating B-cells enter lymph 
nodes  and  most  B-cell  quickly  pass  through the  T-ceU  zone  to  enter  the B-cell 
zone {the primary follicle).  However, those B-cells possessing B-cell receptors that 
specifically bind the antigen are trapped within the T-cell zone.  The interaction 
between activated TH cells and B-cells leads to the formation of a primary focus 
of clonal expansion of both lymphocytes for several days.  .  This constitutes the 
first phase of the primary humoral  immune  response.  Many of the  cells  in the 
primary focus die by apoptosis at the end of the first phase.  Those that survive 
can have either of twp fates.  Some B-cells differentiate into plasma cells capable 
of antibody secretion  and  migrate to  the  medulla  of lymph  nodes.  Antibodies 
secreted from these plasma cels provide immediate protection to the individual.
Some of the remaining B-cells and T-cells migrate to the primary follicles where 
they proliferate and form a germinal center.  Events  that  transpire  in  germinal 
centers  serve  to provide  effective  later  response  in  case  of re-infection.  B-cells 
undergo a number of differentiation events in germinal centers including somatic 
hypermutation,  affinity maturation and isotype switching.  This serves  to select 
for B-cells displaying increased affinity for the antigen and enables these selected 
B  cells  to  perform  various  effector  functions  depending  on  the  isotype.  These 
B-cells can now differentiate further into plasma cells and memory cells.  Plasma 
cells are terminally differentiated  non-dividing cells that secrete antibodies  at  a 
high rate.  They migrate to the bone marrow where the bone marrow cells provide 
survival signals to plasma cells.  These plasma cells serve as a long-lasting source of 
high-affinity antibodies.  Memory cells are long-lived cells that provide long-term 
immunological memory.1.3.6  B-cell effector-response
The  first  encounter  with  an  antigen  leads  to  a  primary  humoral  response  (de­
scribed  above)  that  culminates  in  the  production  of plasma  cells  and  memory 
cells.  The primary humoral response is characterized by a lag phase, which is the 
time required for clonal selection, proliferation and differentiation of naive B-cells. 
Memory B-cells that arise from the primary humoral response are key to initiating 
the secondary humoral response in case of re-infection by the same antigen.  The 
secondary response is characterized by a much shorter lag period and an immune 
response of greater magnitude as compared to the primary response.
Antibodies  synthesized  in response  to  an  infection  effectively  eliminate  antigens 
by a variety of means including:
1.  Acting  as  opsonins,  thus  enabling  easy  recognition  by  antigen-presenting 
cells.
2.  Activating the complement system to bring about lysis of infecting cells.
3.  Binding to target cells and facilitation recognition by cytotoxic T-cells, thus 
leading to antibody-dependent cell-mediated cytotoxicity  (ADCC).
4.  Binding and neutralizing bacterial toxins
The  large  number  of  antibody  molecules  secreted  by  plasma  ensures  that  the 
invading pathogen is effectively eliminated.
481.4  T-cell  responses  and  cell-mediated  immune 
system
1.4.1  T-cell receptor
T-cell receptors are heterodimers composed of either aj3 chains or 7 S chains.  Like 
B-cell receptors,  the diversity of T-cell receptors is generated by gene rearrange­
ments.  The T-cell receptor is also associated with a signal-transducing complex 
CD3 which functions in a similar way to the lg-a/lg-j3 complex in the B-cell re­
ceptor.  The cytoplasmic tail of CD3 possesses the immunoreceptor tyrosine-based 
activation motif (ITAM)  by which  it  can interact  with  downstream  kinases  and 
activate downstream signal transduction kinases in response to T-cell receptor ac­
tivation.  The T-cell receptor recognizes an antigen only in a complex with MHC 
molecules.  While the variable region of the T-cell receptor binds to the peptide 
fragment in the peptide-MHC complex,  the extracellular  domains of coreceptors 
CD4 and  CD8  mediate  interaction  of the  T-cell  with  the  MHC  molecule  in the 
peptide-MHC complex.
1.4.2  T-cell maturation
T-lymphocytes  originate  in  the  bone  marrow,  but  subsequently  migrate  to  the 
thymus for development in the eighth or ninth week of gestation in humans.  Sim­
ilar to  B-cell  development,  T-cells  also  undergo  a series  of gene  rearrangements
49that give rise to cells expressing different cell surface molecules.  T-cell maturation 
starts with the expression of a pre-T cell receptor lacking surface CD4 and CD8 
(referred  to  as  the  double-negative  state)  consisting  of the  CD3  protein,  the 
^-chain of the  TCR and  a pre-Ta.  First  the TCR  /5-chain gene  rearrangement 
takes  place  following which the  expression  of CD4  and  CD8  is  induced.  These 
thymocytes are now called double-positive or CD4+8+ T-cells possessing identical 
/?-chain sequence.  It  is  only  when  these  double-positive  T-cells  stop  proliferat­
ing  that  the  TCR  a-chain  gene  rearrangements  take  place.  T-cells  that  fail  to 
make a productive gene rearrangement do not mature and they die by apoptosis. 
Those  T-cells  that  survive  are  subjected  to  the  next  phase  of selection  termed 
thymic-selection.  This step is important in ensuring that only those T-cells that 
recognize  self-MHC  molecules  in  conjunction  with  foreign  antigens  are  released 
into circulation.  Thymic-selection occurs in two phases:
1.  Positive selection of T-cells capable of recognizing self-MHC molecules thus 
resulting in MHC restriction.  This is brought about by an interaction with 
thymic epithelial cells.  During this selection,  cy-chain gene rearrangements 
continues to take place and those T-cells that fail to express  a(5-TCR with 
self-MHC recognition die by apoptosis in 3-4 days.
2,  Negative selection of T-cells possessing high-affinity receptors for self-antigens 
displayed by self-MHC molecules, or to self-MHC molecules alone, resulting 
in self-tolerance.  Positively selected T-cells interact with dendritic cells and 
macrophages bearing  class  I  and  class  II  MHC  molecules  and  self-reactive 
T-cells are eliminated by apoptosis.
50At the end of thymic-selection,  only those T-cells capable of recognizing altered- 
self cells  are able to  survive  and  mature.  By the time  these  mature T-cells  are 
released  into the periphery,  they are either single-positive  CD4+  thymocytes  or 
single-positive CD8+ thymocytes.  These T-cells that have not yet been activated 
by an antigen are termed naive T-cells.
1.4.3  T-cell activation
Naive T-cells that exit from the thymus continuously circulate between the blood 
and lymphatic system.  This includes a passage through the various lymph nodes, 
where .the chance of encountering an antigen or an antigen-presenting cell display­
ing an antigenic peptide is very high.  Upon infection by an antigen,  professional 
antigen presenting  cells ingest,  process  and display  antigenic  fragments on their 
cell surface.  These antigen-presenting cells then migrate to the nearby lymph node 
where they  are sampled by circulating naive T-cells.  The most  potent  activator 
of naive  T-cells  are dendritic  cells.  T-cells  that  are  not  specific  for  a particular 
MHC-peptide complex quickly re-enter  circulation,  while  those displaying  speci­
ficity to the complex are efficiently retained in the lymph node.  Interaction of the 
TCR with the peptide-MHC complex initiates a series of events in the naive T-cell 
leading to it’s exit from the resting GO phase and entry into the cell cycle.  This is 
accompanied by the expression of several genes whose products enable the naive 
T- cell to proliferate, differentiate, and stimulate effector functions.
The interaction between TCR and CD4/CD8 on the T-cell and the peptide-MHC 
complex  on  the  antigen  presenting  cell  alone  is  not  sufficient  to  induce  activa­
51tion of nave T-cells.  Accompanying this interaction is an antigen-nonspecific co­
stimulatory  signal  provided  by  the  interaction  between  CD28  molecule  on  the 
T-cell and B7 molecule on the antigen-presenting cell.  Co-stimulation of the T- 
cell leads to the increased production of the cytokine interleukin-2  (IL-2)  and its 
receptor  (IL-2R)  by  the  activated  T-cell,  stimulating  it’s  own  proliferation  and 
differentiation.
1.4.4  T-cell differentiation
The  initial  proliferative  phase  of T-cell  activation  lasts  for  about  4-5  days  ,af­
ter which  activated T-cells differentiate  into armed effector  T-cells  and memory 
T-cells.  Differentiated  T-cells  do  not  need  stringent  conditions  for  stimulation 
and  therefore,  any  subsequent  encounter  with  the  peptide-MHC  complex  leads 
to  a  rapid  response.  For  example,  armed  effector  T-cells  no  longer  need  a  co­
stimulatory signal for their activation.  Armed T-cells are capable of synthesizing 
all the effector molecules needed'to bring about an effective cell-mediated immune 
response.  CD4+ T cells differentiate into armed effector TH (T helper) cells while 
CD8+ T cells differentiate into armed effector TC (T cytotoxic)  cells.
CD4+ T cells are capable of differentiating into either of two subsets, which differ 
in the cytokines they produce and also their effector functions:
•  T # 1 subset which activates the cell-mediated functions of the immune sys­
tem including activation of cytotoxic T-lymphocytes.  This subset of CD4+ 
T-cells secretes cytokines like IL-2, IFN-7and TNF-(3.
52•  T #2 which functions as a helper cell for B-cell activation and secretes IL-4, 
IL-5, IL-6 and IL-10.
Activated CD8+  T cells enter into circulation and recognize and actively kill in­
fected cells by two major pathways:
1.  The release of cytotoxic proteins like perforins and granzymes.  Perforins are 
pore-forming  proteins  and  they  lead  to  cell  death  by  virtue  of disrupting 
the membrane integrity of target cells.Granzymes are lytic enzymes that are 
believed  to  trigger  a  cascade  leading  to  DNA  fragmentation  of target  cell 
and it’s apoptosis.
2.  The activation of apoptosis in target cells by engaging Fas ligand on cytotoxic 
T-cells with Fas receptor on target cell surface.
1.5  Importance of the immune system
Each and every player of the immune system is essential for effectively preventing 
infections and diseases.  This is highlighted by the manifestations of immunodefi­
ciency diseases.  These diseases can arise from a defect in any or several components 
of the immune system e.g.  defects in the phagocytic system, complement system, 
cell-mediated  immune  system  or  humoral  system.  Immunodeficiencies  affecting 
the humoral immune system can arise from defects in B-cell maturation,  defects 
in mature B cells,  ineffective  TH  cell activation or inappropriate T cell suppres­
sion.  Examples of such diseases  include X-linked hyper-IgM syndrome,  common
53variable immunodeficiency etc.  Cell-mediated  immunodeficiencies can arise from 
defects  in  T  cell maturation for  example  DiGeorge syndrome.  One of the  most 
severe immunodeficiencies arises due to defects in the humoral and cell-mediated 
branch  of the  immune  system.For  example,  defective  T  and  B-cell  maturation 
gives rise to Severe Combined Immunodeficiency Disease  (SCID)  while failure to 
express MHC molecules gives rise to the Bare-Lymphocyte Syndrome.  Such severe 
disorders usually result in an early death unless an effective treatment to replace 
the defective immune cells is given.
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Introduction to computational 
methods in bioinformatics
2.1  An introduction to genetic algorithms
The  principles  of biological  evolution  have  inspired  many  developments  in  the 
field of computer  science.  Genetic  algorithms  (GAs)  are search  algorithms  that 
mimic principles of natural selection and natural genetics to find the best possible 
solution in a search space that is large and complex.
Genetic algorithms, together with Evolution strategies (Rechenberg, 1965; Rechen- 
berg,  1973)  and  Evolutionary programming  (Fogel  et  a/.,  1966)  comprise  a field 
termed as Evolutionary computation.  GAs were originally developed by John Hol­
land and colleagues  (1975) with the following aims:
55•  To synopsize the processes involved in evolution and natural selection.
•  To design computational methods that would be based on the principle of 
natural selection.
The  core  theme  behind  GAs  has  been  searching  for  optimal  solutions  in  large 
and complex search spaces with reduced cost  and extended  functionality for ar­
tificial systems.  The  capabilities  of GAs in finding optimal solutions  have  been 
established in numerous papers  (e.g.  Axelrod  (1984),  Axelrod and Dion  (1988)) 
and the themes of adaptation and evolution appeal naturally as potential ways of 
finding solutions to complex problems where the search space is enormous.  GAs 
incorporate these philosophies through  crossover and  mutation.  In addition,  the 
fundamentally parallel nature of GAs makes it possible to examine large popula­
tions of candidate solutions to problems simultaneously.
2.1.1  Elements of a genetic algorithm
The technical terms used in describing genetic algorithms bear close semblance to 
scientific terms in biology.  Understanding the biological terms is therefore a useful 
step in understanding the basic components of a genetic algorithm.  The following 
biological terms constitute the basic terms of a GA:
Chromosome  The term  Chromosome in biology used to denote strings of DNA. 
A chromosome in a GA is used to refer to a potential solution to the problem
56being addressed and is usually encoded as a bit string (i.e.  a set of boolean 
values)  (See Section 2.1.3).
Gene  In biology, the term  Gene refers to a block of genomic sequence which per­
forms a specific function.  In GAs, a gene is either a single bit or short blocks 
of adjacent bits in a chromosome that correspond to a specific characteristic 
of a chromosome.
Allele  The biological meaning of the term  Allele  is a member  of one of several 
forms of a gene.  Each allele of a gene encodes for a specific trait or function. 
In a GA, an allele represents all the possible combinations of values at every 
position (generally a 0 or  1).
2.1.2  GA  Operators
Further,  two  commonly  used terms  in  GAs  are  parent  and  child  populations of 
chromosomes.  The parent population of chromosomes is initially created by ran­
domly  assembling  strings  with  combinations  of alleles  (0  and  1  in  GAs).  The 
quality of every chromosome is evaluated to select parents and a new population 
of  child  chromosomes  is  created  by  Crossover  and  Mutation.  These  steps  are 
described below and are commonly referred to as GA  operators:
1.  Selection:  This term is used to describe the process of choosing parent chro­
mosomes for reproduction.  Parent chromosomes are evaluated for their qual­
ity and assigned scores and selection for reproduction is biased towards par­
ents that  have  good scores.  There are several  methods of selecting parent
57chromosomes which are described in the following sections.
2.  Crossover:  Once two parent chromosomes have been selected for reproduc­
tion, a random locus is chosen and the parent substrings are spliced together 
to form a new chromosome.
3.  Mutation:  Once parent substrings have been spliced together to form a new 
chromosome, some alleles in the new chromosome are changed randomly and 
this operation is known as Mutation.
2.1.3  Encoding a problem
The  process  of representing  a  problem  to  the  computer  is  termed  as  encoding 
the problem.  Optimal encoding of problems for genetic  algorithms is central to 
their success.  Most genetic algorithms are encoded as fixed length chromosomes. 
However, the encoding scheme is largely problem-specific and a number of encod­
ing schemes  have  been devised  for  GAs.  Some of the  most prominent  encoding 
schemes are:
1.  Binary encoding:  This is the most common encoding method for a GA and 
traces  its  history  back  to the  time when  genetic  algorithms  were  first  de­
scribed by John Holland and colleagues (Holland,  1975).  Binary strings are 
used to encode potential solutions to the problem at hand with each posi­
tion containing one of two possible alleles:  0 or  1.  Holland  and colleagues 
established  that  the  binary scheme  has an inherently  parallel nature  com­
pared with shorter strings that have more than two possible alleles at every
58position.  However,  for some problems such as evolving weights in a neural 
network, the binary encoding scheme is not the best option.
2.  Many-character  and  real-valued  encoding:  There  are  some  problems  for 
which a simple binary encoding will not be adequate.  For example, when one 
of the inputs to a genetic algorithm is the torsion angle of a specific residue 
in  a protein,  it  would  be  more  convenient  to  have  a real-valued  encoding 
scheme where each position in the string is represented by numbers between 
0 and 9.  However,  there are no established standards on the best encoding 
scheme and while a real-valued encoding is useful in one problem,  a simple 
binary encoding scheme might suffice for another.  The encoding scheme will 
depend on the problem being addressed in the genetic algorithm.
3.  Tree encoding:  In this scheme, every chromosome is represented as a tree of 
objects.  This scheme  is most suited for evolving rules or programs.  It has 
an open-ended  limit  on the  search space.  However,  there  are  no standard 
benchmarks for the efficacy of this encoding method, as development efforts 
for this scheme of encoding are currently at a very nascent stage (O’ Relilly 
and Oppacher,  1995; Tackett,  1994).
2.1.4  Selection  methods
The process of selection in a GA implies the selection of parent chromosomes to 
create a new chromosome.  All selection methods are biased towards the selection 
of parents that have very high scores.  There are many different selection methods 
and their applicability depends on the nature of the problem.  The following are
59examples of the most commonly used selection methods:
Roulette wheel selection
This is fitness-proportionate selection method where the likelihood of a particular 
parent being selected is given by the fitness of the parent divided by the average 
fitness of the entire population of chromosomes.  The steps involved in this algo­
rithm are detailed below.  These steps are typically used to select  2 parents which 
are then crossed over to create a new chromosome.
•  Sort the fitnesses of the parent chromosomes in ascending order.
•  For the population of parent chromosomes, calculate the total fitness  T.
•  Select a random value  r between  0  and  T.
•  The  chromosome  whose  fitness  puts  the  sum  (when  summed  in  ascending 
order of fitnesses) above the randomly chosen value r is chosen for crossover.
One problem with Roulette wheel selection is premature convergence of the pop­
ulation of chromosomes.  Initially,  the population is quite diverse.  Some parents 
that score significantly better than others are selected frequently and, when crossed 
over,  result  in the same set of child chromosomes being created.  This can cause 
the population to converge in a local minimum and become saturated.
60Sigma selection
Several  techniques  have  been  developed  to  overcome  the  problem  of premature 
convergence of the chromosome population.  One such strategy is Sigma selection 
(Forrest, 1985).  In this selection method, the use of the raw scores of the chromo­
somes is avoided.  Instead,  an  expected  value  is calculated  for each chromosome, 
the value of which depends on the score of the chromosome,  the mean score for 
the population  and  the  standard  deviation  in the  score  of the population.  The 
expected value is calculated as:
=   <
1 +  X^ # 1  if o(t)  7^ 0
Mt)  (2.1)
1  if a(t)  =  0
where e(i,t)  is the expected  value for chromosome  i  at  time  t,  f(i) is the fitness 
(or score)  of chromosome  i,  f(t) is the average fitness of the population at time  t 
and a(t)  is the standard deviation of the population fitness at time  t  (Mitchell, 
1996).
Melanie Mitchell reasons that, at the beginning of the GA when the fitness scores 
are fairly divergent,  the expectation value for chromosomes with high scores will 
not  be  much  higher  than  the  average  score  of the  population  (f ( t)).  However, 
after several  time steps  of the  GA  when  the  population  starts  to  converge,  the 
standard deviation in fitness levels (a(t)) is small, and the chromosomes with high 
scores will stand out.
61Boltzmann selection
Boltzmann selection is only slightly different from Sigma selection in that a ‘tem­
perature’ component is involved while calculating the expectation value for every 
chromosome.  A high temperature factor ensures that all genes have roughly equal 
chances of being selected for crossover.  At the beginning of the GA run, the pop­
ulation of chromosomes is likely to be more diverse and therefore the variance in 
their  scores  is  also  high.  In  order  to  boost  variability  in the  population  at  the 
earlier stages of the  GA,  a high temperature factor  is applied in calculating the 
expectation factor.  However, as convergence occurs, the variance in scores reduces 
and the temperature factor is also reduced.
The expectation value for every chromosome is calculated as follows:
/(*)
e(M ) =  6  L   (2-2)
H(e  t  )
where f(i) is the score of chromosome i, T is the temperature, fi(e^ ) denotes the 
average score of the entire population at time  t.
Rank selection
This scheme was originally developed by Baker (1985) in which every chromosome 
is assigned a rank depending on its score.  Assuming a population of N chromo­
62somes which  are all distinct,  the  highest-scoring  chromosome is assigned  a rank 
of N and the lowest-scoring chromosome is assigned a rank of 1.  In this way, the 
need for absolute scores is eliminated.
The procedure of selecting two parents for crossover is similar to Roulette-wheel 
selection with the difference being that scores are replaced by ranks.  Every chro­
mosome in the population is assigned a rank between 1 and N -  the chromosome 
with the lowest  score is given a rank of  1  and the chromosome with the highest 
score is given a rank of N.  The following steps are performed twice to select two 
parents for crossover.
•  Sort the parent chromosomes in ascending rank order.
•  For the population of parent chromosomes,  calculate the total rank  T.
•  Select a random value r between  0 and  T.
•  The chromosome whose rank puts the sum (when summed in ascending order 
of ranks)  above the randomly chosen value r is chosen for crossover.
Tournament  selection
Several of the selection methods described above employ time-consuming computa­
tions to calculate the probability of selection of every chromosome in a population. 
For example,  in Rank-based selection,  chromosomes are required  to be sorted in 
increasing  order  of their scores so that  selection can be biased towards  chromo­
somes that have high scores and therefore low ranks.  Similarly in Sigma selection,one  round  of calculations  is used  to  calculate the  mean  score  of the  population 
and another to calculate the probability of selection for each chromosome in the 
population.
Tournament selection avoids these problems by employing simple selection proce­
dures.  The selection of chromosomes for crossover are performed as follows:
•  Select  N  chromosomes at random from the population.
•  Choose a random number  r between  0 and  1.
•  If  r  is  less  than  k  (a  user-defined  parameter  of the  algorithm),  then  the 
most fit of the  N  chromosomes is chosen.  Otherwise,  one of the remaining 
chromosomes is chosen at random.
2.1.5  Replacement  strategies
Once child chromosomes have been created after crossover of parent chromosomes, 
the process by which the parent  and child chromosomes are combined to yield a 
new  population  is  termed  as  replacement.  The  two  most  common  replacement 
strategies are:
64Generational replacement
This  is  the  oldest  replacement  strategy  and  came  into  existence  when  genetic 
algorithms were originally developed.  This method  mimics the biological model 
in which a whole population of parents are replaced by children.  In this method, 
the population of parent chromosomes is completely replaced by a population of 
child chromosomes.
Steady State Replacement
The  Steady  State  Replacement  strategy  is  a slight  variation  of generational  re­
placement.  In this method, only a few individuals from the parent population are 
replaced by individuals  from the child  population.  The  replaced individuals  are 
usually the  least-fit  parents.  This  method  is used  in systems where  incremental 
learning is important and members of a population collectively represent the so­
lution to a problem (See Sywerda (1989), Sywerda (1991), Whitley  et al.  (1989), 
De Jong and Sharma (1993)).
Elitist  replacement
This  method  is  a  slight  variation  of the  Steady  State  Replacement  method  in 
which  the  best  genes  from  the  common  pool  of child  and  parent  chromosomes 
are retained.  The principle behind this replacement strategy is to retain the best 
chromosomes from every generation so that they are not lost in future generations
65during crossover and mutation to create new populations.  This method has been 
shown  to  be  very  effective  in  significantly  improving  the  performance  of a  GA 
(De Jong,  1975).
2.2  Introduction to artificial neural networks
2.2.1  Machine learning approaches
Machine learning approaches were developed with the aim of identifying patterns 
in  data  where  they  cannot  be  easily  described  by  a  set  of mathematical  rules. 
However,  the  field  of machine  learning  is  vast  considering  that  learning  can  be 
applied to several types of problems such as image recognition, classification prob­
lems, natural language processing and robotics, to name but a few.  In my PhD, I 
have used artificial neural networks along with genetic algorithms to predict the 
packing angle at the interface of The light chain and heavy chain variable region 
from the nature of residues in the interface (See Chapter 5).
The most prominent machine learning techniques are:
Support vector machines  (SVMs)  Support Vector Machines are based on Vap- 
nik’s statistical learning theory  (Vapnik, 2000).  SVMs are principally binary 
classifiers i.e.  they classify a result as belonging to one of two possible out­
come sets.  SVMs are therefore not suitable for the prediction of the packing 
angle.
66Decision trees  (DTs)  Decision  trees  are  usually  used  to  create  a set  of rules 
from which a classification can be made.  They accept a set of properties as 
input and output a series of yes/no decisions (Russell and Norvig, 1995) and 
are therefore not suitable for the prediction of packing angle.  DTs are most 
often used in data mining applications and in classification problems.
Bayesian networks  (BNets)  Bayesian  networks  are  based  on  the  Bayes  the­
orem  (Bayes,  1763)  and  are  amongst  the  most  powerful  machine  learning 
techniques.  However,  a requirement  for the  use  of BNets  is that  the  data 
to be predicted must resemble a normal distribution.  As will become clear 
from Section 5.1 in Chapter 5, the packing angle distribution is indeed nor­
mal.  The use of BNets for the prediction of packing angle was therefore a 
possibility.
Artificial neural networks  (ANNs)  Artificial neural networks assume no prior 
distribution of data and can be applied to learn any type of data.  I decided to 
use ANNs to predict the packing angle as there was more technical expertise 
in the group for ANNs compared with BNets.
2.2.2  Artificial neural networks
An  Artificial  neural  network  (referred  to  as  just  Neural  network)  is  a  system 
inspired by the working of the neural system.  The biological nervous system can be 
imagined as consisting of  neurons (nerve cells) which are connected to one another 
through connections or synapses.  Similarly, artificial neural networks are made of 
neurodes which are the basic functional units.  The schematic representation for a
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Figure 2.1:  Schematic representation of a neurode in an artificial neural network. 
Figure shows the inputs to the neurode XI,  X2,  X3...Xn, weights of synapses  Wl, 
W2,  W3... Wn, summation function cr, bias  b, activation function 0 and output  Y.
68neurode in an artificial neural network  (ANN)  is shown in Figure  2.1.  The main 
components of an artificial neural network are:
1.  Synapses:  Synapses form the interconnects between neurodes.  Each synapse 
that  connects  a certain  input  to the  neurode  is  characterised  by a weight. 
For example, in Figure 2.1, the weight for the synapse that links the second 
input  to  the  synapse  (X 2)  is  represented  as  W2.  For  every  neurode,  the 
input  signal  Xi  is  multiplied  with  the  corresponding  synaptic  weight  Wi. 
These quantities are summed up for all the inputs and together with the bias 
function  b will determine the output of the neurode.  It must be emphasised 
that the synaptic weight may be a positive or negative value.
2.  Adder:  An  adder  adds  the  product  of all the  input  signals  and  the  corre­
sponding synaptic weights.  In Figure 2.1, this is represented as E.
3.  Bias function:  This function is capable of increasing  or reducing the input 
to the activation function.  The bias function is shown as  b in Figure  2.1.
4.  Activation function:  This function limits the output amplitude of a neurode 
and is shown as 4>(.)  if Figure 2.1.
Consider for example the neurode  kth  in an artificial neural network.  The input 
to the neural network as summed by the adder  (u^)  is given by:
m
zik  ^  WkjXj  (2-3)
3=1
69Further, the output of the neurode is given by yk:
yk =  (!>{vk)  (2.4)
where  vk  is  referred  to  as  the  induced  local field  or  the  activation potential  vk 
generally contains a bias function such that:
Vk =  uk + bk  (2.5)
The  bias  function  in  Equation  2.5  has  the  effect  of applying  an  affine  transfor­
mation to the additive  input to the neurode  uk.  It  must  be noted that the bias 
function is a parameter that is external to the neurode and may be either a posi­
tive or a negative value.  Depending on the value of the bias function bk, the plot 
of vk vs.  uk may not pass through the origin  (Figure 2.2).
In the actual implementation of an artificial neural network,  the bias function bk 
of a neurode  k is fed as an input signal Xq which is given by:
x0 = + 1  (2.6)
and the weight of the synaptic connection for this input is:
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Figure 2.2:  Plot of induced local field  (Vk) vs.  the adder function  (Uk)
71W0 = bk (2.7)
The induced potential vk and output yk of a neurode  k may be reformulated as:
vk  =   Y l WkjX3  (2.8)
j= 0
Vk = H vk)  (2.9)
A  neural  network  typically  consists  of a  three-layered  architecture  as  shown  in 
Figure  2.3:  the  Input  layer,  Hidden  layer,  and  the  Output  layer.  Each  layer 
consists  of a set  of neurodes  with  interconnects  between  the  neurodes  in  every 
level.  The interconnects that link the neurodes are the synaptic connections and 
are characterised by weights described above.  Neural networks  learn by adjusting 
the weights of the synaptic links between the neurodes in each layer.
2.2.3  The process of learning:  Learning algorithms
There are primarily two types of signals in fully-connected neural networks  (such 
as that shown in Figure 2.3)  (Parker,  1987):
•  Functional signal:  A functional signal is one that enters the artificial neural
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Figure 2.3:  Three-layered architecture of a neural network.  Each neurode of the 
input  layer  is  connected  to  each  neurode  in  the  hidden  layer  which  in  turn  is 
connected to each neurode in the output layer.
network through the input  layer,  propagates through the hidden layer and 
emerges as the output at the output layer.  The output from every neurode is 
characterised by the inputs applied to the neurode and the synaptic weights 
that lead to the neurode.  These signals are called functional because they 
form the  output  signal,  in  addition  to determining  the  output  from  every 
neurode in the neural network.
•  Error signal:  An error signal is the opposite of a functional signal.  It is used 
to refine errors made during the learning process.  Error signals originate in 
the output layer and back-propagate to the input layer.  They are so called 
because calculation of the error signal at every neurode involves computation 
of an error function in some form.
The process of learning in an artificial neural network involves adjusting the synap­
tic weights for inputs to every neurode.  One of the most common learning tech­
niques is called Back-propagate as it involves the adjustments starting in the last 
layer of the neural network.  The following equation summarises the total weight 
change in the artificial neural network:
73Awji  (n)  =  ■ q 5 j{n)yi(n) (2.10)
The notations used in the equation are as follows:
1.  n indicates the time step and usually implies a specific  training cycle.
2.  i and j indicate neurodes in the network such that neurode j is in a layer to
the right of neurode  i.
3.  AWji(n)  is the change in weight (or correction) applied to the weight Wji(n) 
(weight of the synaptic connection that links neurodes  i and j ).
4.  7] is the learning-rate constant of the back-propagate algorithm.
5.  Sj(n) is the error introduced by neurode j  at time step  n.
6.  yi(n)  is the output of neurode %  at time step  n.
Updates to the weights are carried out using steepest descent minimisation through 
the following formula (Rumelhart  et al.,  1986):
Wji(n'+ 1) = Wji(n) —  r}AE(w(n))  (2-11)
where Wji(n + 1) is the weight at time step n+1, Wji(n) is the weight at time step 
n,  r)  is the  learning  constant,  and  AE(w(n))  is the  sum of square  errors  in the
74weights at time step  n.  For quick convergence,  the rate constant  77 is usually set 
to a value between 0 and 1.  However, it is known that this method is very slow.
A  modification  to  the  Back-propagate  algorithm,  Resilient propagate,  was  pro­
posed  by  Reidmiller  and  Braun  (Riedmiller  and  Braun,  1993)  in  1993.  Unlike 
Back-propagate,  Resilient  propagate  (Rprop)  implements  dynamic  learning-rate 
constants during neural network training.  Rprop has been shown to be far supe­
rior to other learning algorithms in terms of both speed  and  quality of learning 
(Schiffmann  et al,  1993).
A  problem  that  has  often  been  cited  for  the  Back-propagate  algorithm  is  that 
it gets stuck in local minima.  Small changes to the synaptic weight  could cause 
an  overall  increase  in  the  cost  function  (here,  the  negative  overall  error  rate). 
However,  there may also exist  another set of synaptic weights  where the overall 
error  rate  is  lower,  causing  the  algorithm  to  be  caught  in  local  minima.  This 
problem has been overcome in Resilient propagate wherein the size of the weight 
change is determined by a weight-specific update value, given by:
A w lf  =
where 8E(n)/8wij  denotes the partial derivative of the sum-of-square error with 
respect to the weight  of the synaptic link connecting neurodes  i  and j.  Updates 
to the weights are carried out using the formula:
— Aij(n),  if8E(n)/8wij > 0
+Ay(n),  ii8E(n)/ 8wij  < 0  (2-12)
0;  otherwise
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A w i f  -{rj  A<j(n); tfSEjn-l)  SEjn-zl)  < q  (2.13)
A/»n. .  *   A-i#i.  .  '  '
Ay (n —  1); otherwise
Therefore every time the sign of the partial derivative of the weight  (itfy) changes
minimum value),  the update-value  Ay(n)  is decreased  by the value r}~.  On the 
other  hand,  if  the  sign  of the  derivative  is  retained,  then  the  update  value  is 
increased to accelerate convergence.
RProp requires the following parameters to be set:
1.  Increase factor r]+  (Default)  =  1.2.
2.  Decrease factor rj~  (Default)  = 0.5.
3.  Initial update value A0  (Default)  =0.1.
4.  Maximum weight step used to prevent the weight from becoming too large 
A  max  (Default)  = 50 (Riedmiller and Braun,  1993).
2.3  Introduction to protein sequence analysis
After the completion of several genome sequencing projects, sequences of nearly 6.5 
million  proteins  are  available  (http://www.ncbi.nlm.nih.gov/RefSeq/).  The
(implying  that  the  last  update  was  too  big  and  the  algorithm  crossed  a  local
76most thorough way of annotating protein function is using biochemical analysis. 
However,  this is impossible on a genomic scale  considering the costs involved  in 
annotating the function of nearly 6.5 million proteins.
Proteins that show significant  amino acid sequence similarity tend to be homol­
ogous  and  have  similar  or  related  function.  Sequence  analysis  tools  have  been 
developed with the goal of helping to identify homologous proteins.  Some of the 
applications of sequence analysis tools include:
•  Comparing protein sequences to identify homologous proteins.
•  Tracing the evolution of a protein.
•  Identifying conserved regions in the sequence of a protein.
An  important  focus  in  Bioinformatics  has  been  the  development  of protein  se­
quence  comparison  methods.  These  may  be broadly classified  into  one  of three 
types:
•  Pairwise sequence alignment methods to compare two protein sequences.
•  Fast  heuristic  alignment  methods that  compare  a protein sequence  with a 
database of protein sequences.
•  Profile-based search methods to compare a protein sequence with a database 
of protein sequences.
•  Multiple sequence alignment methods to identify regions of conservation in 
the sequences of homologous proteins.2.3.1  Pairwise  sequence alignment
Considering that there are only 20 amino acids,  it is possible that two randomly 
chosen proteins would have a certain number of similar sets of residues entirely by 
chance.  These statistics must be employed to identify significant relationships.  A 
requirement  in establishing regions of similarity between two proteins is to allow 
insertions or deletions in the sequences, commonly referred to as indels.  However, 
the task of identifying indels to align two protein sequences optimally is difficult. 
This is particularly the case when the two proteins are remotely related and have 
very low sequence similarity.
Needleman and Wunsch  (1970)  developed an algorithm using dynamic program­
ming to align two protein sequences automatically.  The procedure uses an n x m  
matrix to score the identities, or similarities, of residues being compared, where n 
and m are the number of amino acids in the two protein sequences.  The main steps 
involved in the Needleman and Wunsch algorithm are described below (Orengo et 
al., 2003):
1.  Scoring the matrix - The 2-dimensional matrix is initially populated with a 
set of scores to represent the identities or similarities of residues associated 
with each  position in  the matrix.  In  the simplest  case,  this  can  be either 
1  or  0 where  1  would  indicate  identical residues  (and therefore  include  all 
residues on the diagonal)  and 0 otherwise.  Another way of populating the 
scores is by using a substitution matrix such as the BLOSUM (Henikoff and 
Henikoff,  1992)  or  Dayhoff matrix  (Dayhoff  et  al.,  1978).  These  indicate
78the probability of one residue substituting for another residue  in a protein 
over time.
2.  Accumulating the matrix -  Once the score for each cell in the 2D matrix has 
been computed, the scores are accumulated from the bottom right corner of 
the matrix.  The best score for a cell represented by the coordinates  (i,j)  is 
selected using the equation:
where  Si+ij+i  indicates the score of a diagonal move from cell i + 1J + 1,
the  introduction  of a  gap  in  one  of the  sequences.  Adding  a  gap  to  the 
alignment is penalised by imposing a gap penalty score of the form:
where o is the gap opening penalty, e is the gap extension penalty, and n is 
the length of the gap.
3.  Tracing the highest scoring path -  Once the score for every cell in the matrix 
has been calculated, a trace-back is performed to find the optimal alignment 
between the two sequences.  This is done by starting with the highest-scoring 
cell near the top  left  corner and tracing the path through which the score
Sij  =  Sij + m ax  Si (2.14)
Si+mj+i is the score of a move from the j + Ith row, and Si+i,j+m is the score 
of a move from the i + 1th column.
An off-diagonal move from either the j + Ith row or i + 1th column,  implies
g =  o +  ne (2.15)was  accumulated  towards  the  bottom  right  corner  of the  matrix.  An  off- 
diagonal  move  implies  the  introduction  of a  gap  in  the  alignment  of one 
of the  sequences.  This  is  in  turn  equivalent  to  an  insertion  in  the  other 
sequence.
While the original dynamic programming method can be slow while aligning long 
sequences, the process may be speeded up by using a window for the matrix.  This 
implies that the score  accumulation and traceback is performed only within the 
window  and  the  length  of insertions  or  deletions  is  restricted  by  the size  of the 
window.
Smith and Waterman  (1981)  developed an alternative algorithm which identifies 
a local region of similarity  (local alignment)  between two protein sequences.  The 
score for each cell in the matrix when aligning sequence  a and  b is calculated by:
Si+l,j+l + S(hj)
max(Si+ k j) ~9  ,
(2.16)
max(Sid+1)  -  g 
0
where  5,  i,  j,  k,  m,  and g  have the same meaning as in the  Needleman-Wunsch 
algorithm.  When  the  score  of a  cell  becomes  negative,  then  a  score  of zero  is 
assigned.  The  traceback  step  starts  at  the  cell  in  the  matrix  with  the  highest 
score and is terminated when the cumulative score falls to zero.  While the highest 
score in the Needleman-Wunsch algorithm is always on the outside the matrix, in
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Sij = max <the Smith-Waterman algorithm, it can appear anywhere in the matrix.
2.3.2  Searches against  a database of proteins
While dynamic programming results in the most reliable alignment, the algorithms 
are computationally expensive and are not practical when trying to align a protein 
sequence with sequences in a large database with the aim of identifying homologues 
or  finding regions  of local alignment.  Alternative  methods  have  been  developed 
using  heuristics  with  the  aim  of improving  the  speed  of searches  against  large 
databases and  identifying  homologues.  These  methods  help  in the  identification 
of putative  homologues  by  assigning  statistical  scores.  The  two  main  heuristic- 
driven  approaches  to  search  against  databases  of proteins  are  FAST  A  (Pearson 
and Lipman,  1988)  and  BLAST  (Altschul  et a/.,  1990).
FASTA and  BLAST
The FASTA program developed by Pearson and Lipman (1988) is used to compare 
a protein  sequence  with  a database  of protein  sequences.  It  uses  the  concept  of 
words  (or tuples)  to identify regions of similarity between two proteins.
The  working  of the  FASTA  program  is  shown  in  Figure  2.4.  FASTA  uses  the 
concept of words where a word represents a set of contiguous residues in a sequence. 
Normally,  a word length of 2 residues is used for proteins.  The sequence  A to be 
compared  against  a  database  of sequences  is  first  split  into  words.  In  addition,
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Figure  2.4:  Steps  involved  in the  FASTA  search  program:  (a)  Find  all  identical 
words  in  the  query  sequence  (A)  and  sequence  in  the  database  (B)  (b)  All  the 
identical  words  are  scored  using  a substitution  matrix  (c)  Identical  words  with 
a score  above  a threshold  value  are joined together  using gaps  and  (d)  The two 
sequences  are  aligned  using  the  Smith-Waterman  algorithm  to  obtain  optimal 
alignment.  Diagram  taken  from  http://www.cbi.pku.edu.cn/im ages/fasta_ 
algorithm .gif.
82to  facilitate  the  comparison  of the  query  sequence  with  every  sequence  in  the 
database, the following steps are performed:
1.  Every sequence  B in the database is split into its constituent words.
2.  The words in A and B are compared and all identical words between the two 
sequences are identified and joined into contiguous stretches
3.  The  best  stretches  are  scored  using  a  substitution  matrix  (such  as  PAM) 
and words with a score below a threshold value are rejected.
4.  All identical words with scores above the threshold value are joined together 
using gaps.
5.  Smith-Waterman dynamic programming is used to perform a local alignment 
between the sequences using a narrow window around the diagonal identified 
in the previous steps.  This provides an optimised score.
The use of dynamic programming allows the calculation of the overall similarity 
measure  between  the  two  protein  sequences.  The  significance  of the  similarity 
measure is estimated by assessing how frequently the similarity score is observed 
when comparing the query sequence against a database of unrelated sequences.
BLAST
BLAST (or gapped BLAST)  (Altschul  et al.,  1990) performs similar steps to iden­
tify  homologues  of a  query  sequence  in  a  database.  For  a word  of length  3,  all 
possible words that score above a threshold value are found and these words are
83then identified in a database.  The regions spanning the words are extended with­
out  introducing  gaps  while  the  score  remains  above  a threshold  value.  If suffi­
ciently good hits are found, then a Smith-Waterman alignment is performed.  The 
main practical difference between BLAST and FASTA is that BLAST requires the 
database to be indexed prior to searching.  This is done to increase the speed of 
searches.
Statistical methods to assess significance of a match
Sequence  identity alone cannot establish whether  a hit  is  a true homologue of a 
query protein.  For example,  it  has been established  that  in the twilight  zone of 
25% sequence identity or lower, it is impossible to tell from sequence identity alone 
whether a hit is a remote homologue, or not a relative at all.  This has led to the 
development of statistical measures to assess the significance of a match during a 
database search.
An assumption in the early versions of FASTA was that the distribution of pair­
wise identities between unrelated sequences was normal.  Hence, initial versions of 
FASTA used Z-scores to report the likelihood of a match between two sequences. 
A  Z-score  gives  the  number  of standard  deviations  of a  certain  value  from  the 
mean  of a  normal  distribution.  A  high  Z-score  value  (e.g.  15)  implied  a  high 
probability of the  hit  being a homologue of the  query protein.  However,  subse­
quent work showed that the distribution of pairwise identities between unrelated 
sequences is an extreme value distribution  (Mott,  1992; Altschul and Gish,  1996) 
(See Figure 2.5 taken from Hobohm and Sander  (1994)).  The tail of the extremeSimilarity Score Distribution
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Figure  2.5:  Extreme  value  distribution  of 200000 sequences  with  less  than  25% 
sequence identity randomly chosen from the PDB. Image taken from h ttp : //www. 
biomedcentral.eom/1471-2105/8/388/figure/F9  (Dundas  et a/., 2007).
value distribution tapers more slowly compared with a normal distribution and is 
directly proportional to the log of the frequency with which a pairwise sequence 
identity score is observed.  The frequency information can be used to estimate the 
probability of a hit being a true homologue of the query protein.  This is reported 
by the P-value.  For example, a P-value of 0.0001 implies that 1 in 10000 sequences 
giving this score or above would be an incorrect hit and not a true homologue of 
the query sequence.  This statistic  is extended  to give  an  E-value  (the expected 
number  of hits  with  a  given  score  or  above  in  a  given  database)  which  is  cal­
culated  by integrating the linear  transformation of the tail of the extreme value 
distribution curve.  In general,  low E-values  (typically less than 0.01)  indicate an 
evolutionary relationship between a hit and the query protein (Pearson,  1998).
852.3.3  Profile-based search methods
A profile is a mathematical representation of a set of related sequences.  For every 
position in the alignment of a set of proteins, a profile contains the probability of 
each amino acid occurring at that position.
A profile is constructed from a multiple sequence alignment of three or more related 
proteins.  Profiles help in identifying the evolutionary conservation of residues with 
specific properties at different positions in the sequence.  If a specific amino acid 
is highly conserved at a certain position, then the amino acid receives a high score 
for that position.  At positions that are not well conserved, all amino acids receive 
low scores.  In addition to profiles,  there are other mathematical representations 
to score  the  conservation  of residues.  These  include  motifs  (regular  expressions 
that  represent  patterns  of  a  sequence,  e.g.  Prosite  (Hulo  et  al.,  2008)),  and 
Hidden  Markov  models  (Schneider  et  al,  1986;  Gribskov  et  al,  1987;  Staden, 
1988; Tatusov  et al,  1994; Yi and Lander,  1994; Bucher  et al,  1996;  Altschul  et 
al,  1997; Durbin,  1998).
An important profile-based database search procedure is the Position-Specific It­
erative Basic Local Alignment and Search Tool (PSI-BLAST).  This program was 
created by Altschul and colleagues  (Altschul  et al,  1997)  as an extension to the 
BLAST program.  The steps involved in PSI-BLAST are as follows:
•  A protein sequence (P) of interest is compared with a database of sequences 
by performing a BLAST search between P and every sequence in the database.
86•  All hits with an E-value below a certain threshold are multiply aligned and 
a profile is constructed from the multiple alignment.
•  In the next iteration, the profile is used to search the database and identify 
new homologues.
•  After  each  iteration  when  a new  homologue  is  identified,  a  new  profile  is 
constructed and further iterations are performed using the modified profiles.
•  The iterations are terminated when no new homologues  are identified  or a 
specified limit is reached.
In Chapter  3,  pairwise sequence  alignments  have  been performed  using the pro­
gram ssearch33 to estimate the degree of humanness of antibodies.  Chapter 4 de­
scribes a profile-based method to identify the start and end of framework regions 
of antibodies and apply numbering to antibody sequences.  Finally, Chapter 5 de­
scribes a method using artificial neural networks using to predict the packing angle 
at the interface of the  light chain-heavy chain variable region from a description 
of the  interface  residues.  However,  since  the  available  training  data are  limited 
compared with the number of potential interface residues,  a genetic algorithm is 
used to pick the a subset of interface residues in which the penalty function is the 
performance of the neural network,  in order to select  an optimal set of interface 
residues.
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Assessing humanness of antibody 
sequences
Rodent (particularly mouse) monoclonal antibodies are widely used in engineering 
antibodies for the treatment of human disease because they may be produced with 
high binding affinity to a wide range of antigens.  The  use of mouse  monoclonal 
antibodies in the human system gives enormous scope for the treatment  and di­
agnosis of several diseases  (Glennie and Johnson, 2000).  For example, Dyer  et al. 
(1989) have reported the effectiveness of treating patients with Chronic Lympho­
cytic Leukaemia (CLL)  with a rat antibody, CAMPATH-1G.  The administration 
of the  antibody  led  to  a significant  clearance  of tumour  cells  in  patients.  How­
ever, the promulgation of therapy using monoclonal antibodies from other species 
(typically mouse or rat)  for human disease  has been slow owing to some  impor­
tant  problems.  First,  in  most  cases,  the  original effector  function of the  rodent
88antibody is not retained after introduction into the human system  (Clark  et al., 
1983)  and second, rodent antibodies are immunogenic in the human system.
This Human Anti-Mouse Antibody (HAMA) response (Schroff et al., 1985; Shawler 
et  al.,  1985)  or  Anti-Antibody  response  (Glennie  and  Johnson,  2000)  prevents 
repetitive administration of the antibody for treatment and may lead to anaphy­
lactic shock.  There are two main ways in which one can approach this problem - 
one could use fully human antibodies produced in phage libraries  (Winter  et al., 
1994;  Low  et al.,  1996)  or transgenic  mice  (Briiggemann  et al,  1991;  Mendez  et 
al,  1997;  Vaughan  et al,  1998),  or one could engineer rodent antibodies so that 
they appear more human.
Several strategies now exist which permit antibodies to be engineered in a way such 
that  they retain the specificity  of the rodent  antibodies while seeming  less  alien 
to the human immune system.  They may broadly be  classified  as chimerization 
(Neuberger  et al,  1984; Boulianne  et al,  1984)  and humanization  (Jones  et al, 
1986; Riechmann  et al,  1988).'
Chimerization involves grafting the Fv region of a rodent antibody onto the con­
stant  region  of a human  antibody.  However,  chimeric  antibodies  still  contain  a 
substantial  rodent  component  and  may  still  lead  to  a  HAMA  response.  In  hu­
manization, the rodent content is minimised by grafting only the CDRs from the 
rodent  antibody  onto  a  human  framework.  Generally  a  small  number  of other 
framework residues need to be changed to the equivalent rodent residue in order 
to restore binding.  Roguska  et  al  (1994)  proposed an alternative technique  of 
‘resurfacing’ where they replace solvent accessible residues in chimeric antibodies
89with human residues.
Clark (2000) has also questioned the value of more elaborate humanization proto­
cols over chimerics.  Data on approval rates for monoclonal antibodies  (Reichert, 
2001) show that 74% of chimerics have completed Phase III trials with 24% of these 
gaining FDA approval.  In contrast, only 34% of humanized antibodies have com­
pleted Phase III trials with 25% gaining FDA approval.  Thus,  overall,  chimerics 
have been at least as successful at getting into the clinic as humanized antibodies 
and a metric for assessing humanness may be of help in selecting rodent variable 
domains that could be used effectively as chimerics without the additional effort of 
humanization (also a patent minefield).  It may also be valuable in selecting human 
frameworks for use in humanization.  One can ask whether some rodent variable 
domains are more human-like than others, and indeed, whether they may be more 
typically human than some unusual human antibodies.  In one case, a murine anti­
body has been approved for therapy (Orthoclone (OKT3),  Ortho Biotech (Glennie 
and Johnson, 2000)).
The  general  question,  therefore,  is  how  typical  an  antibody  sequence  is  of the 
expressed  human  repertoire.  To answer  this question,  I  have derived  a  ‘human­
ness’  statistic.  In the first part,  the mean and standard deviation of human and 
mouse sequences are compared.  Further, a Z-score statistic, to assess how typically 
human an antibody sequence  is of the expressed  human repertoire,  is described. 
Human and mouse variable regions have been compared with the use of this statis­
tic  and  the  analysis  has  been extended  to the  CDRs of light  and  heavy  chains. 
Part of the work described in this chapter has been published in Abhinandan and 
Martin  (2007).
90Type of 
database
Number of sequences 
Mouse  Human
Lambda class 62 1003
Kappa class 1292 645
Heavy chain 1562 1847
Table 3.1:  Number of sequences in each dataset extracted from Kabat database.
3.1  Preparation of the dataset
Sequences of antibody variable regions were extracted from the last public release 
of the Kabat database  (July 2000)  using KabatMan  (Martin,  1996).  Sequences 
were separated on the basis of chain  (light  and heavy  chain),  class  (lambda and 
kappa class for light chains)  and species  (mouse and human).  Table 3.1 gives the 
number of sequences used in the analysis.  The program ssearchSS from the FASTA 
package  (Pearson and Lipman,  1988)  was  used to extract  pairwise identities  be­
tween the antibody sequences.  Graphs were plotted  using  GNUPLOT (http:// 
www. gnuplot. org/) and GRACE (http: //plasma-gate. weizmann. ac. il/Grace/).
3.2  Comparing pairwise identities of human and 
mouse sequences
The  mean  pairwise  identity  Xi  for  sequence  i  in  a  database  of  m  sequences  is 
calculated as:
m
X/  % ij
-   _
m —  1
(3.1)
91where Xij is the pairwise identity between sequence i and j.  The standard deviation 
Gi for sequence  %  in a database of m sequences is calculated as:
Gi  = \
£ X i)2
m   —  1
(3.2)
Xij  is  the  pairwise  sequence  identity  between  sequence  i  and  j,  Xi  is  the  mean 
pairwise identity for sequence z,  and m is the number of human sequences in the 
dataset.
In the first step, I wanted to compare the diversity of mouse and human antibody 
sequences.  In order to do this,  I plotted the mean and standard deviation of ev­
ery mouse and human sequence when aligned with every other mouse and human 
sequence in the dataset respectively.  By comparing the mean and standard devi­
ation of mouse and human sequences,  I wanted to see if the points would cluster 
together depending on species and further, whether there were any common char­
acteristics between mouse and human antibodies.  The algorithm for this is shown 
in Figure 3.1.
Every mouse sequence from a specific dataset was taken and queried against the 
database of mouse sequences using ssearchSS.  A very high e-value cutoff of 100000 
was used to ensure that pairwise identities between every pair of sequences were 
returned by ssearchSS and considered in the calculations.  From the set of pairwise 
identities, a mean pairwise identity was calculated as shown in equation 3.1.  From 
the individual pairwise identities and mean sequence identity, a standard deviation
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Figure  3.1:  Algorithm  to  compute  the  mean  and  standard  deviation  for  every 
sequence in the dataset  (Table 3.1).
93was  calculated  as shown  in equation  3.2.  All the  above steps were  repeated  for 
the human sequences and the distribution of standard deviation against the mean 
percentage identity for the mouse and human sequences were plotted separately. 
These  distributions were plotted for each  dataset  (heavy chain  and  lambda and 
kappa class for the light chain).
Figure 3.2 gives the plot of standard deviation vs.  mean pairwise identity for the 
mouse and human antibody sequences.  It is clear from the graphs that the data 
points  for  the  human  and  mouse  antibodies  form  distinct  clusters.  In  the  case 
of lambda class  light  chains,  there  is  a clear  separation  between  the  mouse  and 
the  human plots.  While  the  human antibodies  tend to  have  a mean percentage 
identity between 40 and 70% and a wide range of standard deviations, the plot for 
the mouse sequences  shows that the mouse lambda light  chains  have  high mean 
percentage identity while showing lesser sequence diversity.  The graph for kappa 
class light chains shows that although the data points for the mouse and human 
sequences are distinct, a few points overlap.  It may also be observed from the plot 
that the mouse sequences are more diverse than the human sequences which is in 
slight contrast with the lambda class where the human antibodies are more diverse 
than their murine counterparts.  The graph for the heavy chains shows a virtually 
complete overlap of both murine and human antibodies.  This also establishes that 
both human and murine heavy chains are equally diverse.
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Figure  3.2:  Plot  of the standard  deviation vs.  the  mean  percentage  identity  of 
mouse and human sequences in (a) Light chain lambda class (b) Light chain kappa 
class and (c)  Heavy chain.
953.3  A statistic to assess ‘humanness’ of antibody
sequences
In the next section, I analysed sequences of antibodies belonging to various chains/classes 
in human and mouse to create a Z-score metric based on percentage sequence iden­
tity between antibody sequences.  This shows distinct differences between human 
and mouse sequences.  Based on mean sequence identity and standard deviation,
I  have calculated  Z-scores for datasets of antibody sequences  extracted from the 
Kabat database.  I have applied the analysis to a set of humanized and chimeric an­
tibodies including a number of sequences where data are available on anti-antibody 
responses,  and  to  human  germline  sequences.  The  aim  was  to  see  whether  this 
approach  may  aid  in  the  selection  of more  suitable  mouse  variable  domains  for 
antibody engineering to render them more human.
3.3.1  Analysis  of pairwise  sequence identities
Initially, every human variable domain sequence was taken and compared with the 
variable  domain  of every  other  human  antibody  in  the  respective  dataset  (light 
or heavy chain,  lambda or kappa class in the case of light chain sequences).  The 
program ssearchSS was used to generate pairwise alignments and the pairwise se­
quence identities were recorded.  The same procedure was repeated for the mouse 
sequences i.e.  every mouse sequence was compared with every human sequence in 
the respective  dataset  and the  pairwise  identities  were  recorded.  The  frequency 
distribution  of the  pairwise  identities  of the  human  and  mouse  sequences  were
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Figure  3.3:  Histogram  of  human/human  and  mouse/human  pairwise  sequence 
identities in (a)  light and  (b)  heavy chains.
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Figure  3.4:  Histogram  of  human/human  and  mouse/human  pairwise  sequence 
identities in a)  lambda and b)  kappa class light chains.
98then plotted together.  It must be noted that there are significant  differences be­
tween the number of murine and human antibodies in the dataset for lambda and 
kappa class  light chains.  It was therefore decided to use the normalised percent­
age frequency.  The normalised frequency is calculated by dividing the frequency 
by  the  total  number  of pairwise  identities  for  the  respective  comparison.  Fig­
ure 3.3 shows the frequency distribution of pairwise identities for human/human 
and  mouse/human  between  the  mouse  and  human  light/heavy  chain  sequences. 
The graphs show that both mouse and human distributions are near-normal and 
they share peaks around  50%  sequence  identity when  compared with human se­
quences.
Similarly, a graph was plotted to examine the lambda and kappa light chain classes 
separately  (Figure 3.4).  These plots separate the light  chain classes with a more 
clear  distinction  between  the  mouse  and  human  distributions.  The  histograms 
are  near  normal  distributions  with  the  human  kappa  light  chains  (Figure  3.4b) 
appearing to show two overlapping sub-classes.  The human lambda class sequences 
as seen in Figure 3.4a have several peaks.  However, the lowest human peak, which 
occurs at about 50% sequence identity, is still considerably higher than the murine 
peak, which occurs at about 41% sequence identity.
3.3.2  Analysis  of mean  sequence identities
This initial analysis provides a histogram of sequence identities for each antibody 
analysed.  In the second stage, I replaced this with a mean sequence identity such 
that  each  antibody  was  represented  by  a  single  value.  All  antibody  sequences
99belonging  to  a  given  dataset  were  aligned  with  human  sequences  of the  corre­
sponding chain/class as above.  The pairwise identity between every non-identical 
pair of sequences was then obtained.  By calculating the mean sequence  identity 
of a sequence scored against the set of human sequences,  I obtain a value which 
represents how typical a sequence is of the human repertoire.  I call this the ‘raw 
humanness’.
For each mouse antibody sequence,  z, the mean is calculated as:
N
Vi = ^2 Pij/N  (3.3)
3 =1
while the mean sequence identity for every human antibody is calculated as:
Mi=  E   P a /(N - 1)  (3.4)
'  j =
where  N  is  the  number  of sequences  in the respective human dataset  and  is
the pairwise sequence  identity between the i ’ th and the  j ’ th sequence in  the query
and target dataset respectively.  The second equation uses N  —  1 since both query 
and target database are the same and the human probe sequence is not compared 
against itself.
A ‘mean raw humanness’  (p)  can be calculated for each dataset:
100Organism Light chain Heavy chain Light chain Light chain
lambda class kappa class
Mouse 50.61 49.85 42.79 58.84
Human 55.21 55.01 59.93 67.57
Table 3.2:  Mean raw humanness  (/i)  for each dataset.
M
=  (3.5)
i=1
where M  is the number of sequences in the probe dataset  (mouse or human).
Table 3.2 lists the calculated means for each dataset of sequences for human and 
mouse with respect to human.  As expected, there are marked differences between 
the human and murine antibody datasets:  the human sequences show higher av­
erage sequence identity than the murine sequences.
3.3.3  Z-Score analysis
Having obtained individual raw humanness scores  (/x*)  and mean scores for each 
human dataset  (human /i, Table  3.2),  Z-scores were calculated as a form of nor­
malisation.  A  Z-score  indicates  how  many  standard  deviations  above  or  below 
the mean a certain value is.  Z-scores  for  both the  mouse  and  human sequences 
were calculated with respect to the appropriate human distribution to assess the 
degree of divergence  of each sequence  from the  human  average.  For the  human 
sequences,  these Z-scores are approximately normally distributed with a mean of 
zero.  The Z-score was defined as the final measure of how typical a sequence is of 
the human repertoire.  For simplicity, this was termed the ‘humanness’  (although
101every human sequence is clearly 100% human).  Thus a Z-score of zero represents 
a sequence which shows average similarity to the repertoire of human sequences. 
Positive  Z-scores  represent  sequences  which,  on  average,  show  higher  sequence 
identity  with  other  human  sequences  and  negative  Z-scores  represent  sequences 
with less typically human character.
The standard deviation,  a is calculated as:
a =
where  is the ‘raw humanness’ of an individual sequence and Jl is the mean raw 
humanness of the human dataset.
Finally, the Z-score of each sequence was calculated as:
Zi = (n i-p )/a   (3.7)
Z-scores were calculated for every dataset of the mouse and human sequences and 
the frequency distribution of the two were overlaid,  as shown in Figures  3.5 and 
3.6.  The two  plots show distinct  differences  between the mouse  and the  human 
distributions.  Figure 3.6a appears slightly skewed as the number of mouse lambda 
class sequences is less than  10% of the number of human lambda class sequences 
(see  Table  3.1).  Although  the  mouse  lambda  class  sequences  are typically  non-
XXft -  n)2/M   (3.6)
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Figure 3.5:  Z-score distribution for (a)  Light chain (b)  Heavy chain sequences.
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Figure 3.6:  Z-score distribution for  (a)  Light chain Lambda class and  (b)  Light 
chain Kappa class.
104human,  it can be seen that in general,  there are significant overlaps between the 
mouse and the human plots.  This indicates that many mouse sequences are more 
typically human than some human sequences.
3.3.4  Assessment  of humanized antibodies
The methodology was applied to a small selection of humanized antibodies.  Two 
papers reporting humanization of murine antibodies were identified from literature 
(Yazaki  et al., 2004; Roguska  et al.,  1994).  The humanness of the original murine 
antibody and the humanized antibody were calculated and compared.
Yazaki et al.  (2004) have reported the humanization of T84-66, a murine antibody 
that binds with high affinity to the carcinoembyonic antigen  (CEA)  (Wagener  et 
al.,  1983).  They made two humanized antibodies M5A and  M5B differing only in 
the sequence of the heavy chain.  Roguska et al.  (1994) have employed a technique 
called resurfacing where human surface residues are grafted onto a murine variable 
domain.  Two  ‘resurfaced’   antibodies  N901  and  B4  have  been  made  using  this 
procedure.
Table 3.3 gives the humanness scores for the original murine and the humanized 
antibodies.  Prom  the  table,  it  can  be  observed  that  the  humanness  values  for 
the  humanized  antibodies  are  clearly  higher  than  those  of  the  original  murine 
donor antibodies.  It must  also be highlighted that in the case of N901 produced 
by  resurfacing,  only  two  residues  in  the  murine  antibodies  were  replaced  with 
their  human  counterparts  in  the  light  chain.  Despite  this,  there  is  a small,  yet
105Humanness Z-score  (a)
Murine Humanized Human
T84.66 Light  -1.847 -1.152
Heavy  -1.161 0.836(M5A)
0.464(M5B)
N901* Light  -1.929 -1.775
Heavy  0.110 0.728
B4* Light  -2.055 -1.762
Heavy  -1.686 -1.420
HPC4t Light  -2.246 0.187 1.390
Heavy  -2.413 0.135 1.875
Table 3.3:  Results of applying the Z-score analysis to humanized antibodies.  All 
light chain scores are in comparison with human light chain kappa class sequences. 
* Antibodies humanized by the resurfacing method of Roguska  et al.  (1994).  ^The 
human  light  chain  sequence  was the consensus  for light  chain  k subgroup  I  and 
the heavy chain was the consensus for human heavy chain subgroup III.
appreciable increase in the humanness score establishing the method’s sensitivity 
even to small changes in sequence.  This also shows that the human residues chosen 
by Roguska are generally typical of human antibodies and not just a small subset 
of human  sequences.  It  must  however  be  noted  that  the  humanness  scores  of 
the humanized  T82.66 are higher than those of the resurfaced  antibodies  as the 
resurfaced antibodies are based on chimeric rodent variable domains rather than 
human variable domains.
3.3.5  Analysis  of  humanness  of  human  immunoglobulin 
germline genes
The  method  is  also  capable  of identifying  that  humanized  antibodies  are  ‘less 
human’  than the original human acceptor sequence.  O’Connor  et al  (1998)  have 
reported the use of consensus sequences as human acceptors, selecting a consensus
106Family VBase Gene name Humanness Family VBase Gene name Humanness
VA1 13-7(A) la 0.40 VA3 11-7 3e -0.17
VA1 14-7(A) le 1.17 VA3 11-7 3m 0.50
VA1 13-7(A) lc 0.90 VA3 11-7 2-19 0.32
VA1 13-7(A) lg 0.89 VA4 12-11 4c -3.27
VA1 13-7(A) lb 0.92 VA4 12-11 4a -2.28
VA2 14-7(A) 2c 1.09 VA4 12-11 4b -2.62
VA2 14-7(A) 2e 1.27 VA5 14-11 5e -1.70
VA2 14-7(A) 2a2 1.02 VA5 14-11 5c -1.91
VA2
i
—
*
i
> 2d 1.24 VA5 14-11 5b -2.38
VA2 14-7(A) 2b2 0.92 VA6 13-7(B)  6a -0.34
VA3 11-7 3r 0.67 VA7 14-7(B)  7a -2.39
VA3 11-7 3j 0.46 VA7 14-7(B)  7b -2.26
VA3 11-7 3p 0.44 VA8 14-7(B)  8a -1.27
VA3 11-7 3a 0.04 VA9 12-12 9a -3.28
VA3 11-7 31 0.19 VA10 13-7(C)  10a -1.19
VA3 11-7 3h 0.42
Table 3.4:  Humanness scores for the lambda class germline genes.
human subgroup V/d light chain and VH-III family heavy chain.  Similarly, Hwang 
et  al.  (2005)  selected  germline-expressed  sequences  most  similar  to  the  mouse 
sequence,  the  rationale  being  that  germline  sequences  would  be  expected  to  be 
non-immunogenic.
It is clear that some germline sequences tend to be used more frequently than oth­
ers so,  it was decided to examine the  ‘humanness’  of human germline sequences. 
The amino-acid sequences of human V-region germline genes were extracted from 
VBase (h ttp : //vbase. mrc-cpe. cam. ac. uk/) and were queried against the database 
of expressed human antibodies to obtain their humanness scores.  Table 3.7 gives 
the number of germline genes for A and  k light chains,  and heavy chain germline 
families.  Figure 3.7 gives the plot of humanness score distributions of the germline 
genes shown as vertical lines.  The humanness scores of individual germline genes 
are given in Tables 3.4-3.6.Heavy chain
Z-Scores
(a)  Heavy chain
Light chain lambda class
Z-Scores
(b)  Light chain lam bda class
Light chain Kappa class
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Figure  3.7:  Results  of the  Z-score  analysis  for  human  germline  sequences.  The 
germline sequences  are indicated by vertical lines overlaid on the distribution of 
humanness scores for expressed human sequences.
108Family VBase Gene name Humanness  Family VBase Gene name Humanness
V/d 2-l-(l)  012 1.20 V/dl 3-l-(l) 01 -1.79
V/d 2-l-(l) 02 1.20 V/dl 4-l-(l) A17 -1.97
V/d 2-l-(l) 018 0.56 V/dl 4-l-(l) Al -2.09
V/d 2-l-(l) 08 0.56 V/dl 4-l-(l) A18 -1.71
V/d 2-l-(U)  A20 0.78 V/dl 4-l-(l) A2 -1.77
V/d 2-l-(l) A30 0.34 V/dl 4-l-(l) A19 -1.40
V/d 2-l-(l) L14 -0.19 V/dl 4-l-(l) A3 -1.40
V/d 2-l-(l) LI 0.89 V/dl 4-l-(l) A23 -2.37
V/d 2-l-(l) L15 0.75 V/dll 6-l-(l) A27 1.05
V/d 2-l-(l) L4 1.02 V/dll 6-l-(l) A ll 0.87
V/d 2-l-(l) L18 1.02 V/dll 2-l-(l) L2 0.94
V/d 2-l-(l) L5 0.84 V/cIII 2-l-(l)  L16 0.94
V/d 2-l-(l) L19 0.84 V/cIII 2-l-(l)  L6 1.04
V/d 2-l-(l) L8 0.86 V/dll 2-l-(U)  L20 0.98
V/d 2-l-(l) L23 0.36 V/cIII 6-l-(l) L25 1.00
V/d 2-l-(l) L9 0.69 V/dV 3-l-(l) B3 0.07
V/d U-l-(l) L24 0.54 V kV 2-l-(l)  B2 -3.67
V/d 2-l-(l) L ll 0.68 V/cVI 2-l-(l) A26 -1.28
V/d. 2-l-(U)  L12 1.04 V/cVI 2-l-(l) A10 -1.28
V/dl 3-l-(l)  O il -1.79 V/cVI 2-l-(l) A14 -1.12
Table 3.5:  Humanness scores for the lambda class germline genes
In general, it can be seen that the germline genes correspond to peaks in the distri­
butions.  Some germline genes are more typical of the expressed human repertoire 
than  some  others.  Each  germline  falls within  a cluster  of humanness  scores  re­
flecting the relative frequency with which they are used in the expressed  human 
repertoire;  some families are also seen to overlap.  The VH-III,  V/dll  (and some 
of V/d)  and VA2  (and some VA1)  are families that have very  high  Z-scores and 
thus are likely to be the germline families from which the high-scoring expressed 
human sequences are derived.
Choosing germline sequences as the basis for humanization from one of the high- 
scoring sequences  is likely to be more effective than choosing germline sequences 
from one of the low scoring sequences.  This is because a large number of expressed
109i*
Family VBase Gene name Humanness Family VBase Gene name Humanness
VH-I 1-3 1-02 0.04 VH-III 1-3 3-43 1.44
VH-I 1-3 1-03 0.12 VH-HI 1-3 3-48 1.81
VH-I 1-3 1-08 -0.34 VH-III 1-U 3-49 0.89
VH-I 1-2 1-18 0.00 VH-III 1-1 3-53 1.87
VH-I 1-U 1-24 tO 50 VH-III 1-3 3-64 1.76
VH-I 1-3 1-45 -0.84 VH-III 1-1 3-66 2.18
VH-I 1-3 1-46 0.38 VH-III 1-4 3-72 1.19
VH-I 1-3 1-58 -0.64 VH-III 1-4 3-73 1.10
VH-I 1-2 1-69 0.15 VH-III 1-3 3-74 1.94
VH-I 1-2 1-e 0.32 VH-III 1-6 3-d 1.24
VH-I 1-2 1-f -0.36 VH-IV 2-1/1-1 4-04 0.44
VH-II 3-1/2-1 2-05 -2.12 VH-IV 2-1 4-28 0.14
VH-II 3-1 2-26 -1.83 VH-IV 3-1 4-30.1 0.35
VH-II 3-1 2-70 -1.79 VH-IV 3-1 4-30.2 0.11
VH-III 1-3 3-07 1.88 VH-IV 3-1 4-30.4 0.38
VH-III 1-3 3-09 1.36 VH-IV 3-1 4-31 0.35
VH-III 1-3 3-11 1.99 VH-IV 1-1 4-34 -0.01
VH-III 1-1 3-13 1.26 VH-IV 3-1 4-39 0.12
Vh-iii 1-U 3-15 1.48 VH-IV 1-1 4-59 0.52
VH-III 1-3 3-20 1.37 VH-IV 3-1 4-61 0.38
VH-III 1-3 3-21 1.89 VH-IV 2-1 4-b 0.50
VH-III 1-3 3-23 2.17 VH-V 1-2 5-51 0.18
VH-III 1-3 3-30 2.07 VH-V 1-2 5-a 0.32
VH-III 1-3 3-30.3 2.20 VH-VI 3-5 6-01 -1.00
VH-III 1-3 3-30.5 2.07 VH-VII 1-2 7-4.1 -0.12
VH-III 1-3 3-33 2.15
Table 3.6:  Humanness scores for the heavy chain germline genes.
110VBase Gene Family  Number
Light chain -  A class
VL1  5
VL2  5
VL3  9
VL4  3
VL5  3
VL6  1
VL7  2
VL8  1
VL9  1
VL10  1
Light chain - k class
H I  
VK2 
VK3 
VK4 
VK5 
VK6
'  Heavy chain
“VHT 
VH2 
VH3 
VH4 
VH5 
VH6 
VH7
Table 3.7:  Number of V-region genes in Lambda and Kappa class light chain and 
heavy chain germline families.
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111Antibody AAR  Light chain  Heavy chain  Notes
Humanized
Zenapax 34% -0.129 -0.136 Immuno-suppressant action
HuBrE-3 14% -1.811 0.252 Patients may be immuno-suppressed
Synagis 1% -0.497 -1.708 Neonatal
H^rceptin 0.1% 0.462 0.965 Patients may be immuno-suppressed
Hu-A33 17% -0.401 0.850 Patients may be immuno-suppressed
Xolair 0.1% 0.309 0.657
Campath-IH 1.9% -0.009 -0.564 Patients may be immuno-suppressed
Chimeric
Infliximab 61% -2.237 -0.684 Immuno-suppresant action
Rituximab 0% -1.813 -1.350 Patients may be immuno-suppressed
chl4.18 0% -1.829 -1.605 Patients may be immuno-suppressed
U36 40% 0.135 1.308 Patients may be immuno-suppressed
Fully human
Humira 12% 0.874 0.886 Immuno-suppressant action
Table 3.8:  Anti-antibody response  (AAR, expressed  as a percentage of patients 
who showed a response — data taken from Hwang and Foote (2005) and from full 
prescribing information of antibodies approved for therapy) and humanness scores 
for seven humanized and four chimeric antibodies.  All light chains were of the k 
class.
sequences similar to the high-scoring germlines is observed in the human repertoire 
and these may be less likely to be immunogenic.  Highly used frameworks will have 
been ‘seen’ by the immune system in the context of different CDR regions (after 
somatic hypermutation).  This will make it likely that peptides derived from these 
antibodies have previously been seen and tolerated by the immune system.  It is 
not known why some germline sequences  are used more frequently than others, 
but  one possibility  is  that  variations  on  the  less  commonly  observed  germlines 
*  leads to higher immunogenicity and B-cells producing these antibodies are rapidly 
eliminated from the body.
112Antibody Reference for
name sequence
Infliximab USP 6284471
Rituximab 2B8
chl4.18 USP 6969517
Re-labelled Chimeric U36 USP 6972324
Zenapax (Queen et al, 1989)
Hu-BrE-3 (Couto et al., 1994)
Synagis (Johnson et al, 1997)
Herceptin (Carter et al, 1992)
Humira USP 6509015
Campath-IH (James et al, 1999)
Hu-A33 USP 5773001
Table  3.9:  Table  listing  clinical  antibodies  and  the  references  containing  their 
sequence.  Abbreviation  USP stands for US Patent.
3.3.6  Correlating immunogenicity with humanness
I further investigated the potential of the humanness score as a predictor of anti­
antibody response  (AAR). Recently,  Hwang and Foote (2005) reviewed reported 
AAR data against murine, chimeric and humanized antibodies and classified the 
Responses as negligible  (<  2%),  tolerable  (2-15%)  and  marked  (>  15%).  As ex­
pected,  they found that the change from mouse to chimeric  antibodies leads to 
the greatest reduction in immunogenicity, while humanization leads to a further 
decrease.  Their  paper provides  a summary  table which  reports  the percentage 
of patients suffering an anti-antibody response.  I attempted to obtain sequence 
data for the antibodies described.  Despite searches of the original literature and 
patent data (both from the original patents and the patent sequence data avail­
able through the SRS server at the EBI, http: //s r s. ebi. ac. uk/, and the IMGT 
list of monoclonal antibodies with clinical indications,  http://im gt.cines.fr/ 
textes/IMGTrepertoire/GenesClinical/monoclonalantibodies/), it proved dif-
113ficult to obtain sequence data for more than a handful of the antibodies.  A list of 
clinical antibodies and the source of their sequences is shown in Table 3.9.
These  sequences  were  tested  using  the  humanness  assessment  and  humanness 
scores are listed in Table 3.8.  The results are very difficult to interpret as there 
are a number of other factors that may contribute to the AAR. In particular, as 
shown in the table, patients may be immuno-compromised as the result of other 
treatments (many of the antibodies are used in cancer therapy) and the antibody 
itself may have an immuno-suppressant  action.  Nonetheless,  in the case of the 
humanized antibodies it can be seen that the sequence with the best humanness 
scores (Herceptin) results in virtually no AAR while the worst individual human­
ness score  (Infliximab) results in the worst AAR. To investigate the relationship
j
between  humanness  and AAR further,  I  decided  to  plot  the  variation  of AAR 
against the following variables:
•  Light chain humanness score.
•  Heavy chain humanness score.
•  Mean humanness score of the light and heavy chain.
•  Maximum humanness score between the light and heavy chain.
•  Minimum humanness score between the light and heavy chain.
The  graphs  for  these  variations  are  shown  in  Figures  3.8  and  3.9.  Averaging 
the  humanness  scores  for  light  and  heavy  chains  for  each  humanized  antibody 
and calculating the Pearson’s correlation coefficient with AAR values showed no
114Type
Pearson’s correlation 
coefficient  (r)
Humanized Chimeric
Light -0.290 0.144
Heavy 0.105 0.576
Mean -0.090 0.408
Min -0.029 0.144
Max -0.169 0.577
Table 3.10:  Correlation coefficient between the AAR and humanness scores of the 
antibodies approved  for therapy.  A  negative correlation coefficient  implies  that 
the AAR decreases as the humanness score increases.
significant  correlation  (R=-0.09).  In contrast,  amongst the chimeric  antibodies, 
the most typically human antibody, U36 (an anti-CD44 v6-domain antibody) leads 
to the second highest AAR and surprisingly,  there is a positive correlation  (r =
0.50).  Table 3.10 summarises the correlation coefficients  between  AAR and the 
different  categories of Z-scores described earlier.  Clearly there  is  a very  limited 
amount of data and the interpretation of the data is complex.  From preliminary 
investigations, there does not appear to be a direct relationship between AAR and 
Humanness scores of the therapeutic antibodies (Table 3.8.
Surprisingly Humira, the first ‘fully human’ antibody (generated by phage display) 
to be approved for use in therapy is not any less immunogenic than the humanized 
antibodies.  Immunogenicity data indicate that  12%  (Hwang and Foote, 2005)  of 
people who were repeatedly injected with the drug without an adjuvant developed 
neutralising antibodies.  This was lower (1%) when Humira was administered with 
Methotrexate.  Humanness scores for Humira were 0.874 (Light chain Kappa class) 
and 0.886 (Heavy chain).  While these scores are quite high, there are similar (and 
in some cases higher) scores amongst the humanized and chimeric antibodies.
11570
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Figure  3.8:  Figure  showing  the  variation  of AAR  percentages  for  the  chimeric 
and humanized antibodies against (a) light chain and (b) heavy chain humanness 
scores.
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Figure 3.9:  Variation of AAR percentages for chimeric and humanized antibodies 
against  (a)  Mean (b)  Minimum and (c)  Maximum humanness scores.
117In conclusion, while (with the limited data available) there does not appear to be a 
correlation between humanness and AAR, as stated above, it is worth noting that 
the least  human  individual chain  also  led  to the  worst  AAR while the antibody 
with the highest humanness led to the lowest AAR.
3.4  Assessing humanness of antibody  CDRs
While it  is  largely  assumed  that  human  antibodies  are  not  immunogenic,  it  has 
been shown that this is not necessarily  the case  (Macias  et  al.,  1999).  As  Clark 
(2000) points out, every antibody has a unique idiotype encoded by the hypervari­
able regions and even fully human antibodies may elicit an immune response.  This 
‘HAHA’   (Human Anti-Human Antibody) response is a concept familiar to immu­
nologists  as  the  ‘network  hypothesis’  in  which  every  antibody  provokes  another 
anti-idiotypic antibody to regulate the immune response  (Jerne,  1974).
Based  on this  assumption,  I  decided  to  investigate  the  humanness  of the  CDRs 
alone  in  a  similar  way  (the  work  described  above  included  both  the  framework 
regions  and  the  CDRs).  Sequences  of antibody  CDRs  were  extracted  from  the 
July 2000 release of the Rabat database using KabatM an and the sequences were 
split  into  3  sets  based  on  chain/class  (heavy,  lambda,  and  kappa)  and  species 
(murine and human).  Humanness of the CDRs was evaluated in two ways:  first, 
the  individual  CDRs  of murine  and  human  antibodies  were  compared.  In  the 
second stage,  the three  CDRs for each dataset were concatenated and compared 
together using ssearch33 as above to calculate pairwise identities.
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Figure  3.10:  Z-score  distribution  for  CDRs  in the  lambda  class  light  chain  (a)
CDR-L1  (b) CDR-L2  (c) CDR-L3.
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Figure 3.11:  Z-score distribution for CDRs in the kappa class light chain (a) CDR-
L1  (b)  CDR-L2 (c)  CDR-L3.
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Figure 3.12:  Z-score distribution for CDRs in the heavy chains,  (a)  CDR-H1  (b)
CDR-H2  (c)  CDR-H3.
1 2 1The plots comparing the Z-Scores of the individual murine CDRs with the human 
CDRs  are  shown  in  Figures  3.10,  3.11  and  3.12  for  the  light  chain  lambda  and 
kappa classes  and the heavy  chain respectively.  It  may be seen that the  human 
and mouse plots overlap almost completely in all the CDRs suggesting that they 
are very similar in both species.  While calculating humanness, percentage identity 
must  be calculated  over  long stretches  of sequence  as short  sequence  alignments 
may  be  incorrect  and  skew  the  measure  of percentage  identity.  As  CDRs  vary 
considerably  in  length  (see  Table  4.9  on page  154)  and  it  was  therefore  decided 
that humanness of the CDRs would be reassessed by concatenating their sequences 
instead of treating them independently.
The plots for the concatenated  CDRs for each dataset  are shown in Figure 3.13. 
From the  plots,  it  is  clear  that  there  is  almost  a  complete  overlap  between  the 
mouse  and  human  plots.  From  the  individual  CDR plots  and  the  concatenated 
plots, it can be seen that the mouse and human CDRs are not very different and 
that the main differences appear to be encoded in the framework regions.
3.5  Discussions and conclusions
The  use  of Z-scores  allows  a normalised  ‘humanness’  score  to be  assigned  to  an 
antibody sequence.  While, by definition, it is the case that every human sequence 
is  100%  human,  this analysis shows very clearly that some human sequences  are 
more  typical  of the  human  repertoire  (as sampled  in  the  Kabat  database)  than 
other sequences.  The fact that differences in ‘humanness’ can be detected between
122-3  -a a  3
(a)  Lambda class light chain
Light  chain  human  class,  Loop  KAPPA
(b)  K appa class light chain
;
i*
(c)  Heavy chain
Figure  3.13:  Z-score  distribution  for  the  concatenated  CDRs  (a)  Lambda class 
light chain (b)  Kappa class light chain (c)  Heavy chains.
123humanized antibodies and the human acceptor sequences used in the humanization 
indicates  that the CDRs play an important role in the overall humanness score. 
Nonetheless,  looking  at  the  CDRs  out  of context  of the  framework  shows  little 
difference in humanness of mouse and human CDRs.
Of course there are many other factors that may contribute to immunogenicity.  For 
example, the nature of the target, whether it is endocytosed or not, the aggregation 
state and formulation of the antibody,  the patient’s genetic background,  disease 
state, etc.  However, the notion of typically human antibodies has been exploited 
elsewhere.  As described above, an approach to humanization had been described 
by Hwang et al. (2005) which involves selecting germline-expressed sequences most 
similar to a human germline sequence.  Using the repertoire of expressed sequences 
rather than the germline provides a more realistic sample of circulating antibodies.
Thus while there may be no means to abolish an anti-idiotypic anti-antibody re­
sponse completely (given that mouse and human CDRs are very similar), measures 
can be taken to minimise the likelihood of the framework leading to a response. 
It is reasonable to assume that an antibody which is more typical of the human 
repertoire will be less likely to be immunogenic than a sequence which is less typ­
ical.  Analysis  indicates  that  a significant  number  of mouse  antibodies are more 
human-like than many human antibodies.
In a recent Phase I drug trial, six healthy volunteers were injected with a human­
ized  anti-CD28  antibody,  TGN1412  (Hopkin,  2006).  This  led  to  a massive  and 
life-threatening  immune  response  in all six subjects.  Initially  it  was  not  known 
whether this was the result of severe anaphylactic shock induced by TGN1412 it­
124self, or whether the mode of action of the antibody in binding to CD28 induced a 
‘cytokine storm’.  The TGN1412 sequence was obtained from US Patent Applicar 
tion 20060008457 and showed humanness scores of 0.48 (light) and -0.85 (heavy). 
The light  chain  has a similar  humanness  score to the best  humanized antibody 
shown in Table 3.8  (Hereeptin),  while the heavy chain is  much higher than the 
score for Synagis.  Both of these antibodies are very well tolerated.  Thus, before 
more information on the mode of action of TGN1412 became available, we were 
able to conclude that  it was  unlikely that the immune response seen  in the six 
volunteers was a reaction to the humanized antibody itself.
Our analysis of correlations between humanness scores and anti-antibody responses 
(Table 3.8)  was very limited because finding sequence data for antibodies where 
AAR data are available was a near-impossible task.  While the small sample is 
probably  statistically  insignificant,  it  appears  that  humanness  score  does  show 
some correlation with reduced AAR amongst the humanized antibodies,  but not
i
amongst the  chimerics.  Clearly there  is a lot  more involved  in  immunogenicity 
than the simple similarity to the human repertoire and it seems likely that there 
are specific features within some mouse sequences that render them visible to the 
human immune system.  I therefore analysed all the sequences in Table 3.8 with 
the T-celf epitope prediction server,  SYFPEITHI  (Rammensee  et  a/.,  1999),  to 
discover whether antibodies leading to a marked anti-antibody response showed a 
higher concentration of likely T-cell epitopes.  In fact,  no differences were found 
between the immunogenic and non-immunogenic antibodies.
The process  of humanization has usually involved  the selection  of a human  an­
tibody that  has  a high sequence  identity with the murine  donor antibody from
125which the CDR sequences are taken (Queen et ol, 1989) .  Tins is done to maximise 
the chances of obtaining good binding.  However,  in some cases, such humanized 
antibodies still show significant AAR. As described above, an alternative strategy 
has been to use germline sequences  (Hwang  et  al> 2005), or consensus sequences 
derived from germline sequences (1998; 1992) as the human acceptors.  The efficacy 
of using consensus human sequences in obtaining good binding has been compared 
with selecting the most similar human sequence  (Kolbinger  et  a l,  1993; Sato  et 
a£.,1994) and these studies show that, while both methods give similar results, the 
use of the human acceptor sequence with the best sequence identity gives some­
what better binding.  There has been no direct comparison of the efficacy of the 
methods in avoiding AAR.  The strategy of using (consensus)  germline sequences 
as acceptors is designed to maximise the hunian nature of the acceptor sequence 
in the hope that this will be leas likely to elicit an anti-antibody response,  even 
if more mouse donor residues need to be introduced into the framework to obtain 
good binding.  Our analysis of germline sequences indicates that certain germline 
families and specific genes within these families giver higher humanness scores and 
are therefore more representative of observed expressed antibodies.
As  described  above,  selecting  a  human  acceptor  framework  on  the  basis  of se­
quence similarity with the  mouse donor  may give better  binding than selecting 
a  (consensus)  germline  sequence.  Of course,  there  is  a trade-off between  good 
binding and AAR.  Poorer binding may mean that more antibody has to be ad­
ministered  thus  increasing  the  amount  of AAR.  Germline,  or expressed,  human 
antibodies with high positive Z-scores may be good candidates for use as acceptor 
sequences in humanization to minimise the chance of AAR. It may be possible to 
select human acceptor sequences which balance sequence identity with the mouse
126donor (to optimise binding) and the humanness score (to reduce AAR)*
One possible problem with the method is that humanness has been evaluated based 
on average similarity to the human repertoire as sampled by the Kabat database. 
It could therefore be biased simply by the selection of sequences which appear in 
the database, or by the frequency of occurrence of particular antigens.  However, 
the fact that the consensus  human sequences  used  by O’Connor  et  a l  (1998), 
and certain germ-line sequences, obtain very high humanness scores suggests that 
bias in the selection of antibodies in Kabat is not a problem.
Recent work by an undergraduate project student  (Michael Eckett)  using IMGT 
sequence data suggests that bias in the smaller Kabat dataset is not a problem.
In  conclusion,  the  method  I  propose  allows  antibodies  from  any  species  to  be 
screened for their similarity to the expressed human repertoire (their ‘humanness’). 
Thfs gives us a tool which may be used to investigate the importance of humanness 
in triggering an anti-antibody response.  The method suggests a modified strategy 
fori selecting  human  frameworks  for  humanization  and  may  contribute  towards 
predicting chimeric antibodies with low antigenicity.
127Chapter 4
An automatic method for 
applying numbering to
-
antibodies:  Analysis and 
applications
In the analysis of protein sequence and structure, having a standardised number­
ing scheme allows comparison of features without explicit alignment.  A numbering 
scheme defines standard positions in the sequence and possibly in relation to struc­
ture.  Numbering of antibodies was first established by Kabat and Wu (1983) who 
analysed antibodies for variability of residues at various positions in the sequence 
(Wu  and  Kabat,  1970).  They  established  that  certain  regions  in  the  antibody 
sequence are more variable than others and termed these hypervariable regions as29  29
(a)  (b)
Figure 4.1:  Two CDR-L1  loops fitted using rigid body superposition.  The short 
loop  (in red)  is  11  residues long while the long loop  (in blue)  is  16 residues,  (a) 
The numbers give the sequential numbering of residues in the loops (24-34 for the 
short loop, 24-39 for the long loop)  (b)  The two CDR-L1 loops numbered so that 
structurally equivalent residues have the same number.
‘Complementarity  Determining  Regions’  (or  CDRs)  which  they predicted would 
interact with the antigen.
This initial  analysis  has been expanded  by other groups leading to the develop­
ment of several numbering schemes.  Figure 4.1 explains the concept of numbering 
in  antibodies.  The  figure  shows  CDR-L1  from  the  light  chains  of two  different 
antibodies structurally fitted to one another.  The shorter loop (coloured in red) is 
11 residues long while the longer loop (in blue) is 16 residues long.  If the residues 
are numbered sequentially, then the numbering is as indicated in the Figure 4.1a.
129However, from Figure 4.1b, it can be seen that the residues highlighted by the grey 
circles are structurally equivalent and it would be appropriate to assign the same 
number to such residues.  Therefore in a structurally correct numbering scheme, 
the protrusion in the longer loop is regarded as an insertion at position L30 and 
residues  in this  protrusion  are  numbered  L30A,  L30B,  L30C,  L30D,  and  L30E. 
(The prefix L is used to indicate the light chain.)
As  stated  above,  a  standardized  numbering  scheme  for  antibodies  was  first  in­
troduced by Wu and Kabat  (1970).  This numbering scheme was derived  on the 
basis of sequence  alignments when  no structural  information for antibodies  was 
available.  Chothia and Lesk  (1987) examined the structures of antibody variable 
domains  and showed  that the sites  of insertions  and  deletions  (indels)  in  CDRs 
LI and HI suggested by Kabat on the basis of sequence were not structurally cor­
rect leading to the introduction of the Chothia numbering scheme.  Unfortunately 
in  1989  (Chothia  et  a l,  1989),  the  numbering  scheme  was  erroneously  changed 
but in 1997 (Al-Lazikani  et  al.,  1997), the structurally correct numbering scheme 
originally  proposed  in  1987  was  reintroduced.  Since  then,  two  further  schemes 
have been introduced.  The IMGT numbering scheme  (Lefranc  et  a l,  2003)  tries 
to  unify  numbering  for  antibody  light  and  heavy  chains  with  T-cell  receptor  a  
and ft chains.  However, since IMGT is predominantly a DNA database, the num­
bering stops at the end of the region encoded by the V-gene segment.  The AHo 
numbering scheme  (Honegger and Pliickthun,  2001) extends the IMGT number­
ing scheme  into CDR-3  and framework 4 in the antibody variable region.  Both 
IMGT and AHo schemes accommodate indels by allowing sufficiently long gaps so 
that all known sequences may be numbered without insertion letters  (e.g.:  30A). 
Nonetheless,  it  is possible in future that unusual antibodies with extremely longinsertions will be identified wkicb cannot be numbered using theseschetoes.  While 
a common scheme for light and heavy chains and  T-cell receptors has a certain 
elegance,  the  practical  applications  are  less  obvious.  It  remains  true  that  im­
munologists tend to continue to use the Kabat scheme while those interested in 
structural analysis use the Chothia scheme.
Thus for however, there has been no resource whereby numbering of an antibody 
sequence  can  be  performed  automatically and  accurately.  In this  chapter,  two 
methods to number antibody sequences automatically are described,  Section 4.1 
describes a method that uses pairwise sequence alignments to number an antibody 
sequence.  This was a refinement of a method previously developed by Dr.  A. C. 
E. Martin.  The target antibody sequence is aligned with a sequence representing 
the consensus pattern of an antibody sequence and based on the alignment,  the 
target antibody sequence is numbered.  Section 4.2 describes a more rigorous and 
accurate method that uses profiles to fix anchor points in the antibody sequence 
and then numbers the framework regions  and the loops independently.  A Web­
server  for this program has also been made available.via the webpage at http: 
/ /iiww. b io in f. org. uk/abs/abnum/.
I assessed the performance of the numbering method (Section 4.3) by comparison 
with  numbering  annotations  in  the  last  publicly  available  release  of the  Kabat 
database  (July 2000)  (Johnson and Wu,  2001).  Prom this analysis,  several sig­
nificant  errors  have  been  identified  in  the  manual  Kabat  annotations  and  this 
automated numbering method can be used to rectify these errors.  A further inter­
esting outcome of this analysis has been the correction of insertion and deletion 
positions ip the framework regions of the antibody. While Chothia et  a l  (1989)
131corrected  the  positions  of indels  in the  CDEs  of the  Kabat  numbering  scheme 
Based on structural information, the framework regions were not included in their 
analysis.  In Section 4.4 of this chapter, I suggest corrections to the Chothia num­
bering scheme for the positions of indels in the framework regions.  Some of the 
work  presented  in  this  chapter  has  been  published  in  Abhinandan  and  Martin 
(2008).
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4.1  An alignment-based method to number an­
tibody sequences
4 .1 .1   A n   e x is t in g   t o o l  For  n u m b e r in g
Martin  (1996)  has described a method  automatically to apply numbering to  an 
antibody sequence by performing a global alignment of the sequence with a con­
sensus pattern.  However, this method fails to number a sequence accurately under
h
the following conditions:
•  When a leader sequence precedes the N-terminal end.
•  When there are truncations to the sequence.
•  When  there  are  unusual  insertions  or  deletions  which  tend  to  distort  the 
alignment thereby introducing mistakes into the numbering.
132TVpe of Number of
dataset sequences
Lambda class 1525
Kappa class 2453
Heavy chain 4724
Table 4.1:  The  number  of sequences  in each  dataset extracted  from the Kabat 
database.
As an improvement to this method, it was decided that refinements to this program
!
could be developed to correct the errors introduced for the above reasons.
4.1.2  Preparation of the test  dataset
Using  KabatMan  (Martin,  1996)  a  test  dataset  was  prepared  by extracting se­
quences of the variable region of antibodies from the most recent public release of 
the Kabat database (July 2000)  (Johnson and Wu,  2001).  These sequences were 
filtered by KabatMan for 100% sequence identity and were grouped on the basis 
of chain (light and heavy chain) and class (Lambda and Kappa in the case of light 
chain sequences).  Table 4.1  gives the number of sequences  that populated each 
dataset.
4.1.3  Principle of the algorithm
The program was written in the C programming language and a simplified version 
of the algorithm is as shown in Figure 4.2.
The first step  in the procedure was deriving a consensus pattern to represent  aSTART
Perform global alignn 
of sequence with 
consensuspatterr
Move gaps in the 
lignment so that they 
conform with the 
numbering scheme
From alignment 
apply the numbering
^   STOP  ^
Figure 4.2:  Numbering algorithm based on pairwise sequence alignment.
134Light  chaim:
LFR1  (Framework  I):  "AVLTQPPXS!%!S !GXXVTI%C 
LI  (Loop  1):  XXSXXXXXXXXXXXXIX 
LFR2  (Framework  2 ):  WYQQKXGXXPK!LIY 
L2  (Loop  2 ):  XX%XXXS
LFR3  (Framework  3 ):  GVPXRFSGS!SGTXX%LXISX!XXEDX!XY#C 
L3  (Loop  3 ):  XXXXXXXXXXXPXX 
LFR4  (Framework  4 ):  FGXGTKLEIXKRA
Heavy  chain:
HFR1  (Framework  i) :  XVQLXXSG^L! XPGXS! $! SCX! SG#%F*/.
Hi  (Loop  1):  XXXXXXX
HFR2  (Framework  2):  WV$QXPG$XLaH  I
H2  (Loop  2 ):  XIXXXXXXGXXXYXXXXK!
HFR3  (Framework  3 ):  $XX! %XDXSXX%! YXXXXSLXXED7.AXYYCXX
H3  (Loop  3):  XXXXXXXXXXXXXXXXXXXXXXXXXX 
H F lf (Framework  4 ):  WGQGTXYTYSS
The  fo llo w in g   symbols  represent  groups  of  amino  a cid s  of  a  s p e c ific   nature:
" •.A cid ic 
!:  Hydrophobic 
#:  Aromatic 
$:  B asic
i% :  Hydroxyl  con tain in g
Figure  4.3:  Light  and  Heavy  chain  consensus  sequences  derived  from
the  multiple  alignment  of  48  structures  from  the  PDB  (described  in 
hUp://www. bioinf. org. vk/abs/seqmethod. html).
light and heavy chain.  Martin (1996) describes deriving a consensus pattern from 
i  the multiple alignment of Ught and heavy chain sequences from 49 structures,  (see 
h ttp : //www. b io in f. org.u k /a b s/seqmethod.html),  Figure 4.3 gives the original 
consensus sequences derived for the light and heavy chain.
The  nw program developed by Dr.  A. C. R. Martin that implements the Needle-
r   '
man and Wunsch method for global pairwise alignment (Needleman and Wunsch,
135Type of Gap insertion Gap extension Type of  -   '
chain penalty penalty matrix
Light 10 1 BLOSUM62
Heavy 15 1 Noimalized MDM78
Table 4.2:  Optimal parameters for alignment of light and heavy chain sequence 
"alignment,  —
1970)  was  used  to perform alignment  between  the antibody  and  the consensus 
sequence,  Since the numbering scheme depends on the alignment, it is imperative 
to ensure correct alignment so that residues are numbered correctly.  In order to 
ensure correct alignment, the following alignment parameters were varied:
1:  Substitution matrix - PET, BLOSUM62, Normalized MDM-78.
2.  Gap insertion penalty - 10,  15, and 5.
3.  Gap extension penalty - 0, 1, 2, 3, and 5.
After manual examination of several pairwise alignments,  the parameters shown 
in Table 4.2 were chosen as they gave the most correct alignments of the antibody 
sequences with the consensus sequences.
4.1.4  Deriving consensus sequences
An antibody variable region sequence consists of 7 regions, as shown in Figure 4.4. 
For unusually long antibody sequences, the pairwise alignment with the consensus 
sequence  could  be  incorrect.  To  resolve  this  problem,  it  was  decided  to  derive
136LFR1 L1 LFR2 L2 LFR3 L3 LFR4
HFR1 HI HFR2 H2 HFR3 H3 HFR4
Figure 4.4:  Schematic representation of the seven regions of the antibody variable 
region.  The prefix L or H indicate light or heavy chain respectively.  LFR1, HFR1, 
LFR2,  HFR2,  LFR3,  HFR3,  LFR4,  HFR4  -  Light  or  Heavy  chain  framework 
regions.  LI, HI, L2, H2, L3, H3 - Complementarity Determining Regions (CDRs) 
or loops.
Chain/Class FR1 Loopl FR2 Loop2 FR3 Loop3 FR4
Lambda 0 0 62 119 132 0 0
Kappa 4 0 3 13 19 1 0
Heavy 1 0 18 3 3 0 3
Table 4.3:  Numbers of sequences that gave insertions in the consensus alignment. 
FR = framework region
alternate  consensus  sequences  for  the  unusual  cases.  Having  fixed  the  optimal 
alignment parameters, all alignments between the antibody sequence and the orig­
inal consensus sequence  (Figure 4.3) were examined.  Sequences that gave gaps in 
the  consensus  sequence  alignment  were  isolated  and clustered  based  on  regions 
where  they  have  more  residues  than  the  consensus  sequence.  These  sequences 
were  multiply  aligned  using  M USCLE  (Edgar,  2004)  and  an  alternate  consen­
sus  sequence  was  derived  on  the  basis  of sequence  conservation.  The  alternate 
consensus sequences are shown in Figure 4.5.
Table 4.3 shows the number of sequences that were clustered based on the region 
of insertion in the original consensus sequence.
137LFR1: ~AVLTQPPXS! 7.! S ! GXXVTI7.C
LI: XXSXXXXXXXXXXXXIX
LFR2: WYQQKSPGSAPVTVIY
L2: X7.DSDXXXXGS
LFR3: GVPXRFSGS$D! SGTXX7.LXISX! XXEDX! XY#C
L3: XXXXXXXXXXXXXXX
LFR4: FGXGTKLEIXKRA
(a)  Consensus  sequence  fo r  in ser tio n s  in   LFR2  segment.
LFR1: ~AVLTQPPXS! 7.! S ! GXXVTI7.C
LI: XXSXXXXXXXXXXXXIX
LFR2: WYQQKXGXXPK!LLRY
L2: X7.DSDXXXXGS
LFR3: GVPXRFSGS$D! SGTXX7.LXISX! XXEDX! XY#C
L3: XXXXXXXXXXXXXXX
LFR4: FGXGTKLEIXKRA
(b)  Consensus  sequence  fo r  in ser tio n s  in  L2-LFR3.
HFR1: XVQLXXSGXXL! XPGXS! $!  SCX!   SG#7.F7.
HI: XXXXXXXXXXXXX
HFR2: WV$QXPG$XLEW!!
H2: XIXXXXXXGXXXYXXXXK!
HFR3: $XX! 7.XDXSXX7.1  YXXXXXSLXXXED7.AXYYCXX
H3: xxxxxxxxxxxxxxxxxxxxxxxxxxxx
HFR4: WGQGTXVTVSS
(c)  Consensus  sequence  fo r  in sertio n s  in  the  heavy  chain.
Figure 4.5:  Alternate consensus sequences to be used when there are insertions in 
(a)  LFR2 segment of Light chain  (b)  L2 or LFR3 in Light chain (c)  Heavy chain.
1384.1.5  Identifying chain type using Z-scores
Since the numbering program is applicable only to antibody sequences,  the need 
to develop a method to differentiate antibodies from non-antibodies and further, 
to  differentiate  light  and  heavy  chains,  was  realised.  Deret  et  al.  (Deret  et  al, 
1995) have described a method to assign subgroups to human antibody sequences 
( Johnson and Wu, 2001)  based on sequence conservation in framework 1.  It was 
initially decided to use their procedure  (SUBIM)  to classify sequences.  However, 
the program suffers from two significant limitations:
•  An inability to differentiate antibody sequences from non-antibody sequences.
•>
•  Assigning incorrect chain types in several cases.
It  was  then  decided  to  develop  a completely  new  procedure  using  Z-scores  (de­
scribed  in Section 3.3).  The procedure for doing this is shown in Figure 4.6 and 
is detailed below:
1.  For every sequence in the input file, do the following steps:
2.  Check the length of the input sequence.  If it is less than 80 residues  long, 
report that a chain type cannot be assigned to the sequence and proceed to 
the next sequence.
3.  Run  8search33  (from the  FASTA  package  (Pearson  and  Lipman,  1988)) 
for  the  query  sequence  against  the  database  of human  light  chain  kappa
t
139class sequences.  An E-value cutoff of 100000 is used so that pairwise iden­
tities between the query sequence  with every sequence  in the database are 
obtained.
4.  If the  length  of the  alignment  with  the  top  hit  is  less  than  94  residues, 
then goto step 7.  Some antigens tend to have high sequence similarity with 
antibody sequences over short stretches of alignment.  This filter ensures that 
only sequences with similarity over the entire variable chain of an antibody 
are considered for further processing.
5.  Calculate the mean sequence identity for the query from the set of pairwise 
identities.  From this, calculate the Z-score for the query using:
^query ~   {f^query  Inhuman) /  &  human  (4.1)
where
Zquery - Z-score of the query sequence.
Hquery - Mean percentage identity of the query sequence against the library 
of human sequences.
inhuman ~  Mean percentage identity of database of human sequences calculated 
by  averaging  the  mean  percentage  identities  of all  human  sequences  when 
compared with all other human sequences..
&  human - Standard deviation of database of human sequences from the aver­
age from the mean percentage identities.
6.  If the  Z-score  is  less  than the  threshold  Z-score  for  the  database  (-3.9  for 
Kappa,  -4.5  for  Lambda,  and -3.1  for Heavy)  assign the  database  type  to
140Chain/Class
type
Z-score
threshold
Lambda class -4.4970
Kappa class -3.8730
Heavy chain -3.0630
Table  4.4:  Table  showing the  Z-score thresholds  for  identifying  chaintype.  The 
thresholds were set after examining the Z-scores of murine and human antibodies 
in the Kabat database.
the sequence.  Goto step 2 to process the next sequence.
7.  Goto step 2 and run ssearchSS against a different database (human lambda 
or heavy chain sequences).
8.  If  none  of the  Z-scores  of the  query  is  above  the  threshold  Z-scores  (see 
below),  assign ANTIGEN type to the sequence.  Go to step  2  and process 
the next sequence.
The threshold  for  length was  decided  after  manual examination of antibody se- 
quences in the Kabat database.  Sequences that are shorter than 80 residues do not 
contain features typical of antibodies and it was decided to set this as the length 
threshold.  Any  antibody sequence  that  is  less  than 80 residues  in  length  is  not 
assigned a chain type.  Similarly, the threshold for Z-scores was set after evaluating 
the Z-scores for mouse and human antibody sequences extracted from the Kabat 
database.  The thresholds  are shown  in  Table 4.4  and were  decided  upon  based 
on  the  lowest  Z-scores  observed  for  the  human  and  mouse  antibodies  for  every 
dataset  (Lambda/Kappa class light chains and heavy  chains).  It  must  be noted 
that the thresholds were set after considering the lowest score for a murine anti­
body sequence and the humanness scores of antibodies belonging to other species 
were  not  considered.  However,  experience suggests these thresholds  are  suitable
141Start
Is the Z-score 
greater than the 
threshold vaiue for 
any (database?
Read next sequence
Aaatgn ttw respedve 
chain type to tha antibody
______sequence______
Aaatgn ANTtQEN 
(or non-antibody) 
type to the sequence
Report ttiat tha sequence 
■ ■   cannotbe assigned a 
chain type
CaicUate fhemean sequence 
Identity tor the sequenoe 
agalneteach ofthe databaaea
Run aseareh33 against 
«ie database et Hunan 
Lambda, Kappa and'Heavy 
chains secsjenoea at an 
E-value oif 100000
CaicUate Z-aoorewtth 
reaped to the human 
mean and standard deviation 
for every database
Figure 4.6:  Identifying type of chain/class of an antibody sequence by calculating 
,the Z-score with respect to the distribution of human antibody sequences.
142for antibody sequences from other species.
4.1.6  How the numbering algorithm works
The overall algorithm is as shown in Figure 4.7.  The first step involves the iden­
tification of the  chain type  (heavy  chain  or  lambda/kappa class  for light chain) 
using either SUBIM  (Deret  et al,  1995)  or the Z-scores procedure that has been 
described in Section 4.1.5.  The sequence is aligned with the appropriate consensus 
light or heavy sequence.  The alignment is checked for possible errors by examining 
the consensus sequence alignment for any gaps in which case it is aligned with an 
alternate consensus sequence.
An important problem that needed addressing was the case of light chain sequences 
with truncations towards the C-terminal end of the variable region.  It was noticed 
that incorrect alignments were found particularly in the L3-LFR4 region and these 
had to be dealt with separately.  The following section gives details of the methods 
developed to handle these cases.
4.1.7  Adjustments to alignments in the L3-LFR4 regions
As  stated  above,  it  was  noted  that  the  alignment  was  frequently  incorrect  and 
adjustments were required.  The following steps were followed while adjusting the 
alignment in the L3-LFR4 region.  Examples provided show the way the alignment 
changes are effected.
143Are there gaps in 
consensus alignment?
Are there gaps in 
consensus alignment?
Are there gaps in 
consensus alignment
Are there gaps In 
consensus alignment
STOP
Print alignment and 
numbering
For every sequence 
do the following
Accept PIR file 
with antibody sequences
Display warning: Input 
sequence has unusual insertions
Display warning: Input 
sequence has unusual insertions
Determine chain types of 
input sequences using 
SUBIM/Z'Scores
Globally aHgn query sequence 
with light chain consensus sequence
Globally align quety sequence 
with heavy chain consensus sequence
with alternate heavy cha 
consensus sequence
Globally align quety sequence 
with alternate light chain 
consensus sequence
Figure 4.7:  Overall algorithm for the alignment-based numbering method.
1441.  Extract the antibody sequence  in  LFR4 from the alignment with the con­
sensus-  1
2.  If there is no gap in the first position of LFR4, exit from the routine.
3.  If LFR4 is not empty, check whether the start of LFR4 has a gap.  If it does 
and the last residue in L3 is either of ‘T’,  ‘S’,  ‘P ’,  ‘F’,  ‘L \ or ‘W ’, move 
the  last  residue  from  L3  into  the first  position of LFR4 in the alignment. 
Having  performed  this,  exit  from the  routine.  The  position  at  which  the 
alignment is adjusted is indicated by the  symbol.
Example:
*
DHYC  SSYTSINTWVS--------
XY#C  XXXXXXXXXXXXXXX
II  U   i l   fj,  H  it H H I f  I I   | f  | f  | |
T H r W T P   f l  11  ##' f f 1  ft It f f ' f f l r  ft  TF' rf f f 1  r r r r
End  o f  L3
LFR3
After adjustment, this becomes:
DHYC  SSYTSINTWV  ;
XY#C  XXXXXXXXXXXXXXX
4.  If LFR4 is empty, check the length of L3.  If it is less than 4, then exit from 
the routine.
5.  Pick the last 4 residues from L3 and match the following patterns of amino 
acids in them.
a)  FG b)  GSP c)  FSP d)  FDG e)  FVD f)  FR g) FW h)  FXGG
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-GGGT--------------
FGXGTKLEIXKRA
#############  II  FI  fl'  II  II  f l  11  FI  II  II  II  II  II  .
LFR4
SGGGT--------------
FGXGTKLEIXKRA
IIf one of these pattens  is observed  in the last  4 residues of L3, 
these residues into LFR4 and exit from the routine.
Example:
move
DYYC  SSYTSISLTVLFG—
XY#C  XXXXXXXXXXXXXXX FGXGTKLEIXKRA
»   M  M wwww
End  of 
LFR3
« J  » «  M U  I J  M  « t »* M  II  M  i «   U
t f W T l g H  .1. .11.  -M  IF T r 
IV  Ir  II  IF  II  IT rl  II  II  n   rl  If  II  II  II
•  L3
#############  M  ff if w ff if1  if ff ft1  it" fi ir fi1
LFR4
After adjustments, this becomes:
DYYC  SSYTSISLTVL------
XY#C XXXXXXXXXXXXXXX
FG--------------------
FGXGTKLEIXKRA
6.  Check the number of Glycines in the last 4 residues of L3.  If it is less than 
2, exit from the routine.
7.  If there are at least  2  Glycines amongst the last 4 residues of L3,  examine 
the residue preceding the first Glycine.  If it is one of ‘T ’,  ‘S’,  ‘P ’,  ‘F’,  ‘L’, 
or ‘W ’, then move the segment from the residue preceding the first glycine 
to LFR4.  Exit from the routine.
Example:
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l*
DYYC  QTW GTQGG    ------
XY#C  XXXXXXXXXXXXXXX  FGXGTKLEIXKRA
If  i||  II U  M   JI II M  M  ilJi JI II II l »  il » t   II U  II H  H  H  M  il il M  M  U  I I ^ L J l L J E L ^ L   m ' W ' . i w h ' W ' h . i i   H i w n i r » i - i i   w   i i 1   w w w T g w w w i r i f w f f w w
FI  II  W  II  .  II  II  II  II  II  II  II  VI  II1   n   II  II  H U   II  W Tf  ri  f f   II  ff  If  II  f f   Ff  11  f?  Ff
End  of  L3  LFR4
LFR3
After adjustments, this becomes:
DYYC  QTW G  -----------  TGGG  -----™
XY#C  XXXXXXXXXXXXXXX  FGXGTKLEIXKRA
AS II 1*  St
II  II  ft
H   II  IV  FI
End  of 
LFR3
8.  If the first residue among the last 4 residues in L3 is a Phenylalanine and the 
third residue is Glycine, then move the last 4 residues from L3 into LFR4. 
Having performed this, exit from the routine.
Example:
a
147GlATAW^M^VYHNYLYYGIKELGARGLIiVTVSS---------------------- -
XED%AXYYCXXXXXXXXXXXXXXXXXXXXXXXXXXXXWGQGTXVTVSS 
*  *
(a) Erroneous alignment in HFR3 end-H3-HFR4
GEATAVYYVAEVYNNYIiYYGIKEL  — .-----------_ -GARGLLVTVS S
XED%AXYYCXXXXXXXXXXXXXXXXXXXXXXXXXXXXWGQGTXVTVSS
ie  *
(b)  Correct alignment
Figure 4.8:  Example of an error in the alignment for an equine heavy chain se­
quence in the HFR3-H3-HFR4 region.  The erroneous alignment (output from the 
numbering propam)  is shown in  (a)  and the correct  alignment  is shown in  (b). 
The beginning of H3 and HFR4 are marked by the  symbol below the alignment.
*
DYHC  GADHGSGSDFVGG—  -------- --------- -—
XY#C  XXXXXXXXXXXXXXX  FGXGTKLEIXKRA
II  | |   | |   i |   n   i l   I#  | |   | |   | |   | f  | |   II  | |   | |   it   | |  | i  | |   | |   »   I]  i#   | j   | |   | |   II  | |   | |   | |   | |   | |
Tr f f 1  Tf'Tf  .  f»' fr  tr ?r"rr f*  f f   W  If  IF  if'Ir   rr ft'TT  ff" ff  If1   ff1  "rr IF fl' f'f fl' IT I f  II  f t
End  o f  L3  LFR4
LFR3
After adjustments, this becomes:
DYHC  GADHGSGSD    FVGG---------------
XY#C  XXXXXXXXXXXXXXX  FGXGTKLEIXKRA
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t4.1.8 D is c u s s io n
Prom preliminary  analysis,  it  could be  said  that  although  the method was rear 
sonably  accurate,  there  was  no  guarantee  that  the  numbering  output  from the 
program would be perfect owing to inherent limitations with using an alignment- 
based  approach.  It also required  a large set of relatively arbitrary rules to deal 
with  special  cases.  Unusual  sequence  features  may  lead  to  a wrong  alignment 
and therefore wrong numbering.  An example of this is shown for an equine IgE 
heavy chain sequence (Navarro et  a l, 1995) in the HFR3-H3-HFR4 region in Fig­
ure 4.8.  The  consensus  sequence  for  CDR-H3  contains several  X s  to  represent 
the longest sequence that has been observed for this loop.  However,  this causes 
a wrong alignment  because  the start  of HFR4 is unusual.  HFR4 usually starts 
with a Tryptophan (W) whereas the start of HFR4 in this sequence is a Glycine 
residue (G). It was therefore decided to implement a profile-based approach to ap­
ply numbering to antibody sequences in the hope that this would be less arbitrary
i
and more accurate.
4.2  A profile-based numbering method
This numbering  algorithm uses  profiles  derived  from  the Kabat  database  to fix 
anchor points in an antibody sequence.  By fixing anchor points in the sequence, 
it  became  possible  to  isolate the sequence of every  region  (framework  region or 
. loop) and number each of them independently.
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«Chain type Sequence type Number of sequences
Light Complete 794
Light Truncated 3044
Heavy Complete 2641
Heavy Truncated 1272
Table  4.5:  Number  of complete/ truncated  light  and  heavy  chain  sequences ex­
tracted from the Kabat database.
4.2.1  Preparation of the dataset
Using  KabatMan  (Martin,  1996),  sequences  of antibodies  were  extracted  from 
the  Kabat  database  (Johnson  and  Wu,  2001).  For  ease  of benchmarking  the 
efficiency  of the  algorithm,  the  initial  set  of sequences  were  classified  as  being 
truncated/complete light  or  heavy  chain  sequences.  Any  sequence  with  Kabat 
annotations for the first and last residues of the variable region (LI, L109 in the 
light  chain  and  HI,  HI 13  in the  heavy  chain)  m s  regarded  as  being  complete 
and all other sequences were treated as truncated sequences.  Table 4.5 gives the 
number of complete and truncated light and heavy chain sequences extracted from 
the Kabat database using KabatMan.
For structural analysis, a fist of antibody structures was prepared by parsing the 
XML  file  from  SACS  (Allcorn  and  Martin,  2002)  and  the  structure  files  were 
obtained from the PDB  (Berman  et  al., 2000).
4.2.2  Creation of profile sets
The strategy  adopted  was  to define  a set  of anchor points  in the sequence  and 
to  fill  in the  numbering  based  around these  locations.  The  anchor  points  were
150Anchor points for profile
Profile name Light Heavy
FRl Start LI - L6 H1-H6
FR1 End L18 - L23 H20 - H25
FR2 Start L35 - LA O H36 - H41
FR2 End L44 - L49 H44 - H49
FR3 Start L57 - L62 H66 - 3371
FR3 End L83-L88 H89 - H94
FRA Start L98 - L103 H103 - H108
FRA End L104 - L109 H108-H113
Table 4.6:  Kabat positions used in the profile definitions.
Chain type  Sequence type  Sequences that could 
    not be numbered (%)
Light Complete 1/794 (0.12%)
Light Truncated 44/3044 (1.44%)
Heavy Complete 2630/2641  (99.58%)
Heavy Truncated 1260/1272 (99.05%)
Table  4.T:  Number  of complete/truncated light  and heavy  chain  sequences  ex­
tracted from the Kabat database that could not be numbered using just 3 profile 
sets (lambda, kappa, heavy).
chosen so that they would represent the start and end of every framework region. 
For this I extracted the propensities of each of the 20 amino acids in the first and 
last six positions of every framework region using KabatMan (Martin,  1996) arid 
a Perl script to analyse results.  Each set of six residues was termed a profile and 
a set of profiles representing the start and end of the four framework regions was 
termed a profile  s e t  Table 4.6 gives the list of Kabat positions that were used to 
construct the profiles for the light and the heavy chain.
Initially,  three  profile  sets  were  created,  classified  on the  basis  of chain-  heavy 
chain and lambda and kappa for the light chains.  However,  a significant number 
of the sequences could not be numbered as anchor points for the start and end of 
the framework regions could not be fixed in the correct order (See Table 4.7).
151Classification Number of
profiles
Human subgroups:  Lambda class 6
Human subgroups:  Kappa class 4
Human subgroups:  Heavy chain 6
Species:  Lambda class 6
Species:  Kappa class 6
Species:  Heavy chain 4
Table 4.8:  Classification scheme and number of profile sets.
Additional profile sets were then created to make each more specific.  Table 4.8 
lists 32 profiles that were created on the basis of the following criteria:
a)  Human  subgroup  classes  as  identified  by  Kabat.  From  the  1994  version  of 
the  Kabat  database,  sequences  were  divided  into  families  based  on  amino  acid 
identity where members of a family differ by 12 amino acids or fewer (Deret et a l, 
1995).  This led to the creation of 16 human sub-group-specific profiles as shown 
in Table 4.8.
b)  Species  of origin  for  the  Lambda,  Kappa and  Heavy  chain  sequences.  This 
resulted in a further 16 non-human species-specific profiles as shown in Table 4.8.
As  will  be  shown  later,  the  development  of more  specific  profiles  significantly 
improved , the number of sequences that could be annotated using the numbering 
program (see Table 4.11).
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l4.2.3  The numbering algorithm
To number a sequence, a sliding-window protocol is applied in which each window 
consists of a set of six consecutive residues.  The window is scored against a profile 
before it is moved by a single residue to span the next set of 6-residues.  The score 
for a profile match is calculated as:
■   t  .  '
M  =  m ax^pj); (J  - 0 ..N  -  6)
SpJ =  'tlo g ( S i+j)  (4.3)
where  M   represents  the  score  and  Spj   represents  the  score  profile  in  the  j ’th 
iwindow of the sequence.
Once anchor  points for the starts  and ends of the framework regions have been 
fixed,  the sequence  for every region  (framework  1,  loop 2,  etc)  is extracted and 
numbered, independently.  However,  it was noticed in several sequences  that the 
order of the anchor  points was incorrect.  For example,  the anchor point of the 
end  of framework  region  1  could  appear  after the  anchor  point  for the start  of 
framework region 2.  While  detecting out-of-order misassignments  is trivial,  de­
tecting all misassignments of anchor points proved tedious requiring the design of 
-elaborate protocols to ensure error-free assignment.
<4.2)
153Region name
Range of lengths
Light Heavy
Min Max Min Max
Framework 1 22 23 24 29
CDR-1 7 17 6 18
Framework 2 14 16 13 14
CDR-2 5 12 10 23
Framework 3 31 40 29 34
CDR-3 5 18 2 30
Framework 4 10 15 10 12
Table 4.9:  Minimum and maximum observed lengths of the 7 regions in the light 
and heavy chain.
A direct inference of anchor-point misassignment could be made when the order 
of the profiles was incorrect.  In a few cases where the profile assignments were in 
the correct order, the separation between the profile assignments was clearly too 
large or too small.  Such cases were detected by examining the separation between 
the profile assignments to see if they fell within pre-set limits shown in Table 4.9. 
These limits were set after the distribution of region lengths in the Kabat database 
was manually examined.  It must be realised that it may be necessary to extend 
these limits in  future to accommodate unusually long sequences.  However,  this 
would require  cautious  modification to ensure that sequences  are not numbered 
incorrectly.  ^
A ranking scheme was introduced to cope with profile misassignments.  When a 
profile misassignment is detected on the basis of profile order and separation, the 
best seven profile set assignments are examined in turn to see if the correct match 
can be found.  If not, it is reported that the sequence cannot be numbered.  Once 
profile assignments are completed, the sequence of every region is extracted.
Once  the  anchor  points  for  the  starts  and  ends  of the  framework  regions  have
154been fixed in the  antibody  sequence,  the sequence  of every  individual region is 
extracted.  This is shown in Figure 4.9.  The boundaries for every region are set 
after the  best  profile  assignments  have  been  made  and  are known  to  be  in the 
correct  order.  In some  cases,  the  input  sequence  contains  a leader  sequence  at 
the N-terminal end, or the constant region sequence at the C-terminal end.  This 
process excludes extraneous residues from the N-terminal or C-terminal end of the 
antibody as they are not included in the alignment.
To ensure error-free assignment for the region boundaries  (start and end of loop 
and framework regions), a final check is performed by concatenating the sequences 
in the individual regions and examining whether the concatenated sequence is a 
substring of the original sequence.  This check is particularly useful When the profile 
representing the end of FR1  or the start of FR4 have been incorrectly assigned. 
An example is shown in Figure 4.10.
i Numbering is applied in every region based on one of the following rules:
;  1.  Normal  numbering where  deletions  are  made  before the position of inser­
tion -  For example,  the Kabat definition for region CDR-L2 is L50 to L56 
giving it a standard length of 7 residues.  A maximum length of 12 residues 
(antibody  Z84995  (Ignatovich  et  a l,  1997))  and  a  minimum  length  of 6 
residues  (antibody  R er5  (Rast  et  al.,  1994))  have  been  observed  for  this 
region.  The  position of insertion according to the  Kabat  standard  is  L54 
(L54A,  L54B, L54C etc).  Deletions are placed before the position of inser­
tion  (L54).  For example,  in the case of a 5-residue CDR-L2,  residues  L53 
and L54 are deleted.  This is demonstrated in Figure 4.11.
155Schematic representation of an antibody sequence
CDR1 CDR2 CDR3
FR1 FR2 FR3 FR4
Sequence to be numbered
After scanning for best profile assignments
D -
t
■ O -
▲
FR1
Start
FR1
End
FR2
Start
■0-
FR2
End
o
FR3
Start
FR1 Loop 1 FR2 Loop 2
V V  V  V
FR3
V
FR3
End
-U -----D
4  4
FR4  FR4 
Start  End
Loop 3  FR4
V  V
Extract sequences of every region
Figure 4.9:  Isolating the sequence of every region from the best profile assignments. 
Each profile represents the start or the end of a framework region.
156Sequence to be numbered
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKMQFSLQLNSVTPEDTAVYYCARAVGGTTGTR®
After best profile assignments
|QVQLQ(jsGPGLVKPSQTLsjLTCAI^GDSVSSNSAAWljwiRQS^SRt;LEWL^RTYYRSKWYMDYAVSVKs(RITIN^DTSKNQFSLQLKSVTPEDTj|vYYCA4AVGpTTGTI^G(
f    t  t  t  t
FR1  FR1  FR2  FR2  FR3
Start  End  Start  End  Start
After extraction of the sequence in the regions
FR1: QVQLQQSGPGLVKPSQTLSLTCAIS
Loopl: GDSVSSNSAAWN
FR2: WIRQSPSRGLEWLG
Loop2: RTYYRSKWYNDYAVSVKS
FR3: RITINPDTSKNQFSLQLNSVTPEDTAVYYCAR
Loop3: AVG
FR4: GTTGTRGGMDVW
Alignment with FR4 consensus
GTTGTRGGMDVW..........
  WGQGTXVTVS  S
Figure 4.10:  Example showing the detection of errors through alignment with a 
consensus sequence pattern.  In this example, the profile assignment of heavy chain 
framework region 4 start is incorrect as framework 4 is truncated after the first 
residue (W). The alignment with the framework 4 consensus is shown in the final 
box.
t  t
FR3  FR4 
End  Start
157L50 L51 L52 L53 L54 L55 L56
G T T - - R T
(a) CDR-L2: GTTRT
L50 L51 L52 L53 L54 L55 L56
G T T R - G T
(b) CDR-L2:  GTTRGT
L50  L51  L52  L53  L54  L54A  L55  L56 
E D S T T   R  G T
(c)  CDR-L2:  EDSTTRGT
Figure 4.11:  Normal numbering in CDR-L2.  The standard indel position is L54. 
Deletions  are  made  before  the  position  of insertion.  The  Kabat  numbering  is 
shown  for  varying  lengths  of CDR-L2.  (a)  5  residues  (GTTRT)  (b)  6  residues 
(GTTRGT)  (c) 8 residues  (EDSTTRGT).
2.  Reverse numbering where deletions are made after the position of insertion - 
For example in CDR-L1, whose Kabat definition is L24 to L34, the standard 
length is 11 residues.  A maximum length of 17 residues and minimum length 
of  7  residues  have  been  observed  in  this  region.  Insertions  are  placed  at 
position  L27 according to the  Kabat  standard.  Deletions  are  placed  after 
the position of insertion (L27).  For a 7-residue.CDR-L1, residues L28, L29, 
L30, and L31 are deleted.  This is shown in Table 4.12.
3.  Straight numbering where residues are numbered sequentially - In the heavy 
chain framework region 4,  residues  are numbered  sequentially  as there  are 
no defined indels in this region.  This is shown in Figure 4.13.
In some regions, the Kabat numbering does not impose a fixed site for indels.  For 
instance, in the heavy chain framework region 2 (HFR2) the deletion appears to be 
placed at the most likely position based on sequence.  In these cases, an alignment
158L24  L25  L26  L27  L28  L29  L30  L31  L32  L33  L34
S  A  S  V  . . .   Y  Y  M  Y
(a) CDR-Ll:  SASVYYMY (8 residues)
L24
S
L25
A
L26  L27  L28  L29  L30  L31 
S  -  -  S  V  Y
L32
Y
L33
M
L34
Y
(b) CDR-L1:  SASSVYYMY (9 residu
L24
S
L25
A
L26  L27  L28  L29  L30  L31 
S  S c   S  V  Y
L32
Y
L33
M
L34
Y
(c) CDR-Ll:  SASSSVYYMY (10 residues)
Figure 4.12:  Reverse numbering in CDR-L1.  The standard Kabat indel position 
is  L?7.  Table  shows  the  Kabat  numbering  where  deletions  are  made  after the 
position of insertion (L27).
H103  H104  H105  H106  H107  H108  H109  H110  Hill  H112  H113
W  G  Q  G  T  M  V  T  V  S  -
(a) HFR4 - WGQGTMVTVS (10 residues)
L98 L99 L100 L101 L102 L103
F G P G T K
L104 L105 L106 L106A L107 L108
V T A L S Q
L109 L110 Llll
P - -
(b) LFR4 - FGPGTKVTALSQP (13 residues)
Figure 4.13:  Straight numbering in HFR4.  The sequence in the region is WGQGT­
MVTVS and numbering is applied sequentially to residues.
159Region
name
la alignment performed
for this region?
Is alignment used 
in numbering?
Numbering
method
LFR1 Yes  1 No 1
LI No No 2
LFR2 No No 1
L2 No No 1
LFR3 No No 1
L3 No N o. 1
LFR4 Yes No 3
HFR1 Yes Yes 1
HI No No 2
HFR2 Yes Yes 3
H2 No No 2
HFR3 No  : •   No 1
H3 No No 1
HFR4 Yes No 3
liable 4.10:  Regions in the light and heavy chain and methods that  are used to 
number them.
is performed between the sequence in the region and a consensus pattern for that 
region andnumbering is applied based on the alignment.  Table 4.10 summarises 
the  numbering  methods  used  for  the  different  regions  in  the  Kabat  numbering 
scheme.
Figure 4.14 gives a flowchart of the numbering algorithm.
4.2.4  Benchmarking the numbering algorithm
In order to assess the performance of the profile-based numbering program, Ab- 
Num, sequences of antibodies and their Kabat numbering were extracted from the 
July 2000 release of the Kabat database.  This was done using KabatMan and four 
*  test datasets were prepared on the basis of chain type  (light or heavy chain)  and 
nature of sequence  (complete or truncated), as described in Section 4.2.1.
160Ttanstetetfwpwfge 
— p   segroemasstgnmeBlslo 
region boundaries
For wary profile segment in ft 
profile set, find the appropriatety 
ranked segment assignment In sequence
Fteed'aHsequenoeeWo 
.  -memory
Calculate profile set acora by 
summing tndMduel segment scores Align sequence in region 
with a consensus pattern 
for the region arid adjust 
region sequencer if required
Reed numbering fies 
Wo memory  ^ Bead next sequence
Any proffle segment  . 
misassignments^ ftead region information 
into memory Concatenate sequences 
of individual regions
Report that sequence 
cannot be numbered
End
Program
Figure 4.14:  Flowchart of the numbering program.  Profile segment:  First or the 
last 6 residues in every framework region Region:  Either means one of the seven 
framework regions  (LFR1,  HFR3, etc)  or a loop  (CDR-Ll,  CDR-H2,  CDR-L3, 
; etc).
161Figure 4.15 gives the algorithm for  benchmarking  the numbering pfcogrnin.  All 
sequences annotated in the Kabat database were numbered using AbNum.  The 
numbering  of AbNum  was  compared  with  the  Kabat  numbering.  The  Kabat 
database standard for numbering is very inconsistent in the range of L106-L111 
in light chains and H10G-H101  (including all residueinsertions at HI 00:  H100A, 
H100B,  H100C,  etc.)  in  the  heavy  chain.  For  ease  of comparisons  residues  in 
these zones were excluded from examination.  Sequences where the AbNum num­
bering matched the Kabat database numbering were regarded as being correctly 
numbered.  For the other cases where mismatches occurred,  a random sample of 
sequences  was selected  and  manually  examined to  determine  whether the error 
was in the AbNum numbering,  or in the Kabat database.  These statistics were 
then extrapolated to estimate the overall error percentages for the Kabat database 
and AbNum as shown in Formulae 4.4and 4.5:
and
where  E k  is  the  estimated  percentage  of errors  in  Kabat,  E a  is  the  estimated 
percentage of errors in  A bN um,  ek  and ea  are the number of errors identified in 
Kabat  and  AbNum  respectively  in  a sample of N s  sequences,  Ua  is the number 
of sequences that  A bN um was unable to number,  N m is the total number of mis­
matches between A bN um and Kabat and N t is the total number of sequences.
ek  x  N m  100
E k = — v r * N ;
(4.4)
(4.5)Chain type Status Total number 
of sequences
Numbered Match Kabat  '
Light Complete 794 793 682
Light Truncated 3044 3014 2688
Heavy Complete 2641 2622 2416
Heavy Truncated 1272 1245 793
Table 4.11:  Number  of sequences  numbered  by  AbNum  that  matcb the Kabat 
database annotations.
Table 4.11  gives the  numbers  of sequences  that  could be numbered  by AbNum 
and agreed with manual numbering in the Kabat database.
Table 4.12 shows the results of the benchmarking study.  All discrepancies in the 
AbNum numbering and Kabat database annotations were attributed to errors in 
the manual Kabat numbering.  Every sequence that could be numbered by AbNum 
appears to have been numbered accurately.
- r6 ’
4,3  Analysis of errors in the Kabat database
Siiace the manual examination of discrepancies between AbNum numbering and 
the Kabat database numbering seemed to suggest that all were errors in the Kabat 
database, I set out to examine the source of these errors.  All sequences for which 
the  AbNum  numbering  differed from the Kabat  numbering were isolated and  a 
region-wise distribution of these differences is shown in Table 4.13.
The  following  sections  detail  the  nature  of errors  in  each  of these  regions.  All 
definitions of regions described here are Kabat standard definitions.
163Kabat
Split into 4 datasets
Can sequence 
be numbered 
using AbNum Select a random sample of 
50 sequences
Does Kabat database 
numbering match 
AbNum numbering?
Manually pxaminas 
each sequence to 
ascertain source of error
Consider AbNum 
numbering and 
Kabat numbering 
annotation as correct
Categorize error as 
Kabat annotation error 
or AbNum error
Extrapolate to total 
number of errors
Calculate overall percentage of 
Kabat database annotation 
error and AbNum error
Figure 4.15:  Algorithm for benchmarking the numbering program.
164Chain type Total number Not numbered Do not match Sample Error (%)
of sequences Kabat size Kabat AbNum
Light chain complete 794 1 111 50 50/50 (14%) 0/50 (0.12%)
Light chain truncated 3044 30 326 40 40/40 (10.7%) 0/40 (1%)
Heavy chain complete 2641 19 206 50, 50/50 (7.85%) 0/50 (0.72%)
Heavy chain truncated 1272 27. 452 39 39/39 (10.7%) 0/39 (2.12%)
Table  4.12:  Benchmarking  the  performance  of AbNum:  comparison  with  the  Kabat  database  annotations.  The  percentages 
reported in the last two columns are estimated error percentages based on the sample set examined manually.Chain type Total number of 
mismatches FRl Loopl
Number of errors 
FE2  Loop2  FR3 Loop3 FR4
Light chain complete 111 0 13 5  54  72 43 8
Light chain truncated 326 5 71 7  112  73 187 49
Heavy chain complete 206 70 4 13  71  47 92 10
Heavy chain truncated 452 294 11 2  34  34 149 73
Table 4.13:  Region-wise distribution of errors in the Kabat database.
/Label LI L2 L3 L4 L5 L6
AbNum Q S A L T Q
Kabat Q  • S A L T Q
Label L7 L8 L9 L10 L ll L12
AbNum P A S - V S
Kabat P A S V S G
Label L13 L14 L15 L16 L17 L18
AbNum G S P G Q S
Kabat -  • S P G Q 3
Label L19 L20 L21 L22 L23
AbNum I T I a  . . C
Kabat I T I S C
Figure 4.16:  Kabat annotation error in LFRl.  The l*residue deletion is placed at 
LI 3 1  % Kabat although the Kabat  standard, imposesthat it  must instead be at 
L10.
Analysis of errors in the light chain
The Kabat standard assigns residues L1-L23 to LFRl.  The usual length of LFRl 
is  23  residues  with a  possible  1-residue  deletion  which  according  to  the  Kabat 
standard is at position L10.  However, as the LFRl numbering for the protein B3 
(Kalsi  et d.,  1996)  in Figure 4.16 demonstrates the position of deletion in Kabat 
is not consistent.  Such errors have been corrected by AbNum as the position of 
deletions has been enforced.
Similarly, incorrect numbering has been observed in CDR-Ll.  The Kabat standard 
*  assigns residues L24-L34 to CDR-Ll with L27 as the indel position.  A number of 
incorrect assignments have been observed in this region such as the one shown in 
Figure 4.17 for the protein SSbPB (Ivanovski et d., 1998).  In the example, the one- 
residue insertion must be placed at L27A (the second Serine in RASQ5VSSSYLA) 
whereas the Kabat database places the insertion at L27F with no L27A....L27E.
167Label L24 L25 L26 L27 L27A L27R
AbNum R A S Q S ■
Kabat R A s Q
-   ■ -
Label L27C L27D L27E L27F L28 L29
AbNum - - - - V S
Kabat - - - s V S
Label L30 L31 L32 L33 L34
AbNum S S Y L A
Kabat s s Y L A
Kabat annotation error  in LI. The one-res
(RASQ5VSSSYLA)  has been assigned L27F by  database. although it
should have been assigned L27A.
A dilferenttype of error has been observed to occur for the regions LI, LFR2, L2 
and LFR3 as shown in Figure 4.18,  The example shown is for the light chain of 
the antibody SBLC5.1 (Hohman et al., 1992).  The end of LI has been incorrectly 
annotated  and the  error  can  be  seen  to  extend  all  the  way  up  to  LFR4.  The 
example in Figure 4.19 shows a similar case where the boundaries of L3 and LFR4 
Have been incorrectly assigned in the Kabat database.
Analysis of errors in the heavy chain
In  the  heavy  chain  too,  similar  errors  with  respect  to  incorrect  assignment  of 
region  boundaries  have  been observed.  This  is  particularly  clear  in  the  case  of 
the H2-HFR3 region.  The Kabat numbering for HFR3 is from H66  to H94 and 
most sequences have a 3-residue insertion at H82 (H82A, H82B, H82C). However, 
my  analysis  of  mismatches  between  the  Kabat  and  AbNum  numbering  led  me 
to discover a large number of discrepancies between the two annotations  (nearly 
30%).  An example of this is shown in Table 4.20 which gives the Kabat database 
numbering  and  the  AbNum  numbering  for  CDR-H2  and  HFR3.  This  sequence
168Original  sequence
DPVLTQPGSISSSPGKTVTITCTMSGGTISSYWASWYWQ
KPDSAPVFVWSESDRMASGIPNRFAGSVDSSSNKMHLTI
TNVQSEDATDYYCAAAASRSPYRSIFGSGTKLNLGSPR
AbNum assignment
LFRl:  DPVLTQPGSISSSPGKTVTITC 
LI:  TMSGGTISSYWAS 
LFR2:  WYWQKPDSAPVFVWS 
L2:  ESDRMAS
LFR3:  GIPNRFAGSVDSSSNKMHLTITNVQSEDATDYYC 
L3:  AAAASRSPYRSI 
LFR4:  FGSGTKLNLGSPR
Kabat  database assignment
LFRl:  DPVLTQPGSISSSPGKTVTITC 
LI:  TMSGGTISSYWASWY 
LFR2:  WQKPDSAPVFVWSES 
L2:  DRMASGI
LFR3:  PNRFAGSVDSSSNKMHLTITNVQSEDATDYYC 
L3:  AAAASRSPYRSI 
LFR4:  FGSGTKLNLGSPR
Figure 4.18:  Errors in the Kabat annotation in regions L1-LFR3.  AbNum assigns 
the boundaries of each of the regions correctly (marked in blue) whereas the Kabat 
annotation (which is wrong)  is marked in red.
169Original sequence
SYELTQPPSVSVPPGQTARITCSGDALPKKFAYWYQQ
KSGQAPVLVIYEDNKRPSEIPERFSGSSSGTMATLTI
SGAQVEDEGDYYCYSADINAKRVFGGGTKLTVLGQP
AbNum assignment
LFRl:  SYELTQPPSVSVPPGQTARITC 
LI:  SGDALPKKFAY 
LFR2:  WYQQKSGQAPVLVIY 
L2:  EDNKRPS
LFR3:  EIPERFSGSSSGTMATLTISGAQVEDEGDYYC
L3:  YSADINAKRV
LFR4:  FGGGTKLTVLGQP
Kabat  database assignment
LFRl:  SYELTQPPSVSVPPGQTARITC 
LI:  SGDALPKKFAY 
LFR2:  WYQQKSGQAPVLVIY 
L2:  EDNKRPS
LFR3:  EIPERFSGSSSGTMATLTISGAQVEDEGDYYC 
L3:  YSADINAKRVFG 
LFR4:  GGTKLTVLGQPKA
Figure  4.19:  Errors  in the  Kabat  annotation in  L3-LFR4.  AbNum  assigns  the 
boundaries of each of the regions correctly (marked in blue) and the Kabat anno­
tation (which is wrong)  is marked in red.
170Label H50 H51 H52 H52A H52B H53 H54 H55
AbNum R F H S G R N P
Kabat R F H - - S G R
Label H56 H57 H58 H59 H60 H61 H62 H63
AbNum P Q Y A S E A V
Kabat N p P Q Y A S E
Label H64 H65 H66 H67 H68 H69 H70 H71
AbNum K G R V T A S T
Kabat A V K G R V T A
Label H72 H73 H74 H75 H76 H77 H78 H79
AbNum D S S S C Y M Q
Kabat S T D S S S C Y
Label H80 H81 H82 H82A H82B H82C H83 H84
AbNum M N S L - - K T
Kabat M Q M N S L K T
Label H85 H86 H87 H88 H89 H90 H91 H92
AbNum E D T G I Y Y C
Kabat E D T G I Y Y C
Label H93 H94
AbNum E D
Kabat E D
Figure 4.20:  Kabat database error in the H2-HFR3 region of Axol.
does  not  have  the  usual  3-residue  insertion  at  H82  and  this  has  been  correctly 
identified by AbNum.  However, since the Kabat database annotations have largely 
been manual and the  3-residue  insert  at  H82  is very common,  the sequence  has 
been incorrectly annotated as having residues at H82A-C whereas the insert should 
have been at position H52 in CDR-H2.
1714.4  Structural analysis:  An alternate structure- 
based  numbering  scheme  to  accommodate 
indels in the framework regions
As described above, the two most widely used numbering schemes for antibodies 
are the Kabat and the Chothia schemes.  The Kabat numbering scheme (Kabat  et 
al,  1983) was based on sequence alignments and placed insertions where they oc­
curred in sequence.  Chothia and co-workers (Chothia and Lesk, 1987; Al-Lazikani 
et al, 1997) examined structures of antibodies and proposed a numbering scheme 
correcting  the  positions  of insertions  at  the  structural  level  rather  than  at  the 
sequence level.  However, only CDRs were included in this analysis and framework 
regions were not examined.
A list of antibody structures was extracted from SACS (Allcorn and Martin, 2002). 
Light chain and heavy chain sequences from 561  structures were extracted from 
the SEQRES records of the PDB files.  These were numbered using AbNum and 
the  numbering  was  patched  into  the  PDB  files  using  patchpdb  (Dr.  A.  Martin, 
unpublished).  The sequence of every framework region was extracted and analysed 
for  deviations  from  the  standard  lengths  described  in  Kabat  (Wu  and  Kabat, 
1970).  Structures  whose  framework  region  lengths  differed  from  the  standard 
were fitted using ProFit (Martin, ACR, h ttp : / /www. b io in f. org. uk/softw are/ 
profit/).  Where  structures  of variable  regions were  not  available,  four  or  five 
structures were chosen and fitted together to see if certain positions in the region 
are more flexible than others and therefore likely to accommodate indels.
172Region
Name
Kabat definition 
(Standard length)
Length range 
Min - Max
Kabat indel 
position
Structural 
ins.  pos.
Structural 
del.  pos.
LFR1 LI - L23 (23) 22-23 L10 - L10
LFR2 L35 - L49 (15) 14- 16 - L40 L41
LFR3 L57 - L88 (32) 31 - 40 L66 L68 L68
LFR4 L98 - L110 (12) 12-13 L106 L107 -
HFR1 HI - H30 (30) 29-34 H6 H8 H8
HFR2 H36 - H49 (14) 13-  14 - - H42
HFR3 H66 - H94 (29) 30-34 H82 H72 -
Table  4.14:  Table  comparing  the  Kabat  indels  with  the  structurally  corrected 
indels.
Table 4.14 compares the results of this analysis with the Kabat standards for the 
positions of insertions and deletions in the framework regions.  For LFR1  (Kabat 
definition LI to L23) which has a standard length of 23 residues, a structure with 
22 residues  (PDB  Code 2vit  (Fleury  et  a l,  1998))  was found.  2vit  also has an 
LFR4  (Kabat  definition  L98  to  LI 10)  length  of  13  residues  compared  with  the 
standard  length of 12  residues.  I fitted the  LFR1  and  LFR4  regions  of 2vit  to 
that of 12e8  (Trakhanov et al., 1999) which has standard lengths in these regions. 
For the remaining regions however,  no structures with unusual framework region 
lengths exist.
The fitted structures of light and heavy chain framework regions are shown in Fig­
ures 4.21  and 4.22 respectively indicating the Kabat indel sites and my proposed 
structurally correct sites.
The case of HFR3  is particularly interesting.  The Kabat definition for HFR3 is 
from H66 to H94, a standard length of 29 residues.  In most heavy chains however, 
there  is a 3-residue  insertion  in  HFR3  which Kabat  designates  as  being at  H82 
(H82A,  H82B,  H82C);  see Figure 4.23a.  There are a small number of sequences
173that do not contain this insertion, but because this situation is rare, the majority 
of these are erroneously annotated in Kabat as containing the 3-residue insertion 
in  HFR3  whereas  the  residues  should  be  inserted  in  CDR-H2  at  position  H52 
(Figure 4.23b).  In total,  74 sequences in Kabat were identified where the end of 
the CDR-H2 and the start of heavy chain framework region 3 have been annotated 
incorrectly.
Further analysis of HFR3 indicates that position H82 is unlikely to accommodate 
insertions.  A pairwise sequence alignment  between antibodies axol  (Patel and 
Hsu, 1997) and m ab ll3  (Mantovani et al., 1993) as shown in Figure 4.24 suggests 
that H72  is the likely position of the  3-residue  insertion.  Figure 4.25 shows the 
spacefilled representation of the Fv region of an antibody.  Residues that would be 
numbered H72 and H82 are indicated and it can be seen that H82A-C are relatively 
buried while H72A-C are on the surface making it more likely that these residues 
would be deleted.  This is further corroborated by the work of Annemarie Honegger 
(Honegger  and  Pliickthun,  2001)  who  analysed  the  sequences  and  structures  of 
light chain and heavy chain variable regions of antibodies and suggested that the 
heavy  chain has a 2-residue insertion with respect  to the  light  chain at position 
H72.
4.5  Conclusions
In this chapter,  a new method that uses profiles to apply numbering schemes to 
antibody sequences  has been described.  This approach successfully numbers the
174‘problem’ sequence described in Section 4.1.8.  The analysis of manual annotations 
in the Kabat database shows that there is a high percentage of errors.  Based on 
structural  analysis of insertions  and  deletions  in  the  framework regions  of anti­
bodies, I have extended the Chothia numbering scheme to correct the positions of 
insertions and deletions in the framework regions.
175(a)  LFR1  (b)  LFR2
(c)  LFR3  (d)  LFR4
Figure 4.21:  Rigid body superposition of light  chain framework regions.  Colour 
codes are:  red - kabat indel position, green - structurally correct position of inser­
tion, pink - structurally correct position of deletion.
176(a)  HFR1  (b)  HFR2  (c)  HFR3
Figure 4.22:  Rigid body superposition of heavy chain framework regions.  Colour 
codes are:  red - kabat indel position, green - structurally correct position of inser­
tion, pink - structurally correct position of deletion.
H52  H82
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H53  H66
182a,  b,c
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(b)  Correct
Figure 4.23:  Numbering in H2-HFR3  (a)  The standard numbering for H2-HFR3 
in the Kabat database annotations (b) The correct numbering when the 3-residue 
insertion at H82 are not present.
177axol  QIVLTQSGSEVKKPGESMQLKCTVTGFNVNSYWMHWVRQAPG 
mabll3 QVQLVQSGAEVKRPGAPVKVSCKASGYTFTDYYMHWVQQAPG
.   .  .CDR-H2-  > <-  HFR3  .  .   .  
axol  KGLEWVLRFHSGRNPPQYASEAVKG RVTASTDS-  -  SSC 
mabll3 QGLEWMGRINPNTGGTN-  SAQKFQG RVTMTRDTSISTA
65 6789012abc345
..HFR3->
axol  YMQMNSLKTEDTGIYYCAR 
mabll3 YMELSNLRSDDTAMYSCAR 
6789012345678901234
(a)  Alignment if position of insertion is HT2
axol  QIVLTQSGSEVKKPGESMQLKCTVTGFNVNSYWMHWVRQAPG 
mabll3 QVQLVQSGAEVKRPGAPVKVSCKASGYTFTDYYMHWVQQAPG
.   .   .   CDR-  H2-  > <-  HFR3  .  .  .  
axol  KGLEWVLRFHSGRNPPQYASEAVKG RVTASTDSSSCYM 
mabll3 QGLEWMGRINPNTGGTN-SAQKFQG RVTMTRDTSISTA
65 6789012345678
•.HFR3->
axol  QMNSL-  -  KTEDTGIYYCAR 
mabll3 YMELSNLRSDDTAMYSCAR 
9012abc345678901234
(b)  Alignment if position of insertion is H82 
Figure 4.24:  Sequence alignment between antibodies Axol  and mabll3.
178H72A-H72C
Figure  4.25:  Spacefill  representation  of  the  variable  domain  of  an  antibody. 
The  colour  codes  are:  light  chain  -  blue  gray,  heavy  chain  -  pink,  HFR3  -  yel­
low  and  highlighted  by  the  white  borders.  The  residues  coloured  in  blue  and 
green  are  H72A-C  (if  insert  position  is  H72)  and  H82A-C  (if  insert  position 
is  H82)  respectively.  This  diagram  was  prepared  using  QTree  (Martin,  ACR, 
http: / / www.bioinf.org.uk/software/qtree/).
179Chapter  5
Predicting the  Vjj/Vf  interface 
angle from interface residues
The  variability  of antibodies  is  encoded  in  the  Fv region  which  consists  of two 
protein domains.  Interactions between the light  and the heavy chain contribute 
significantly to the stability  of the variable fragment  (Fv).  The  Vh/V l  interface 
between  the  light  chain  and  heavy  chain  has  been  shown  to  affect  the  binding 
kinetics of a peptide (Chatellier  et al.,  1996).  The framework region at the Vh/V l 
interface  consists  of two  /3-sheets  (Poljak  et  al.,  1973),  the  structures  of which 
are conserved  across  Fab  and  light  chain  dimers  (Chothia  et  al,  1985;  Novotny 
and  Haber,  1985).  However,  the  contribution  of residues  in  the  framework  re­
gions  to  interactions  with  the  antigen  remains  poorly  understood.  It  has  been 
demonstrated that modification of residues distant from the antigen binding site 
of the antibody has a small yet significant effect on the binding affinity with the
180antigen (Chatellier  et al, 1996; Roguska et al, 1996).  For example, Adair and co­
workers have demonstrated that modification of residue H23 significantly affects 
binding of the antibody with the antigen  (Adair  et al,  1999).  While this may be 
an impediment  for  predicting the  affinity  of engineered  antibodies,  it  must  also 
be emphasised that interactions at the V h/V l interface are crucial to maintaining 
stability of the Fab.  Understanding the influence of residues in the Vh /V l interface 
on the packing angle between the two domains would help design antibodies with 
a definable binding site topography.
In this chapter, I present an analysis of the distribution of the Vh /V l packing angle 
and a method to predict the interface angle from the nature of interface residues 
is described.  A set of conserved residues in the framework regions of VL  and  Vh 
were chosen and the interface angle was defined as the torsion angle between these 
points.  The  main  applications of trying to predict  packing angle from interface 
residues  are  in  modelling  studies  of antibodies  and  in  humanization  protocols. 
The packing  angle  between the  variable  chains  of antibodies  has  previously  not 
been  considered  when  modelling  variable  chains  of  antibodies  (Martin  et  al, 
1991; Martin  et al,  1989; Whitelegg and Rees, 2000).  Knowing the packing angle 
prior to modelling the variable region light and heavy chain may help in choosing 
more  appropriate  template  structures  upon  which  models  may  be  based.  This 
work also helps  in identifying  key residues that  influence  the packing  angle and 
therefore,  are instrumental in determining the topography of the paratope.  The 
process of humanization involves grafting of murine CDRs onto human framework 
regions  (Jones et al, 1986).  Further modification of residues flanking the CDRs is 
usually required to restore the binding affinity of the mouse antibody (Riechmann 
et al, 1988).  This could be extended by modifying residues at the V h/V l interface
181in the humanized antibody to their murine counterparts so that the topography 
of the paratope would be preserved.
5.1  Preparation of the dataset
A list of Fv and Fat, structures was extracted from the SACS  (Allcorn and Mar­
tin,  2002)  XML  file.  This  yielded  a set  of 561  antibody  structures  including  6 
anti-idiotype  antibodies  (PDB  Codes:  lcic,  ldvf,  liai,  lpg7,  lqfw,  and  2dtg). 
Anti-idiotype antibodies are antibodies derived against epitopes present in other 
antibodies.  As every anti-idotypic antibody structure consists of two antibodies, 
all anti-idiotype antibody structures were split into two and the final dataset con­
sisted  of 567  antibody structures.  This  set  comprised  314 structures  for  which 
the sequences  of the  light  chain and heavy  chain were  distinct.  Conformational 
changes  in the antibody CDRs  upon binding with the  antigen  have  been estab­
lished  in  several  studies  (Colman  et  a l,  1987;  Bhat  et  a l,  1990;  Herron  et  al, 
1991;  Rini  et  al,  1992;  Wilson  and  Stanfield,  1994;'Mylvaganam  et  al,  1998). 
The  idea  behind  allowing  redundancy  in  the  dataset  is  that  it  allows  for  vari­
ability in a given structure.  Structural fitting of antibodies was performed using 
PrdFit (h ttp : //www. b io in f. org.uk/software/prof it/) which implements the 
McLachlan algorithm (McLachlan,  1982).  The AbNum program described in the 
previous chapter was used to apply Chothia numbering to the structures of anti­
bodies.
Programs for analysis were written in C and PERL.  All graphs were created us­
182ing  GNUPLOT  and  GRACE  (h ttp ://p la sm a -g a te.w eizm a n n .a c.il/G ra ce/).
The  program  ssearchSS from  the  FASTA  package  (Pearson  and  Lipman,  1988) 
was used in the calculation of Z-scores for chain assignment.  The  Stuggart Neu­
ral  Network  Simulator  (SNNS)  (h ttp ://w w w -ra.in form atik .u n i-tu eb in gen . 
de/SNNS/)  was  used  to  make  associations  between  packing  angle  and  interface 
residues.  The  GRASS library  (Team,  2006)  was  used  for  calculation  of Eigen 
vectors and values.  The  Sun gridengine was used to distribute jobs across a grid 
consisting of the C3 and the  Queen.  The C 3 is a farm consisting of 96 IBM series 
335 nodes and the  Queen is a farm consisting of 30 nodes with each node having 
2 dual-core AMD Opteron processors.
The  ‘interface  residues’  are  defined  as  Chothia-numbered  interface  positions for 
which  there  is  a  change  in  accessibility  as  a result  of  Vh /V l  interaction.  As  a 
first step,  sequences of the light and heavy chain were extracted from PDB  files 
of the antibodies.  The Chothia numbering scheme  (Chothia and Lesk,  1987; Al- 
Lazikani  et  al.,  1997)  was applied to all the sequences using AbNum.  In the case 
of FabS, only the variable region was considered for further analysis.  The Chothia 
numbered variable region sequences were patched back into the PDB files to yield 
567 numbered Fv region structures.
Once  the  structure  files  were  prepared  with  the  Chothia  numbering  applied  to 
them, the accessibility of all residues in the light and heavy chains was calculated. 
Simon Hubbard’s naccess program that implements the algorithm described by Lee 
and Richards (1971) was used for the calculation of accessibility.  The accessibility 
of all residues in the Vh/V l complex and in the individual chains was calculated. 
Those  residues  which  sustained  any  change  in  the  accessible  surface  area  were
183regarded as being interface residues.
5.2  Calculation of the packing angle
The packing angle was defined as the torsion angle at the  Vh /V l  interface.  The 
steps involved in the calculation of the packing angle are as described below:
1.  Identify a set of residues  SL and  SH that are structurally conserved in the 
light and heavy chain respectively.
2.  Extract the C a coordinates for the residues in  SL and SH.
3.  Find the centroid for each set  (CL and CH).
4.  For each set,  compute the best-fit line passing through the centroid.
5.  Identify one point on each line P L and P H  on the same side relative to the 
respective centroid.
6.  Calculate the packing angle as the torsion angle between the points PL, CL, 
CH , and PH .
Five  antibody light  and  heavy chains  were fitted together on  all residues  in the 
variable region using ProFit to identify conserved residues at the Vh /V l interface. 
The  backbone  representations  of the  fitted  structures  are  shown  in  Figures  5.2 
and 5.3 respectively.  The regions coloured in blue correspond to residues that are 
highly conserved  across  antibody  structures.  These  are  L35-L38,  L85-L88  in
184Stop
Find the centroid 
for each set
Extract CA coordinates of 
the residues in SL and SH
For each set, compute 
a best-fit line passing 
through the centroid
Calculate packing angle as 
the torsion angle between 
these points
Perform rigid-body 
superposition for a set 
light and heavy chain 
variable domains
Identify one point on each 
line on the same side relative 
to the respective centroid
Identify a set of structurally 
conserved positions in each 
chain - SL (light chain) 
and SH (heavy chain)
Figure 5.1:  Algorithm to calculate the packing angle at the Vh/V l interface.
185Figure  5.2:  Rigid  body  superposition  of the  Ca  atoms  in five structures  of the 
light chain variable region.  The structures used were:  12e8,  15c8,  laOq,  la31, 
la3r.
186Figure  5.3:  Rigid  body superposition of the  Ca  atoms  in  five  structures  of the 
heavy  chain  variable  region.  The  structures  used  were:  :  loax,  lyec,  lyef, 
2ddq,  8fab.
187Figure  5.4:  The beta strands at the  Vh/V l interface,  best-fit  lines,  and packing 
angle.
188the  light  chain  and  H36-H39,  H89-H92  in  the  heavy  chain.  These  positions 
form part  of a beta-sheet  which  is  at  the  core  of the  interface  and  outside  the 
hyper-variable  loops.  Figure  5.4 shows  the  beta sheets,  the best-fit  lines drawn 
through them, and the packing angle.
The next step was to calculate a best-fit line for the points in  SL and  SH.  Only 
the  coordinates  of the  Ca  atoms  were  used  to  compute  the  best-fit  line.  The 
method employed was Principle  Component Analysis  (PCA) and the calculations 
were performed according to the algorithm shown in Figure 5.5.
After calculation of the packing angle across the 567 structures in the dataset, their 
frequency distribution was plotted and this is shown in Figure 5.6.  The packing 
angle varies quite considerably across different structures.  The smallest and largest 
packing angles observed were 30° and 60° in the structures 1FL3 (Simeonov et al., 
2000) and 1BGX (Murali  et  al.,  1998) respectively.  The extreme packing angles 
are shown in Figure 5.7.
5.3  Identifying interface residues
Interface residues for the 567 structures were defined as described in Section 5.1. 
Owing  to  the  variability  in  the  Vh/V l  packing  angle,  the  interface  residues  in 
any  given  structure  will  be  a  subset  of the  total  set.  A  total  of  124  positions 
(63  light  chain  and  61  heavy  chain positions)  were  identified  as  contributing to 
the interface  in at  least  one of 567 structures.  Figure 5.8 shows  the plot  of the
1891.  For points in a set  (SL or  SH) calculate centroid C  (CL or CH).
2.  Compute the covariance matrix.  The pseudocode for this is given below:
For  i®0  to   3 (number  o f  dim ensions)
Do
For  j*0  to   3 (number  o f  dim ensions)
D o   ' *   ;
T otal  *  0
For  start= 0  to   4  (number  of  p o in ts  in   s e t  SL  or  SH)
Do  \
T otal+*(  x [ s t a r t] [ i]   -   C ti]  )  *
(  x [sta r t] [j]  -  C [j]  )
Done  /*   End  of  loop  For  sta rt* 0   to   4  * /
C o v a ria n ce(i,j)  *  Total/(num ber  o f  p o in ts  in   SL  or  SH)
Done  /*   End  of  For  to   3  * /
Done  /*   End  of  For  i=0  to   3  */
3.  Perform an eigen decomposition for the covariance matrix.  Calculate eigen 
values and eigen vectors.
4.  The eigen vector represented  by the largest eigen value is the best-fit line 
when it passes through the centroid.
Figure 5.5:  Algorithm used in the calculation of the best-fit line for the light and 
heavy chain variable regions.
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Figure 5.6:  Frequency distribution of the packing angle.
191(a)  1FL3
(b)  1BGX
Figure 5.7:  Extreme packing angles in (a)  1FL3 - 30°  (b)  1BGX - 60°.
192Frequency distribution at interface: light chain
6 0 0
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(a)  Light chain 
Frequency distribution at interface: heavy chain
600
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Figure 5.8:  Frequency distribution of interface residues in (a) The Light chain and 
(b) Heavy chain.
193frequency distribution of interface residues in the light chain and heavy chain.
5.4  Predicting packing angle from interface residues
It  was  decided  to  use  a  neural  network  to  predict  the  packing  angle  from  the 
interface  residues.  Amino  acids  representing  the  interface  residues  in  different 
structures  were  used  as  input  for  the  neural  network  and  the  output  was  the 
packing angle.  The process of training a network involves supplying a set of input 
patterns  and  the  output  (the  result  to  be  predicted)  values  to  help  the  neural 
network ‘learn’ from the data.  Once the network has passed the learning phase, it 
is supplied with inputs for which it is expected to make predictions of the output 
values.  The predictions of the neural network are compared with the actual values 
and  the  performance  of the  neural  network  is  assessed.  Here,  a  five-fold  cross 
validation was performed.  In this procedure,  the neural network is trained on  | 
of the total data available and the quality of its training is evaluated by assessing 
its predictions on the remaining  |  of the data.  This is repeated on each slice of 
the data and the overall performance is averaged over the five folds.
The  input  is  fed  to  the  neural  network  in  the  form  of numbers  that  represent 
the  amino  acids  at  the  interface.  A  common  method  of doing  this  is  using  a 
20-dimensional  binary vector  representing  the  20  amino  acids  or  values  from  a 
similarity matrix.  The binary vector contains nineteen O s and one  1  to indicate 
a specific amino acid or values from a similarity matrix.  The input layer size is 
calculated as:
194Si =  Naa X Se (5.1)
where 5*, N m , and S e represent the Input layer size, Number of amino acids and 
size of the encoding vector respectively.  As described above, there are a total of 
124 potential interface positions.  By applying equation 5.1 and using 20 numbers 
to represent one of the 20 amino acids, the size of the input layer would be 2480.
The total number of variables in the network is defined as:
Nv~($iX: Sh)HSkXS0 ) .  (5.2)
where  N v  is the number of variables in the network,  Si  is the number of nodes
in the input layer,  Sh is the number of nodes in the hidden layer,  and  SQ  is the 
£   •   -   -  
number of nodes in the output layer.  If we use 10 hidden nodes and a single output
node to represent the packing angle, then the number of variables in the network
would be 24810.  As a rule of thumb,  it is recommended to use 3Nv patterns to
train a neural network.  Hence,  it would have ideally required data from about
j  75000 structures to train and validate the network successfully.  Considering that
only about 570 structures were available, I decided to restrict the number of input
variables by applying the following rules:
•  By using only 4 numbers to represent every amino acid instead of 20.
•  By limiting the number of interface positions (used in training and validating
195the neural network) to 20 instead of 124.
The four numbers used to represent every amino acid were chosen on the basis of 
the following physical properties:
1.  Size of the amino acid, in terms of the number of atoms in the side-chain.
2.  Size of the amino acid expressed as the shortest path from the Ca atom to 
the atom farthest away from it, i.e.  the length of the sidechain.
3.  Hydrophobicity
4.  Charge
's-   .  -
Table 5.1 lists the numbers used to represent the 20 different amino acids.  The hy­
drophobicity scales used were taken from the consensus values reported by Eisen- 
berg  et a l.  (1982).  I  decided  to  use  a  4-dimensional  encoding  vector  with  20 
interface residues chosen as being most likely to influence the packing angle.  By 
ddng this, the input layer size was reduced to 80 nodes.
Initially, a manual selection of 20 interface residues most likely to influence the 
packing angle made using the following sets of criteria:
Method I  Highest change in Accessible Surface Area (ASA) in any one structure. 
Method II  Highest average change in ASA
Method III  Most frequently occurring positions with highest change in ASA
196Amino acid Size
NS
Size
SP-
Hydrophobicity Charge
Alanine (A) 1 1 0.250 0
Valine (V) 3 2 0.540 0
Leucine (L) 4 3 0 .5 3 0 0
Isoleucine (I) 4 3 0.730 0
Proline (P) 3 4 -0 07 0
Methionine (M) 4 4 0 26 0
Phenylalanine (F) 7 5 0.610 0
Tryptophan (W) 10 6 0.370 0
Glycine (G) 0 0 0.160 0
Serine (S) 2 2 -0.26 0
. Threonine (T) 3 2 -0.18 .0
Cysteine (C) 2 2 0.04 0
Asparagine (N) 4 3 -0.64 0
Glutamine 5 4 -0.69 0
Tyrosine (Y) 8 6 0.02 0
Aspartate (D) 4 3 -0.72 -1
Glutamate (E) 5 4 -0.62 -1
Lysine (K) 5 5 -1.1 1
Arginine (R) 7  . 6 -1.8 1
Histidine (H) 6 4 -0.4 0.5
Table 5.1:  Amino acid properties for size, hydrophobicity and charge.  N S: number 
of side chain atoms in the amino acid; SP: shortest path to the atom farthest away 
from the Ca atom of the residue.  0.5 was chosen as the charge for Histidine to 
-  represent the fact that it can exist in both charged and uncharged states.
«
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Figure 5.9:  Architecture of a fully connected network.  Not shown in the figure are 
the connections between every pair of nodes in the input layer and hidden layer 
and between nodes in the hidden and output layer.
Method IV  Most frequently occurring positions with highest average change in 
ASA
The top 10 positions in each chain (light and heavy) were taken and a 5-fold cross 
validation was performed.  Table 5.2 lists the interface positions that were manu­
ally selected.  A fully connected artificial neural network was constructed with the 
*  architecture shown in Figure 5.9.  Using the Stuggart Neural Network Simulator 
(SNNS) the neural network parameters:  learning function, update function,  ini­
tialisation function, shuffling and number of cycles were varied and the following 
values were found to be most optimal for the problem:
1.  Number of cycles of training - 150Method IV
Method  ■   '  ~   Interface j^ fio n s
L34, L36, L44, L46, L50 
M  .  , ,  ‘   L87, L89, L91, L96, L98
°a  H35, H47, H91, H100B, H100C
H100D, H100I, H100G, H100M, H103 
L34, L36, L43, L44, L46
y   ,,  , T T   L86, L87, L89,  L91, L98
Me  H35, H47, H91, H100B, H100C
H100D, H100G, HIW, *1®0M, H103 
—   L32;ES4,136,  L44, L46
,,  , T T T   ,L50, M M i L91,  L96, L98
Method 111  H45, H47, H50, H91, H99
HlOO, HlOOA, HiQQB, H1G1, H103 
L34, L36, L38, L43, L44 
L46, L87, L91, L96, L98 
H39, H45, H47,1191,1 »  
HlOO, HlOOA, HIOOB, H101, Hit®
Table  5.2:  Manually  chosen  interlace  positions  based  on  methods  (I)  Highest 
change  in ASA,  (II)  Highest  average  change in ASA,  (III)  Most  frequently oc­
curring positions with highest change in ASA, and (IV) Most frequently occurring 
positions with highest average change in ASA.
2.  Training until sum-of-squares error (SSE) becomes <='1.5
,  3.  Init function - Randomise weights
4.  Learning function - RProp
5.  Update function - Topological order
6.  Pruning function - Magnitude pruning.
7.  Shuffling - TRUE
8.  Number of hidden nodes - 10.
A neural network consists of a set of ‘perceptrons’ which generate values between 
0 and 1 u§ing a sigmoid function applied to a weighted sum of the inputs:
199Method Average Pearson’s coefficient
over 5 folds
I 0.32
II 0.38
III 0.40
IV 0.30
Table 5.3:  Results of a 5-fold evaluation over interface positions chosen manually 
using the four methods described in the text.  The correlation coefficient reported 
has been averaged over the 5 folds.
0 = f (£ w ixi)  (5.3)
i= 1
where O is the output of the perceptron, /()  is the sigmoid transfer function, X i 
is an input,  Wi is an weight and N is the number of inputs.  I therefore decided 
to represent all output values  (packing angles)  by a value between 0 and  1.  The 
scaling of packing angles was done according to:
n  0  $min  / c  a\
9 >  =   a— T T ~   (5'4) "max  "min
where O f is the interface angle fraction, 0 is the interface angle, 0max is the maxi­
mum observed interface angle, and 0m\n is the minimum observed interface angle. 
From manual examination,  it  appeared that  shuffling the training data  (item  7 
in the  list of optimal SNNS  parameters shown above)  while training the neural 
network had a positive effect.  However, this could not be used when training and 
validating the  neural  network  through  scripts  as  it  appears that  this  feature  is 
only supported by the graphical interface to SNNS.
2 0 0To evaluate the performance of the neural network, the Pearson’s correlation co­
efficient  (r)  was initially used to compare the output of the neural network and 
the actual scaled packing angle (between 0 and 1):
rxy  ~
E(xi-x)(yi-y) 
i—1____________________
(71  l)S;j;Sy
(5.5)
where rxy is the Pearson’s correlation coefficient between two variables x and y, 
n is the number of data points, Xi and yi are the individual values of variables x 
and y, and sx and sy are the standard deviations of the two distributions x and y.
Table 5.3 shows the result of training and validating the neural network based on 
the manual selection of interface positions.  None of the methods to select interface 
residues manually worked particularly well as the Pearson’s correlation coefficient 
for all methods was low.  However,  from manual examination of correlation coef­
ficients over single folds, correlation coefficients as high as 0.6 had been observed.
I therefore decided to have the computer sample sets of interface positions to find 
the combination that would be most predictive of the packing angle.
5.5  Using a genetic algorithm to sample the interface- 
residue space
The  use  of a  genetic  algorithm  (GA)  for  feature  selection  (i.e.  to  sample  sets 
of interface residues  and pick the most optimal set)  appeared to be a potential
201L17 L32 L43 L50 L85 H33 H44 H53 H89 H96
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Figure  5.10:  An  individual  to represent  10 interface positions.  From the string 
shown, those  alleles with a 1  imply the inclusion of the residue at the respective 
interface position for training and validation of the neural network.
solution to the problem of low scores of manually selected interface positions.
The  overall  method  of the  genetic  algorithm  developed  to  sample  the  space  of 
interface residues is described below:
1.  Create a random population of individuals where each individual represents 
a set of interface positions, each allele being a 1  or 0 to indicate whether a 
given interface position is included in training the neural net.
2.  Evaluate the quality of each individual by training and validating the neural 
network over 5 folds  (5-fold cross-validation)
3.  Create a new population of individuals by crossover of high-scoring individ­
uals.
4.  Repeat the above steps for as many generations as required.
20 2Parent A;  011100100110
Crossover point  |
Parent B:  010110000110
Offspring A:  011110000110 
Offspring B:  010100100110
Figure 5.11:  Crossover of two high-scoring individuals A and B
The first step involves the creation of a random population of individuals.  Every 
individual is a string whose length is the number of interface positions.  It consists 
of a set of 0s and Is (alleles) and represents a selection of interface positions to be 
used to train and validate a neural network.  This is demonstrated in Figure 5.10. 
The  quality  of every  individual  is  assessed  by  training  the  neural  network  and 
averaging  the  Pearson’s  correlation  coefficient  over  5  folds.  Initially,  a random 
population of individuals is created and the quality of every individual is assessed. 
A new population of individuals is then generated by selective  crossover of high 
scoring individuals which is shown in Figure 5.11.  Newly created offspring individ­
uals are subject to random mutations at a rate referred to as the m utation rate  (pi). 
In this work, unless otherwise specified, a default mutation rate of 0.0001 has been 
used for Rank-based selection (See Section 5.6).  Once the random mutations have 
been effected,  the offspring individuals become  children.  These children become
203the parents for the next generation.  They are scored by training and validating 
the neural network and further  generations  of the  genetic algorithm progress in 
the same way.  These steps are repeated until the required number of generations 
have been completed or the population has converged.
5.6  Methods of selection
In the process of creating offspring through crossover, a bias is made towards the 
selection of parents that have high scores.  There are many selection methods for 
choosing the parents and in this project, I primarily used Roulette-wheel based 
selection and Rank-based selection.  These selection strategies have already been 
addressed in Chapter 2.
Generation Best Pearson’s r
Rank Roulette-wheel
1 0.4964 0.4980
2 0.5039 0.5082
3 0.5039 0.5082
4 0.5007 0.5082
5 0.5039 0.5082
6 0.5167 0.5082
7 0.5159 0.5082
8 0.5122 0.5082
9 0.5581 0.5054
continued  on next page
204c o n tin u e d  fro m ,  p r e v io u s   p a g e
Generation Best Pearson’s r
Rank Roulette-wheel
10 0.5266 0.5082
11 0.5271 0.5082
12 0.5581 0.5054
13 0.5581 0.5054
14 0.5318 0.5082
15 0.5503 0.5082
16 0.5703 0.5082
17 0.5703 0.5054
18 0.5586 0.5082
19 0.5703 0.5082
20 0.5572 0.5082
21 0.5703 0.5054
22 0.5703 0.5082
23 0.5703 0.5082
24 0.5703 0.5082
25 0.5703 0.5082
26 0.5626 0.5082
27 0.5910 0.5082
28 0.5910 0.5082
29 0.5910 0.5054
30 0.5829 0.5082
continued  on next page
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Generation Best Pearson’s r
Rank  Roulette-wheel
31 0.5870 0.5082
32 0.5910 0.5082
33 0.5910 0.5054
34 0.6006 0.5082
35 0.5910 0.5082
36 0.5946 0.5082
37 0.6149 0.5082
38 0.6006 0.5054
39 0.5910 0.5054
40 0.5910 0.5082
Table  5.4:  Comparing  Roulette-wheel  and  Rank-based 
selection methods.  The table shows the best Pearson’s r 
calculated over 40 generations of a GA run.
The effectiveness of a selection procedure is largely assessed by the ability of the 
procedure to keep the population diverse (i.e.  avoid local minima) and yet achieve 
convergence in a reasonable time span.  To decide on the method best suited for 
the  current  problem,  I  performed  test  runs  of the  GA  on  small  populations  of 
individuals for short durations using both Rank-based and Roulette-wheel based 
selection methods.  Results from a sample run are summarised in Table 5.4.  Prom 
the table, it can be seen that the initial scores were nearly equal (0.496 in Rank and
2060.498 in Roulette-wheel based  selection).  However,  there is a steady increase in 
best score for Rank-based selection whereas the best score remains largely static 
for Roulette-wheel  based  selection.  It  was  therefore  decided  to  use  Rank-based 
selection for future runs of the GA.
5.7  Problems:  Redundancy  in  individual popu­
lation and intelligent selection
A problem with Rank-based  selection that  became  apparent  after a few tens of 
generations of the  GA was that the population of individuals was  becoming de- 
creasingly diverse.  Figure 5.12a shows a graph of a GA run where Rank selection, 
together with a mutation rate of 0.0001 were used.  The score of the best individ­
ual at the end of 50 generations was 0.638.  This could have meant either a)  The 
genetic  algorithm was  converging to  a globally optimal  solution,  or  b)  The  GA 
was getting stuck in a local minimum problem.
It was assumed that the GA was getting stuck in  a local minimum and,  as will 
become clear from the following sections, this was indeed the case.  I developed an 
alternative method to alter the mutation rate dynamically during crossover.
In  Rank-based  selection,  the  creation  of new  child  individuals  is  done  by  bias­
ing selection towards high-scoring parents.  A  crossover point is chosen randomly 
within the parents and the two parts of the parents are combined to yield offspring 
(Figure 5.11).  When the number of redundant  individuals in the population in-
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Figure 5.12:  Redundancy of individuals in a GA run using Rank-based selection 
with  (a)  5000 individuals and /i=0.0001  (b)  1000 individuals and /z=0.001.
208creases,  the chances of choosing two identical individuals randomly for crossover 
also increases.  Crossover of identical individuals would clearly yield a child iden­
tical to the parents.  Since the  mutation rate applied to the offspring individual 
is very  low  (0.0001),  the  final offspring  are  likely  to  be  unchanged.  However,  a 
higher mutation rate (/p=0.001) did not help curb the exponential rise in the num­
ber of redundant  individuals with the passage of every generation.  Figure 5.12b 
shows that  the population of individuals quickly saturates and by the end of 60 
generations, nearly the entire population of individuals is redundant.
As  a solution  to the  problem  of individual  redundancy,  I  developed  a combina­
torial approach.  Parent  individuals are selected  using Rank-based selection,  but 
a  modification  to  the  strategy  of using  a  standard  mutation  rate  was  made  so 
that the mutation rate was varied dynamically, depending on how similar the par­
ents selected for crossover are.  The method, which I term  Intelligent selection, is 
described below:
1.  For every child  individual to be created,  select  2 parents PI  and P2  based 
on Rank Based Selection.
2.  Choose a cross over point and splice PI  and P2 to create a child Op
3.  Calculate the degree of similarity 5(pi,p2) between the parents PI and P2 as 
given by:
c  _  C (piiP2)  / c   ^
£>{p i,P2)  -   t ;     (5.6)
(P1,P2)
where C(pi5 p2)  is the number of active alleles common between  P I  and  P 2
209and  iV(Pi,P2)  is  the  sum  of  active  alleles  in  P I  and  P2.  When  the  two 
parents  are  completely  identical,  the  similarity  is  0.5  whereas  when  they 
have no common alleles, the similarity is 0.
If (0.45  <=  S'(pi)p2) <= 0.5), then swap five Os and Is in O*.
If (0.35  <=  S'(pi)p2) <  0.45), then use a mutation rate of 0.01 on O*.
If (0.25  <=  £(pi5 p2) <  0.35), then use a mutation rate of 0.008.
if (0.15  <=  5(pi5 p2) <  0.25), then use a mutation rate of 0.005.
if (0 <= 5(pi,p2)  < 0.15), then use a mutation rate of 0.001.
I used a generational replacement strategy in which the entire population of par­
ents  was  replaced  by  children.  In  addition,  I  maintained  a record  of the  best 
parent  from every  generation.  By  using generational replacement,  the  interface 
position space can be explored better and by keeping a record of the best individ­
ual in every generation, it was possible to report the score of the best-performing 
individual in the entire GA run.
By varying the mutation rate, it became possible to keep the population diverse 
and  therefore  sample  many  different  combinations  of the  possible  ‘interface  po­
sition space’.  Figure  5.7 shows a comparison of the performance of Rank-based 
selection and Intelligent selection for similar runs of the GA using a population of 
5000 individuals over 50 generations.  It must also be highlighted that the best in­
dividual at the end of 50 generations in Rank selection had a Pearson’s r of 0.638 
while  the  Pearson’s  r  for  the  best  individual  after  50  generations  in  Intelligent 
selection was 0.63.  In the limited test of 50 generations,  the intelligent selection
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Figure  5.13:  Comparing  Rank  and  Intelligent  selection  strategies.  Both  plots 
correspond to GA runs with 5000 individuals over 50 generations.
211Predicted vs. Actual interface angle fractions
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Figure 5.14:  Plot of the predicted interface angle fractions vs.  the actual interface 
angle fractions  for  the  individual  with  the  best  Pearson’s  correlation  coefficient 
(0.6442).  Perfect predictions would lie on the blue dotted line.
method was able to find a best solution which was just as good as the best solution 
from rank-based selection but still maintained a diverse population to avoid local 
minima.  I decided to perform all further GA runs using the intelligent selection 
method.
5.8  Scoring the  quality of each individual
Initially,  the  score  of all  individuals  was  evaluated  as  the  Pearson’s  correlation 
coefficient between the predicted and actual interface angle fractions.  However, the
212Pearson’s r is not very reflective of the actual performance of the neural network 
in  terms  of the  accuracy  of predictions.  This  is  demonstrated  by  the  graph  in 
Figure 5.14 which plots the actual interface angle fraction (between 0 and 1) versus 
the predicted interface angle fraction for the individual with the best Pearson’s r 
(0.644).  From the graph, it may be noticed that the errors (given by the distance 
of the data points from the blue dotted line)  in predictions for very low or high 
interface  angles  is  large.  Despite  the  large  error,  the  Pearson’s  r  between  the 
actual and predicted interface angle is high.  I therefore also assessed the quality 
of every  individual  by  means  of the  error  difference  between  the  predicted  and 
actual values.  For this,  I used the Root mean square error which is calculated as:
where R M S E  is the root mean square error, x*  is the actual interface angle frac­
tion, and pi is the predicted interface angle fraction.  The score was calculated as 
1 -  R M S E .
However, the RMSE was not reflective of the actual magnitude of error.  Since the 
packing angles are scaled to a value between 0 and 1, the RMSE is indicative of the 
error at the scaled level and not in terms of the actual angular error in degrees. 
Packing  angles  that  are  either  very  low  or  very  high  and  don’t  have  sufficient 
representation  in  the  dataset  tend  to  be  predicted  with  high  errors.  However, 
this is not adequately reflected in the RMSE as the overall RMSE over the entire 
dataset  tends  to  be  quite  low  owing  to  good  predictions  for  a  majority  of the
n
(5.7)
213packing  angles  that  are  sufficiently  represented  in  the  dataset.  This  led  me  to 
search for an alternate statistic to score the quality of predictions so that the error 
in extreme packing angles would be reflected.
The relative RMS error (Masters, 1993) calculates the RMS value of the error and 
takes the ratio of this value with respect to the sum of the actual values.  This is 
computed as:
where R E L R M S E  is the relative root mean square error, Xi is the actual interface 
angle fraction, and pi is the predicted interface angle fraction.  The Relative RMS 
error is calculated over five folds for every individual and the score for an individual 
is calculated as:
From initial  performance  statistics,  it  appeared  that  the  RELRMSE  was  much 
more sensitive to errors in predictions of small and large packing angles than the 
RMSE  and  I  decided  to  assess  the  quality  of all  individuals  using this  statistic 
instead of the RMSE or the Pearson’s correlation coefficient  r.
E (%i ~ P if
R E L R M S E  =
i= 0 (5.8)
S C O R E  = 1 -  R E L R M S E (5.9)
214Parameter Value
Neural network
Cycles of training 
SSE during training 
Init function 
Learning function 
Update function 
Pruning function 
Shuffling 
NH
Genetic algorithm
Selection method 
Scoring method
Intelligent selection 
Relative RMS error
Randomise weights 
RProp
Topological order 
Magnitude pruning 
FALSE 
10
150
<=  1.5
Table 5.5:  Standard parameters for the Neural network and the Genetic algorithm. 
NH: Number of hidden nodes, SSE:  Sum of square error.
5.9  Results of GA runs
5.9.1  Prediction the  Vh/Vl packing angle
To summarise,  a GA had been designed to perform feature selection for training 
the  neural  network  to  predict  the  V h/Vl  packing  angles.  The  fitness  function 
for the GA was the performance of the neural network evaluated over a five-fold 
cross-validation and averaging the scores calculated using the Relative RMS error 
over the five folds.
Once I had standardized parameters for the neural network and the genetic algo­
rithm  (summarised  in Table 5.5),  I initiated large scale runs of the genetic algo­
rithm involving thousands of individuals for several thousand generations.  Owing 
to the elaborate computations involved in this, it typically takes about 25 seconds
215to perform a 5-fold cross-validation of an individual.  The runs were performed on 
large farms over a period of several months.  Problems were encountered at several 
stages of the GA largely owing to issues related to the Network file system (NFS). 
This slowed down the overall speed of execution of the GA.
Individuals were chosen to represent the following sets of interface positions:
•  All interface positions.
•  Interface positions that are part of the framework regions.
A genetic algorithm run involving all the 124 interface positions was initiated for a 
population of 15000 individuals.  The run was initiated on the C 3 on 10th of June, 
2007 and terminated on the  16th of October,  2007.  Sun Gridengine was used to 
distribute jobs  across the  farm.  Every job involves  training  and validation  of a 
neural network on a set of interface positions which is represented by an individual 
in the GA.
The performance at the end of every generation was monitored and is shown as 
graphs in Figure 5.15.  The performance in the GA is assessed by two parameters:
•  The score of the best individual at the end of every generation.
•  The average score of individuals in every generation.
When the average score of individuals in the population increases, it is also likely
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Figure  5.15:  GA  runs  involving  all  interface  positions.  Figures  shown  are  (a) 
Average score in every generation (b)  Best score in every generation.
217GA
Run type
Interface positions
All interface positions L38
L40
L42
L44
L46
L87
L99
H43
H52A
H55
H64
HI 001
H100K
H100M
H100O
H106
Table 5.6:  Interface positions corresponding to the best individual from a GA run 
involving all interface positions.
that  offspring  individuals  produced  by  the  crossover  of high-scoring  individuals 
will also have a high score.
Prom  Figure  5.15a,  it  can  be  seen  that  the  GA  run, registers  a  sharp  increase 
in  the  average  score  initially  over  the  first  50  generations  and  then  flattens  out 
over  the rest  of the generations.  A  similar  trend  is  observed  for  the  best  scores 
(Figure 5.15b).  The best score increases sharply for the first 50 generations from 
about  0.8  to  a  little  over  0.82.  However,  the  best  score  over  the  entire  genetic 
algorithm run was achieved in generation  1086  (a score of 0.821  which translates 
to  a  relative  RMSE  of 0.172).  The  interface  positions  represented  by  the  best 
individual are shown in Table 5.6.
218GA
Run type
Interface positions
Non-CDR interface positions L38
L40
L41
L44
L46
L87
H33
H42
H45
H60
H62
H91
H105
Table 5.7:  Interface positions corresponding to the best individual from a GA run 
involving only non-CDR interface positions  (CDRs defined according to Chothia 
(Al-Lazikani  et  a l,  1997)).
5.9.2  Choosing key framework interface residues
In  the  case  of humanization  of antibodies,  murine  CDRs  are  transplanted  onto 
a human  framework  region.  This  is  usually  done  assuming that  the  transfer  of 
murine  CDRs  onto  the  human  framework  region  would  confer  the  same  speci­
ficity of the  murine  antibody  to  the  humanized  antibody.  However,  residues  in 
the  framework  regions  flanking  the  CDRs  may  have  to  be  modified  in  order  to 
reinstate the binding specificity of the original murine antibody to the humanized 
antibody  (Riechmann  et a/.,  1988).  I therefore decided to explore the possibility 
of predicting the packing angle by using only a combination of non-CDR interface 
residues.  Thus the main goal of this work was the identification of key residues in 
the framework regions that would be deterministic of the packing angle and there­
fore aid in the engineering of antibodies to confer appropriate antigen specificity.
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Figure 5.16:  GA runs involving non-CDR interface positions.  Figures shown are 
(a) Average score in every generation (b)  Best score in every generation.
2 2 0A genetic algorithm run involving 64 non-CDR interface positions was initiated on 
a population of 15000 individuals on the  Queen cluster.  All the 64 positions chosen 
are  part  of the  framework  region  according  to  the  Chothia  numbering  scheme. 
Runs were initiated on the 10th of June, 2007 and were terminated on the 4th of 
October, 2007.  A total of 2166 generations completed in this time period.  Results 
of the run are shown in Figure 5.16.  The graphs for the average and best score in 
every  generation  are very  similar  in nature to the graphs involving  GA runs  for 
all interface positions.  The average and best scores increase sharply for the first 
150 generations and then stabilise for the remaining generations.  The best score 
of 0.833  (a relative RMS error of 0.167) was first seen after  146 generations.  The 
interface positions represented by the best individual are shown in Table 5.7.
5.9.3  Jacknifing and analysis of errors of the best  individ­
uals
I performed a jacknifing examination on the best individual which involved train­
ing the  neural  network  over  data from  all  but  one  structure  and  evaluating the 
quality of the training by predicting the interface angle for one structure.  Results 
of the jacknifing run are shown in Figure 5.17.  The graph plots the packing angles 
predicted  by the  neural  network against  the  actual  interface  angles  for the  best 
individuals involving all interface positions (Figure 5.17a) and non-CDR interface 
positions  (Figure  5.17b).  From  the  figures,  it  can  be  seen  that  the  majority  of 
the predictions are close to the ideal line  (represented by the black dotted line). 
It is well known that neural networks do not make good predictions on data that
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Figure 5.17:  Predicted vs.  the Actual packing angle results for jacknifing of the 
best individual from the GA runs for (a) All interface positions and (b) Non-CDR 
interface positions.  Perfect  predictions would  lie on the  black dotted  line.  The 
line in red shows the best-fit regression line for the data points.
2 2 290
(Predicted angle - Actual angle)
80
70
60
g  50  w
J j f   4 0
30
20
10
0 0
Error in prediction
10 20 -20 -10
(a) All interface positions
90
(Predicted angle - Actual angle)
80
70
60
a  so 
I
I
30
20
10
0.
10 20 -20 -10 0
Error in prediction
(b) Non-CDR interface positions
Figure 5.18:  Frequency distribution of the error calculated  as the difference  be­
tween the predicted and actual interface angle for the best individual from the GA 
run involving  (a) All interface positions and  (b) Non-CDR interface positions.
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Figure 5.19:  Plot of errors in packing angle prediction against the actual packing 
angle  (a)  involving  all  interface  positions  and  (b)  involving  non-CDR  interface 
positions.are sparsely represented.  This appears to be the case of predicting packing angles 
that  are  less than 43°  and  greater  than  50°.  For the  remaining  packing  angles, 
the predictions of the neural network are very close to the actual packing angle. 
This is further corroborated by the frequency  distribution plots for the errors in 
predictions shown in Figure 5.18.  The graph approximates a normal distribution 
with a peak around an error value of 0.
Further, to understand the correspondence between the actual packing angle and 
the tendency for an error in the prediction,  the square of the error for each pre­
diction was plotted  against  the  actual packing  angle.  These  plots  are shown  in 
Figures 5.19a and  5.19b for the best  individuals identified from GA runs involv­
ing all interface positions and non-CDR interface positions respectively.  The two 
graphs are very similar and it may be seen that the majority of the data points lie 
close to the X-axis.  This reinforces the conclusion from the graphs in Figure 5.18 
that the majority of predictions are  made with very  low error rates.  Further,  it 
may  also  be  inferred  that  the  large  errors  are  primarily  seen  for  either  low  and 
high packing angles which do not have adequate representation in the repertoire 
of structures that constitutes the dataset.
5.10  Discussions and conclusion
In  this  chapter,  I  have  defined  and  analysed  the  V h /V l  packing  angle.  From 
the  runs  of the  genetic  algorithms,  I  have  identified  a  set  of interface  residues 
(including  the  CDR  residues)  which  can  be  used  to  predict  the  Vh /V l  packing
225angle.  Farther,  important  interface residues in the framework regions have been 
identified  which  influence  the  packing  angle  and  should  therefore  be  considered 
during humanization of antibodies.  From the analysis and discussions presented 
in the above sections, it seems clear that correlations exist between residues in the 
Vh /V l interface and packing angle.
The results of this work can be used to model the framework regions of antibodies 
better  by  including the  correct  packing  angle  between  the  Vh  and  Vl  domains. 
This work also has applications in humanization of antibodies.  The list of interface 
residues  in  Tables  5.6  and  5.7  may  be  therefore  critical  in  maintaining  binding 
site topography.  By  modifying non-CDR residues  in the human framework and 
replacing them with their counterparts  in the murine  antibody,  there are better 
prospects  of the  humanized  version  retaining the binding  affinity  of the  murine 
antibody.  Another future application of this work will be to set up a web-interface 
to predict the packing angle.  A sequence may be submitted to a server which would 
then predict an angle.
However,  there are some remaining questions.  The fact that the overall scores of 
the genetic algorithm (and also the best scores)  remain the same for most of the 
run suggests that the  GA may be caught  in a local minimum despite the  use of 
intelligent selection to sample lots of different combinations of interface positions. 
Another problem  may be that  the neural network is unable to learn adequately 
from the  input  features  presented  to  it.  Such  a situation  may be  addressed  by 
altering  the  nature  of  input  information  representing  interface  residues  to  the 
neural network.
226The errors in the prediction of low and high interface angles are quite large even 
for the  best  individuals  identified  after  several  rounds  of the genetic  algorithm. 
In practice however,  this is not an uncommon problem in the field of neural net­
works as the identification of a single highly precise rule that applies to all data is 
usually very hard.  An easier solution is to identify more general ‘rules of thumb’. 
The procedure  for doing this  is called  boosting  (Haykin,  1994).  In this method, 
different subsets of data are used to train a learning algorithm and general rules 
are identified for each subset.  At the end of the procedure,  all the general rules 
are  combined  to  yield  one  concrete  rule.  There  are  several  implementations  of 
boosting  algorithms,  the  most  notable  amongst  them  being  AdaBoost  (Freund 
and Schapire,  1996a; Freund and Schapire,  1996b).
However, despite the shortcomings, the neural network is able to predict the ma­
jority  of packing  angles  successfully.  The  limitations  posed  by  the  network  in 
predicting packing angles which are not adequately represented may be addressed 
by over-representation of data for the extreme packing angles.
227Chapter 6
Conclusions
In this thesis, I developed tools and performed analysis of antibody sequence and 
structure.  First,  I  described  a  method  to  assess  the  ‘humanness’  of antibodies. 
Next,  I presented a method to number antibody sequences  and a modified num­
bering scheme to accommodate structural insertions and deletions in the frame­
work  regions  of the  antibody variable  region.  Third,  I  described  an  analysis  of 
the antibody packing angle at the interface of the light and heavy chain variable 
domains and a method to predict this angle.
6.1  Assessing humanness of antibodies
In the work to assess  ‘humanness’  of antibodies,  I compared  mouse  and  human 
antibody sequences.  Frequency  distribution plots of human and mouse pairwise
228sequence identities with human sequences reveals significant overlaps as shown in 
Figures  3.3  and  3.4.  Further,  Z-scores  were  calculated  and  chosen  to  represent 
how typically ‘human’ an antibody sequence is.  Comparison of the mouse and hu­
man Z-score distribution showed that a significant portion of the two plots overlap 
(Figures 3.5 and 3.6)  indicating that  many mouse antibodies are more typically 
human-like than some  mouse antibodies.  Analysis  of the  Z-score frequency dis­
tribution of human germline genes showed that certain germline genes tend to be 
used more frequently than certain others  (Figures 3.5 and 3.6).  As a final step, I 
analysed the correlation between the Z-scores of therapeutic antibodies and their 
tendency to be immunogenic.  Overall,  this examination appeared to suggest  no 
clear correlation between Z-scores and the AAR (anti-antibody response) of ther­
apeutic antibodies.  While high humanness scores in humanized antibodies appear 
to give low AAR,  the same trend  does not  hold for Chimeric  antibodies.  Anal­
ysis of the  antibody sequences  for prominent  T-cell epitopes  using  SYFPEITHI 
did not show significant differences between immunogenic and non-immunogenic 
antibodies, but further work in this area would be useful.
A potential problem with the current method of calculating humanness is that it 
is based on the Kabat database which may have introduced a bias towards anti­
bodies against specific targets.  However,  the fact that the frequency distribution 
plots of pairwise identities between human antibodies roughly resemble a Gaussian 
distribution and further, that human germline genes tend to have high humanness 
scores suggests that the bias is not a major issue.  As more clinical data becomes 
available, the idea of correlating humanness scores of therapeutic antibodies and 
AAR  should  be  revisited.  Future  work  should  also  extend  the  analysis  to  the 
larger set of sequences available in IMGT and recent work by an undergraduate
229student in the lab to analyse humanness of antibodies extracted from the IMGT 
database indicates that the nature of the graphs are not significantly different.
Part of work from this chapter was published in Abhinandan and Martin (2007).
6.2  Analysis of antibody numbering
Prom  the  analysis  of antibody  variable-region  structures,  I  found  that  approxi­
mately  10% of sequences in the manually annotated Kabat database have errors 
in the numbering.  Given the fact that the publicly available Kabat data have not 
been  updated  since  July  2000,  the  availability  of reliable  numbering  is  the  key 
reason why people still use these data.  The major alternative source of antibody 
sequence data (IMGT)  does not provide numbered sequence files.
I have been able to suggest corrections to the positions of insertions and deletions 
in the  framework  region  in  comparison  with  the  Kabat  standard  locations that 
are used in both the Kabat and the Chothia numbering schemes.  I have therefore 
proposed  a  new  numbering  scheme  (See  Table  4.14)  that  extends  the  Chothia 
analysis to correct the positions of indels in the framework regions.
The  AbNum  numbering  program  has  been  thoroughly  tested  and  benchmarked 
and can be used to apply numbering schemes to antibody sequences with a very 
high  level  of accuracy.  AbNum  was  able  to  number  99%  of sequences  and  we 
believe that in all cases,  discrepancies from the manual numbering in the Kabat
230database  resulted  from  errors  in  the  Kabat  database  and  not  in  AbNum.  By 
simply supplying different data files, Chothia and Kabat numbering schemes can 
be applied, as can my modified Chothia scheme with structurally correct indels in 
the framework regions.  Thus the program can be used reliably to apply standard 
numbering schemes to sequences in IMGT thereby enhancing the usefulness of this 
resource.
Although most errors in the manual Kabat annotations have been corrected, there 
are still a number of sequences that cannot be numbered by the program AbNum 
(See 4.12).  While the ranking of profiles at the start  and end of the framework 
regions improves the performance of the numbering program, a ranking scheme for 
profile-sets would help improve the coverage of sequences that can be annotated 
automatically.
An alternative approach, which would be likely to overcome many of the problems 
encountered  in positioning the profiles,  would be to score  and  align the  profiles 
against the sequence  using global dynamic  programming.  This would  have  zero 
gap penalties applied when separation between the profiles is within the observed 
ranges with affine penalties applied outside this range.  This approach would ensure 
that profiles are not positioned out of sequence and would probably simplify the 
code considerably.
The work has been published in (Abhinandan and Martin, 2008).
2316.3  Analysis of packing angle at the Vh/V l inter­
face
The Vh /V l packing angle has been defined as the torsion angle at the interface of 
the light and heavy chain variable region.  Analysis of the packing angle has shown 
that it can vary by up to 30° and approximates to a normal distribution.  Neural 
networks,  together with  feature  selection  using genetic  algorithms  has  proved  a 
successful approach to predicting the packing angle.  This confirms the hypothesis 
that the interface residues are important in defining the packing angle.  The best 
neural networks are able to predict the packing angle with an RMSE of 2.4° and a 
Pearson’s correlation coefficient between the predicted and actual interface angle 
of 0.65.  However, there are shortcomings in the prediction of low or high interface 
angles as the errors in these predictions are quite large despite several cycles of the 
genetic algorithm.  The use of  boosting  may alleviate this problem.  In addition, 
over-representation of data for the extreme packing angles may also help improve 
the quality of predictions.
During runs of the genetic algorithm, I noticed that the population of genes was 
becoming increasingly redundant after every generation.  In order to address this 
problem,  I  developed  the  method  of intelligent  selection  to  maintain  diversity. 
In  addition,  I  used  generational  replacement  wherein  an  entire  parent  popula­
tion of chromosomes is replaced by a population of children.  This was done with 
the  intention  of increasing  the  sampling  of the  interface  position  space.  How­
ever,  the  performance  of the  genetic  algorithm  did  not  improve  as significantly 
as might have been expected.  The performance may have been better had elitist
232replacement been used where the best gene from every generation of the genetic 
algorithm is retained  (even if it is from the population of parents).  It would be 
interesting  to  execute  large  runs  of the  genetic  algorithm  with  elitist  selection 
and  analyse  whether  this  represents  a  better  solution  of searching  through  the 
interface-position space.  However,  despite the shortcomings,  the neural network 
is able to predict the majority of packing angles successfully.
In summary,  the work in this  thesis  has  developed  a new method  for  analysing 
humanness  of  antibodies  which  has  potential  applications  in  selecting  and  de­
signing  antibodies  for  use  in  vivo.  A  new  method  for  automatically  numbering 
antibodies has been developed and deficiencies in the Kabat database have been 
highlighted.  Analysis has led to the introduction of a refined chothia numbering 
scheme.  Finally, analysis and prediction of Vh /V l packing angles has applications 
in antibody modelling and the feature selection highlights interface residues that 
inay be important in humanization.
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